ALK PROTEIN DEGRADERS AND THEIR USE IN CANCER THERAPY

PROTAD compounds using PROTAC technology degrade ALK protein to overcome drug resistance in lung cancer, providing a novel treatment approach by targeting ALK kinase activity and other relevant receptors.

JP7594757B2Active Publication Date: 2024-12-05SHANGHAI TECH UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2022134524
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-12-13
Filing Date
2022-08-25
Publication Date
2024-12-05
Estimated Expiration
2038-12-12

AI Technical Summary

Technical Problem

Current treatments for ALK-positive non-small cell lung cancer face challenges due to drug resistance, necessitating the development of new strategies to overcome resistance mechanisms and effectively target ALK kinase activity.

Method used

Development of proteolytic agents (PROTAD compounds) that utilize PROTAC technology to form complexes with ALK tyrosine kinase inhibitors and E3 ligases like VHL or CRBN proteases, leading to ubiquitination and proteasomal degradation of ALK protein, thereby suppressing its activity and overcoming resistance.

Benefits of technology

The PROTAD compounds effectively degrade ALK protein, reducing tumor growth and progression, and can potentially target other kinase receptors, offering a new treatment strategy for lung cancer with precision medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594757000216
    Figure 0007594757000216
  • Figure 0007594757000217
    Figure 0007594757000217
  • Figure 0007594757000218
    Figure 0007594757000218
Patent Text Reader

Abstract

ALK protein degraders and their use in cancer therapy are provided. [Solution] Compounds of formula (I) below have degrading and inhibitory effects on the ALK target protein. The compounds of formula (I) mainly consist of four parts: ALK-TKI, a compound with ALK tyrosine kinase inhibitory activity; LIN, a different type of linker; ULM (ubiquitin ligase binding moiety), a small molecule ligand that ubiquitinated VHL, CRBN, or other proteases; and group A, which may or may not be carbonyl, covalently linking the ALK-TKI to LIN covalently linked to ULM. A series of compounds designed and synthesized in this disclosure have broad pharmacological activity, possess the functions of ALK protein degradation and ALK activity inhibition, and can be used to treat related tumors. JPEG2022174114000224.jpg36150
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure relates generally to compounds of formula (I) for cancer prevention and therapy, and their use in anti-cancer therapy, particularly against cancer-associated proteins including ALK, ROS1, MET, EGFR, and FLT3. JPEG0007594757000001.jpg36150 [Background technology]

[0002] Lung cancer is a leading cause of cancer-related deaths in China and around the world. In China, the incidence rate of lung cancer has already surpassed that of other types of cancer, with approximately 800,000 deaths from the disease each year. The five-year survival rate for lung cancer is extremely low, at only about 17%. Furthermore, this rate has not changed significantly since the 1970s. This is because traditional chemotherapy and radiation therapy kill normal cells along with cancer cells, weakening the immune system and causing abnormalities in the patient's physiological functions. Recently, precision medicine has provided targeted treatments for patients with specific driver genes, significantly reducing the toxic effects of traditional chemotherapy and radiation therapy and significantly improving patients' quality of life.

[0003] Treatment of ALK (anaplastic lymphoma kinase) mutation-positive non-small cell lung cancer (NSCLC) with specific small molecule tyrosine kinase inhibitors has significantly improved the efficacy of cancer therapy and patient quality of life. Based on pathological classification, lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The latter accounts for approximately 80% of all lung cancer patients. Patients with EML4-ALK gene fusions account for approximately 3-7% of all NSCLC patients. There is no significant difference in incidence between Asians and Western Caucasians. Clinically, such mutations are typically observed in young, non-smoking patients (Soda et al. 2007; Nishio et al. 2017; Chan et al. 2017). ALK is a tyrosine receptor kinase. Gene fusions with this gene are potent cancer drivers and were first discovered in patients with anaplastic large cell lymphoma (ACL) and have subsequently been found in many other diseases, including diffuse large B-cell lymphoma and inflammatory myofibroblastic tumor (IMT) (Wellmann et al., 1997). ALK forms fusion genes with different kinase partners, resulting in constitutively activated ALK kinase activity and converting normal cells into cancer cells (Soda et al., 2007; Choi et al., 2008; Cha et al., 2016). In lung cancer, the main fusion partner with ALK is echinoderm microtubule-associated protein-like 4 (EML4). ALK can also form fusion proteins with many other different kinases (e.g., KIF5B) to drive cancer formation (Takeuchi et al., 2008). Such ALK fusion-positive cancer cells are highly dependent on ALK kinase activity, and inhibition of ALK kinase activity results in the death of these cells. Several ALK kinase inhibitors have been approved for the treatment of ALK mutation-positive cancers. In 2011, crizotinib, developed by Pfizer, was approved by the FDA for the treatment of ALK-positive non-small cell lung cancer. In 2016, crizotinib was approved for the treatment of patients with non-small cell lung cancer harboring ROS1 (c-ros oncogene 1 receptor tyrosine kinase, c-ros) mutations. This drug prolongs patients' progression-free survival to approximately 10 months (Nishio et al. 2017). Crizotinib, regardless of whether or not it has been previously treated, demonstrates benefits for patients.As a result, median progression-free survival with chemotherapy has increased from 7.2 months to 9.6 months, and in Asian patients, it has increased to 13.6 months (Nishio et al. 2017). Compared to chemotherapy, the objective response rate has increased from 20% to 65%. Treating ALK fusion-positive patients with specific tyrosine kinase inhibitors has significant clinical benefits for patients and marks a new milestone in lung cancer therapy.

[0004] More than 20 different genes have been reported to be partners of ALK. These different forms of ALK fusion proteins are also highly dependent on ALK kinase activity and sensitive to ALK kinase inhibitors. ALK gene fusions play an important role in non-small cell lung cancer ALK gene amplification and activating mutations have been reported not only in patients with ALK but also in patients with many other diseases, including ALCL, colorectal cancer (Lin et al. 2009; Lipson et al. 2012), IMT (Lawrence et al. 2000), and ovarian cancer (Ren et al. 2012). ALK gene amplification and activating mutations have also been reported in glioblastoma (Chen et al. 2008; George et al. 2008; Janoueix-Lerosey et al. 2008; Mosse et al. 2008). Different ALK fusion forms have been found to be crucial for different types of disease. For example, the most frequently observed form is EML4-ALK in non-small cell lung cancer, and the most common form is NPM-ALK in ALCL. ALK gene amplification and mutations have also been reported in glioblastoma. Some of these ALK mutations are also sensitive to ALK inhibitors and may benefit from the development of these agents.

[0005] Although the use of ALK kinase inhibitors has proven clinically beneficial for patients, drug resistance usually eventually develops approximately one year after drug treatment. This is partly due to ALK gene amplification or acquired resistance mutations in the ALK protein, including L1196M, L1198F, L1152R, L1151TIN, C1156Y, F1174C, G1202R, D1203N, and S1206Y (Bordi et al. 2017; Dagogo-Jack and Shaw 2016; Drizou et al. 2017). The most common mutation is the point mutation L1196M, known as the gatekeeper mutation. Because crizotinib has difficulty reaching the cerebral cortex, resistance also emerges after brain metastasis. Other resistance mechanisms include activation of other driver genes, including EGFR mutations or activation (30–35%), c-KIT amplification (10%), or Kras or other gene mutations (5%) (Bordi et al. 2017).

[0006] Research into drug resistance mechanisms has led to the development of second-generation ALK kinase inhibitors, including ceritinib (Novartis, LDK378), alectinib (Roche, CH542802), and brigatinib (Ariad, AP26113). These drugs can overcome many acquired resistance mutations in ALK, including the gatekeeper mutation L1196M. These drugs also successfully penetrate the brain and inhibit the growth of brain metastatic tumors. Among these drugs, ceritinib was approved by the FDA in 2014 for the treatment of patients who have progressed on or are intolerant to crizotinib. Compared with second-line chemotherapy, second-line treatment with ceritinib increases progression-free survival by approximately 4 months (Shaw et al. 2017). Alectinib was approved in Japan in 2014 and by the FDA in the United States in 2015. Its efficacy in inhibiting ALK kinase activity is approximately 10-fold greater than that of crizotinib. Recently, alectinib demonstrated superiority over chemotherapy in second-line treatment after crizotinib resistance (Asao et al. 2017). This resulted in a 35-month longer progression-free survival for patients. This indicates that the use of ALK kinase inhibitors in an optimized drug treatment strategy can convert uncontrolled tumor growth into a manageable chronic disease. Brigatinib (Takeda) was initially granted breakthrough designation by the FDA on April 28, 2017, for ALK-positive patients who have developed resistance to crizotinib in second-line treatment. Compared with the other two second-generation drugs, brigatinib not only effectively inhibits G1269A, C1156Y, I1171S / T, and V1180L, but also blocks resistance mediated by G1202R (Zhang et al. 2016). Brigatinib can also block the activity of both ALK and EGFR, achieving a response rate of 55% and a disease control rate of approximately 86%. It has now been granted priority review as a first-line treatment for ALK-positive non-small cell lung cancer.

[0007] The development of new, more specific tyrosine kinase inhibitors has demonstrated high response rates in ALK-mutant non-small cell lung cancer (NSCLC), but drug resistance still persists. The third-generation ALK kinase inhibitor lorlatinib (PF-06463922) can overcome many known acquired ALK resistance mutations, but patients eventually develop resistance to lorlatinib. The number of patients with ALK rearrangements continues to grow. Drug resistance to targeted therapies poses a significant obstacle to improving patient survival and does not meet the needs of societal development. There is a demand for overcoming drug resistance, and the development of novel drugs that can overcome this resistance is urgent.

[0008] Proteolysis-directed drug technology is a new strategy for drug design. Traditional small molecule designs only inhibit the kinase activity of the ALK protein, but acquired resistance mutations in the protein are the basis for some resistance mechanisms. Novel ALK-targeted drugs are being developed using the protein degradation-directed drug (PROTAD) platform. These drugs have a different mechanism of action from traditional small molecule kinase inhibitors. These PROTAD drugs not only inhibit the activity of target proteins (e.g., ALK) but also remove them by proteolysis. Using PROTAC technology, we can develop novel drugs that target cancer driver genes (e.g., ALK fusion proteins) and ultimately remove these target proteins, potentially treating cancer and overcoming drug resistance. Summary of the Invention

[0009] The present disclosure provides a compound of formula (I): JPEG0007594757000002.jpg36150 or a salt, enantiomer, stereoisomer, solvate or crystalline polymorph thereof, wherein all substituents or groups are as defined in the detailed description. The present disclosure further provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier. The present disclosure further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament. JPEG0007594757000003.jpg36150 wherein all substituents or groups are as defined in the detailed description. The present disclosure further provides a compound of formula (I) according to the present disclosure or a pharmaceutically acceptable salt thereof for preventing and / or treating cancer, particularly lung cancer. The present disclosure further provides the use of a compound of formula (I) according to the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for preventing and / or treating cancer.

[0010] Cancers include, but are not limited to, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer, Ros1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, EGFR-mutated non-small cell lung cancer, lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), colorectal cancer, glioma, glioblastoma, acute myeloid leukemia (AML), and ovarian cancer.

[0011] The present disclosure further provides a method for treating or preventing cancer, comprising administering to a subject a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to the present disclosure. [Brief explanation of the drawings]

[0012] [Figure 1] 1 shows the ALK proteolytic activity of a PROTAD molecule based on brigatinib analog A according to the present invention in the ALCL cell line SR. [Figure 2] 1 shows the ALK proteolytic activity of a PROTAD molecule based on brigatinib analog A according to the present invention in the lung cancer cell line H3122. [Figure 3]1 shows the ALK proteolytic activity of a PROTAD molecule based on brigatinib analog B according to the present invention in the ALCL cell line SR. [Figure 4] 1 shows the ALK phosphorylation and proteolytic activity of a PROTAD molecule based on brigatinib analog B according to the present invention in the lung cancer cell line H3122. [Figure 5] 1 shows the inhibition of ALK phosphorylation, proteolytic activity and downstream signaling pathways by a PROTAD molecule based on brigatinib analog B according to the present invention in lung cancer cell line H2228. [Figure 6] 1 shows the ALK proteolytic activity of a PROTAD molecule based on brigatinib analog C according to the present invention in the ALCL cell line SR. [Figure 7] 1 shows the ALK phosphorylation and proteolytic activity of a PROTAD molecule based on brigatinib analog C according to the present invention in the lung cancer cell line H3122. [Figure 8] 1 shows the ALK phosphorylation and proteolytic activity of a PROTAD molecule based on brigatinib analog C according to the present invention in the ALCL cell line SR and the lung cancer cell line H2228. [Figure 9] 1 shows the ALK proteolytic activity of alectinib analog A-based PROTAD molecules according to the present invention in the ALCL cell line SR. [Figure 10] FIG. 1 shows ALK phosphorylation, proteolytic activity and downstream signaling pathways of alectinib analog A-based PROTAD molecules according to the present invention in the lung cancer cell line H3122. [Figure 11] 1 shows the ALK proteolytic activity of a ceritinib-based PROTAD molecule according to the present invention against ALK protein in the lung cancer cell line H3122. [Figure 12] Figure 1 shows ALK phosphorylation, proteolytic activity and downstream signaling pathways of crizotinib-based PROTAD molecules according to the present invention in the lung cancer cell line H3122. [Figure 13] 1 shows the reduction of ALK protein stability by a PROTAD molecule according to the present invention. [Figure 14] Shows the time- and concentration-dependent effects of brigatinib on ALK protein in SR cell lines. [Figure 15] 1 shows that the brigatinib-based PROTAD molecule of the present invention degrades ALK protein in SR cell lines in a time-dependent manner. [Figure 16] Figure 1 shows that the PROTAD molecules of the present invention act via the proteasome-mediated protein degradation pathway (SR cell line). [Figure 17] 1 shows the effect of the PROTAD molecule of the present invention on the cell colony-forming ability in the lung cancer cell line H2228. [Figure 18] 1 shows the effect of the PROTAD molecule of the present invention on the cell colony-forming ability in the lung cancer cell line PC9. [Figure 19] 1 shows the effect of the PROTAD molecule of the present invention on the cell colony-forming ability of the lung cancer cell line PC9Brc1. [Figure 20] 1 shows the effect of the PROTAD molecule of the present invention on cell proliferation in the colorectal cancer cell line SW48. DETAILED DESCRIPTION OF THE INVENTION

[0013] The compounds disclosed herein can highly effectively degrade ALK tyrosine kinase, which is associated with lung cancer, in a cellular environment. These compounds according to the present disclosure are based on proteolytic target chimera (PROTAC) technology, with one end linked to a VHL or CRBN protease with ubiquitination function and the other end linked to a target tyrosine kinase. When the compounds disclosed herein are combined with a tyrosine kinase and a VHL or CRBN protease, they form a complex, which brings the VHL or CRBN protease into close proximity with the tyrosine kinase, leading to the ubiquitination of the tyrosine kinase and subsequent proteasomal degradation. Thus, in a first aspect, the present disclosure provides a compound of formula (I): JPEG0007594757000004.jpg36150 or a salt, enantiomer, stereoisomer, solvate or crystalline polymorph thereof, wherein the ALK-TKI is covalently attached to the LIN by group A, and the ULM is covalently attached to the LIN; ALK-TKI is an ALK tyrosine kinase inhibitor or its analogue with the same function,

[0014] LIN is a linking group and represents a straight or branched alkylene chain, spiro-cycloalkylene, 1,4-piperazinylene, or 1,3-dialkynyl, wherein the straight or branched alkylene chain is optionally interrupted one or more times by one or more selected from the group consisting of O, C(O)NH, NHC(O), NHC(O)NH, NH, S, sulfinyl, sulfonyl, aminosulfonylamino, alkynylene, alkenylene, cycloalkylene, arylene, heterocyclylene, or heteroarylene, or any combination thereof, and the straight or branched alkylene chain is optionally substituted with one or more substituents; ULM is a small molecule ligand of VHL or CRBN protease with ubiquitination function. The group A is C(O) or is absent.

[0015] In the present disclosure, the term "alkylene" (which may be used interchangeably with "alkylene chain"), used alone or in combination, refers to a straight or branched chain divalent saturated hydrocarbon group composed of carbon and hydrogen atoms. x -C y Alkylene" or "C x-y The term "alkylene" (where x and y are each integers) refers to a straight or branched chain alkylene containing x to y carbon atoms. 30 Alkylene is C1-C 29 Alkylene, C1-C 28 Alkylene, C1-C 27 Alkylene, C1-C 26 Alkylene, C1-C 25 Alkylene, C1-C 24Alkylene, C1-C 23 Alkylene, C1-C 22 Alkylene, C1-C 21 Alkylene, C1-C 20 Alkylene, C1-C 19 Alkylene, C1-C 18 Alkylene, C1-C 17 Alkylene, C1-C 16 Alkylene, C1-C 15 Alkylene, C1-C 14 Alkylene, C1-C 13 Alkylene, C1-C 12 Alkylene, C1-C 11 Alkylene, C1-C 10 It is preferably alkylene, C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene or C1-C2 alkylene. Representative examples of "alkylene" include, but are not limited to, methylene, ethylene, propylene, isopropylidene, butylene, isobutylene, sec-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, tert-pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tetradecylene, pentadecylene, hexadecylene, heptadecylene, octadecylene, nonadecylene, eicosylene, heneicosylene, docosylene, tricosylene, tetracosylene, pentacosylene, hexacosylene, heptacosylene, octacosylene, nonacosylene, and triacontylene.

[0016] In the present disclosure, the term "arylene," used alone or in combination, refers to a divalent aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenylene, naphthylene, or fluorenylene. In the present disclosure, "arylene" refers to an optionally substituted arylene. Substituted arylene refers to any of C 1-3 Alkyl, C 1-3It refers to an arylene substituted 1 to 3 times with a substituent selected from the group consisting of alkoxy, halogen, amino, or hydroxyl.

[0017] In the present disclosure, the term "aryl," used alone or in combination, refers to an aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenyl, naphthyl, or fluorenyl. In the present disclosure, "aryl" refers to an optionally substituted aryl. Substituted aryl refers to any group including C 1-3 Alkyl, C 1-3 It refers to an aryl substituted 1 to 3 times with a substituent selected from the group consisting of alkoxy, halogen, amino, or hydroxyl.

[0018] In this disclosure, the term "C" as used alone or in combination 1-3 "Alkoxy" refers to a straight or branched chain alkoxy containing 1 to 3 carbon atoms. 1-3 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, and isopropoxy. 1-3 Preferred examples of alkoxy include methoxy and ethoxy.

[0019] In the present disclosure, the term "cycloalkyl," used alone or in combination, refers to a saturated or partially unsaturated (e.g., not having a fully conjugated π-electron system and containing one or more double bonds) mono- or bicyclic hydrocarbon group having 3 to 12 carbon atoms. Representative examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decalinyl, octahydropentalenyl, octahydro-1H-indenyl, and spiro-cycloalkyl.

[0020] In the present disclosure, the term "cycloalkylene," used alone or in combination, refers to a saturated or partially unsaturated (e.g., not having a fully conjugated π-electron system and containing one or more double bonds) divalent monocyclic or bicyclic hydrocarbon group having 3 to 12 carbon atoms. Representative examples of "cycloalkylene" include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decalinylene, octahydropentalenylene, octahydro-1H-indenylene, and spiro-cycloalkylene.

[0021] In the present disclosure, the term "heteroarylene," used alone or in combination, refers to a 5-10-membered monocyclic or bicyclic divalent aromatic ring group containing one or more (e.g., 1 to 6, 1 to 5, 1 to 4, or 1 to 3) heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Representative examples of such heteroarylenes include furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, triazolylene, pyridylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1, 3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolylene, isoquinolylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridylene, 1H-pyrrolo[3,2-b]pyridylene, 1H-pyrrolo[2,3-b]pyridylene, 4H-fluoro[3,2-b]pyrrolylene, pyrrolo[2,1-b]thiazolylene, and imidazo[2,1-b]thiazolylene. In the present disclosure, heteroarylene may be unsubstituted or substituted. Substituted heteroarylene is preferably C 1-3 Alkyl, C 1-3 refers to heteroarylene substituted 1 to 3 times with substituents selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0022] In the present disclosure, the term "heteroaryl," used alone or in combination, refers to a 5-10-membered monocyclic or bicyclic aromatic ring containing one or more (e.g., 1 to 6, 1 to 5, 1 to 4, or 1 to 3) heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Representative examples of such heteroaryls include furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3] Heteroaryls include, but are not limited to, oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolyl, isoquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 4H-fluoro[3,2-b]pyrrolyl, pyrrolo[2,1-b]thiazolyl, and imidazo[2,1-b]thiazolyl. In the present disclosure, heteroaryls may be unsubstituted or substituted. Substituted heteroaryls are preferably C 1-3 Alkyl, C 1-3 refers to heteroaryl substituted 1 to 3 times with substituents selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0023] In the present disclosure, the term "heterocyclylene," used alone or in combination, refers to a 4- to 6-membered saturated monocyclic divalent hydrocarbon group containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Examples of heterocyclylene include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidine, triazolylene, tetrahydrofuranylene, tetrahydrothienylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, and dioxanylene. In the present disclosure, heterocyclylene may be unsubstituted or substituted, as specifically defined. Substituted heterocycloalkylene is preferably C 1-3 Alkyl, C 1-3 refers to heterocycloalkylene substituted 1 to 3 times with substituents optionally selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0024] In the present disclosure, the term "heterocyclyl," used alone or in combination, refers to a 4- to 6-membered saturated monocyclic monovalent hydrocarbon group containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Examples of heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidyl, triazolyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and dioxanyl. In the present disclosure, heterocyclyl may be unsubstituted or substituted, as specifically defined. Substituted heterocyclyl is preferably C 1-3 Alkyl, C 1-3 refers to a heterocyclyl substituted 1 to 3 times with a substituent optionally selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0025] In the present disclosure, the term "spiro-cycloalkylene," used alone or in combination, refers to a divalent alicyclic hydrocarbon group derived by removing two hydrogen atoms from the free valence carbon atoms of an alicyclic hydrocarbon group in which two rings share one common carbon atom. A representative example of a spiro-cycloalkylene is spiro[3.3]heptanylene. JPEG0007594757000005.jpg31136 includes, but is not limited to, spiro[4.5]decanylene, spiro[5.5]undecanylene, 4-methylspiro[2.4]heptanylene, and the like.

[0026] In the present disclosure, the term "alkynylene," used alone or in combination, refers to a straight- or branched-chain divalent hydrocarbon group containing one or more carbon-carbon triple bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkynylene include, but are not limited to, ethynylene, 1-propynylene, 1-butynylene, and 1,3-diynylene.

[0027] In this disclosure, the term "alkynyl," used alone or in combination, refers to a straight- or branched-chain hydrocarbon group containing one or more carbon-carbon triple bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and 1,3-dialkynyl.

[0028] In the present disclosure, the term "alkenylene," used alone or in combination, refers to a straight- or branched-chain divalent hydrocarbon group containing one or more carbon-carbon double bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkenylene include, but are not limited to, vinylidene (e.g., -CH=CH-), 1-propenylene, and 1-butenylene.

[0029] In this disclosure, the term "alkenyl," used alone or in combination, refers to a straight- or branched-chain hydrocarbon group containing one or more carbon-carbon double bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, and 1-butenyl.

[0030] In the present disclosure, the term "halogen atom" or "halogen", alone or in combination, refers to fluoro, chlorine, bromine or iodine, with F, Cl or Br being preferred.

[0031] In this disclosure, the term "alkyl," alone or in combination, refers to a straight or branched chain alkyl. x -C y ) alkyl" or "C x-y The term "alkyl" (where x and y are each integers) refers to a straight or branched chain alkyl containing x to y carbon atoms. 1~10 "Alkyl" refers to a straight or branched chain alkyl containing 1 to 10 carbon atoms. 1~10 Alkyl is C 1-9 Alkyl, C 1-8 Alkyl, C 2-8 Alkyl, C 1-7 Alkyl, C 1-6 Alkyl, C 1-5 Alkyl or C 1-4 Preferably, it is alkyl. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. In the present disclosure, the term "C 1-3 "Alkyl" refers to alkyl containing 1 to 3 carbon atoms, representative examples of which include methyl, ethyl, n-propyl, and isopropyl.

[0032] In the present disclosure, "alkyl" is optionally substituted, and the substituents include halogen, cyano, C 1-3 Alkyl, C 1-3 It may be one or more selected from the group consisting of alkoxy, trifluoromethyl, heterocyclyl, or any combination thereof.

[0033] In the embodiments of the present disclosure, ALK-TKI refers to a compound moiety represented by the following general formula: JPEG0007594757000006.jpg241170

[0034] wherein R represents alkyl or H. In a subembodiment of the present disclosure, R is a straight or branched chain C 1~10 In other subembodiments of the present disclosure, C represents alkyl. 1~10 Alkyl is C 1-9 Preferably it is alkyl, C 1-8 More preferably, it is alkyl, and C 2-8 More preferably, it is alkyl, and C 1-7 More preferably, it is alkyl, and C 1-6 Alkyl, C 1-5 Alkyl or C 1-4 Even more preferably, it is alkyl. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and tert-pentyl.

[0035] In embodiments of the present disclosure, ULM represents a structure represented by formula (II): JPEG0007594757000007.jpg109166

[0036] wherein X represents CH2 or C(O), Y represents CH2, NH or O, and Z represents carbonyl (i.e., C(O)) or is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents N—, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents NH, and Z represents carbonyl. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents NH, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents NH, and Z represents carbonyl. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents O, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents O, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents O, and Z represents carbonyl. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents O, and Z represents carbonyl. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents CH2, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents CH2, Y represents CH2, and Z represents carbonyl. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents CH2, and Z is absent. In a subembodiment of the present disclosure, in the structure of formula (II), X represents C(O), Y represents CH2, and Z represents carbonyl.

[0037] In embodiments of the present disclosure, ULM represents a structure represented by formula (III): JPEG0007594757000008.jpg135144 In the formula, Z represents a carbonyl or is absent.

[0038] In embodiments of the present disclosure, LIN is a linear or branched C1-C 20 Alkylene chain, -(CH2) n1 -(O(CH2) n2 ) m1-, -(CH2) n1 -(O(CH2) n2 ) m1 -O-(CH2) n3 -, -(CR1R2) n1 -(O(CR1R2) n2 ) m1 -O-(CR1R2) n3 -, -(CH2) n1 -(C(O)NH-(CH2) n2 ) m1 -, -(CH2) n1 -(C(O)NH-(CH2) n2 ) m1 -(CH2) n3 -, -(CH2) n1 -(O(CH2) n2 ) m1 -O-(CH2) n3 -C(O)NH-(CH2) n4 -(O(CH2) n5 ) m2 -O-(CH2) n6 -, -(CR1R2) n1 -(O(CR1R2) n2 ) m1 -O-(CR1R2) n3 -C(O)NH-(CR1R2) n4 -(O(CR1R2) n5 ) m2 -O-(CR1R2) n6 -, -(CH2) n1 -C(O)NH-(O(CR1R2) n2 ) m1 -; a straight or branched alkylene chain interrupted one or more times by one or more members selected from the group consisting of NHC(O), NHC(O)NH, S, sulfinyl, sulfonyl, alkynylene, alkenylene, cycloalkylene, arylene, heterocyclylene, or heteroarylene, or any combination thereof; or -(CH) wherein the alkylene carbon chain is interrupted one or more times by one or more members selected from the group consisting of arylene, heterocyclylene, heteroarylene, or any combination thereof. n1 -(O(CH2) n2 ) m1 - represents.

[0039] wherein R1 and R2 are each independently a straight or branched chain C1-C 10 represents alkyl or cycloalkyl, n1, n2, n3, n4, n5, n6, m1, and m2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0040] In an embodiment of the present disclosure, the LIN is: -(CH2)2O(CH2)2OCH2-, -CH2O(CH2)2OCH2-, -(CH2)3O(CH2)2-, -(CH2)3O(CH2)2O(CH2)2-, -(CH2)3O(CH2)3-, -(CH2)2O(CH2)2-, -(CH2)2O(CH2)2O(CH2)2-, -(CH2)2O(CH2)2O(CH2)2-, -(CH2)2O(CH2)2O(CH2)2O(CH2)2-, -(CH2)2O(CH2)2O(CH2)2O(CH2)3-, -(CH2)2O(CH2)2O(CH2)2O(CH2)2O(CH2)2-, -(CH2)2O(CH2)2O(CH2)2O(CH2)2O(CH2)2O(CH2)2-, -(CH2)3O(CH2)2O(CH2)2O(CH2)2O(CH2)2O(CH2)2-, or -(CH2)3O(CH2)2O(CH2)2O(CH2)2O(CH2)2O(CH2)3-.

[0041] In an embodiment of the present disclosure, the LIN is:

[0042] -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2) 11 -, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14-, -(CH2) 15 -, -(CH2) 16 -, -(CH2) 17 -, -(CH2) 18 -, -(CH2) 19 - or -(CH2) 20 - represents.

[0043] In embodiments of the present disclosure, a straight or branched alkylene chain is substituted one or more times with one or more substituents selected from the group consisting of hydroxyl, amino, mercapto or halogen.

[0044] In embodiments of the present disclosure, L-In is a linear or branched C-C alkyl group substituted with one or more substituents selected from the group consisting of hydroxyl, amino, mercapto, halogen, or any combination thereof. 20 In subembodiments of the present disclosure, the number of substituents may be, for example, 1 to 20, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1. In the examples of the present disclosure, LIN represents —(CH 2 ) 3 CH(OH)CH(OH)(CH 2 ) 4 —.

[0045] In an embodiment of the present disclosure, LIN is -(CH) n1 -Triazolylene-(CH2) n2 -, -(CH2) n1 -(O(CH2) n2 ) m1 -O-(CH2) n3 -Triazolylene-(CH2) n4 -(O(CH2) n5 ) m2 -O-(CH2) n6 -, -(CH2) n1 -Triazolylene-(CH2) n2 -(O(CH2) n3 ) m1 -O-(CH2) n4 - or -(CH2) n1 -(O(CH2) n2 ) m1 -O-(CH2) n3 -Triazolylene-(CH2)n4 - represents

[0046] n1, n2, n3, n4, n5, n6, m1, and m2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0047] In an embodiment of the present disclosure, the LIN is: JPEG0007594757000009.jpg25170 Represents. In an embodiment of the present disclosure, the LIN is:

[0048] It represents -(CH2)2C(O)NH(CH2)2-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)6C(O)NH(CH2)7-, or -(CH2)8C(O)NH(CH2)8-.

[0049] In an embodiment of the present disclosure, LIN is -(CH) n1 -NHC(O)-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In an embodiment of the present disclosure, LIN is —(CH 2 ) 3 NHC(O)(CH 2 ) 3 —.

[0050] In an embodiment of the present disclosure, LIN is -(CH) n1 -NHC(O)NH-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In an embodiment of the present disclosure, LIN is —(CH 2 ) 4 NHC(O)NH(CH 2 ) 4 —.

[0051] In an embodiment of the present disclosure, LIN is -(CH) n1-S-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In the embodiments of the present disclosure, LIN represents —(CH 2 ) 5 S(CH 2 ) 5 — or —(CH 2 ) 6 S(CH 2 ) 5 —.

[0052] In an embodiment of the present disclosure, LIN is -(CH) n1 -S(O)-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In the embodiments of the present disclosure, LIN represents —(CH 2 ) 5 S(O)(CH 2 ) 5 — or —(CH 2 ) 6 S(O)(CH 2 ) 5 —.

[0053] In an embodiment of the present disclosure, LIN is -(CH) n1 -S(O)2-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In the embodiments of the present disclosure, LIN represents —(CH 2 ) 5 S(O) 2 (CH 2 ) 5 — or —(CH 2 ) 6 S(O) 2 (CH 2 ) 5 —.

[0054] In an embodiment of the present disclosure, LIN is -(CH) n1 -CH=CH-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In an embodiment of the present disclosure, LIN is —(CH 2 ) 4 CH═CH(CH 2 ) 3 —.

[0055] In an embodiment of the present disclosure, LIN is -(CH) n1-C≡C-(CH2) n2 -or-(CH2) n1 -C≡CC≡C-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In embodiments of the present disclosure, LIN represents -(CH2)2C≡C(CH2)2- or -(CH2)5C≡C(CH2)4-.

[0056] In embodiments of the present disclosure, LIN represents a straight or branched alkylene chain interrupted one or more times by one or more selected from the group consisting of NHC(O), NHC(O)NH, S, sulfinyl, sulfonyl, alkynylene, alkenylene, spiro-cycloalkylene, arylene, heterocyclylene, heteroarylene, or any combination thereof.

[0057] In an embodiment of the present disclosure, LIN is -(CH) n1 -Piperazinylene-(CH2) n2 wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0058] In embodiments of the present disclosure, LIN represents -CH2-piperazinylene-CH2-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, or -(CH2)2-piperazinylene-(CH2)3-.

[0059] In an embodiment of the present disclosure, LIN is -(CH) n1 -phenylene-(CH2) n2wherein n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0060] In embodiments of the present disclosure, L-In represents -CH2-phenylene-CH2-, -(CH2)2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)2-, -(CH2)2-phenylene-CH2-, -(CH2)3-phenylene-(CH2)3-, -CH2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)2- or -(CH2)3-phenylene-CH2-.

[0061] In embodiments of the present disclosure, L-I represents 1,4-piperazinylene, spiro-cycloalkylene, or 1,3-dialkynylene. When L-I is 1,4-piperazinylene, the group A in the compound of formula (I) is carbonyl. In an embodiment of the present disclosure, the LIN is: JPEG0007594757000010.jpg24128. When LIN is 1,4-piperazinylene, the group A in the compound of formula (I) is carbonyl.

[0062] In an embodiment of the present disclosure, L-In represents a spiro-cycloalkylene, and the spiro-cycloalkylene is spiro[3.3]heptanylene. JPEG0007594757000011.jpg33144 It may also be spiro[4.5]decanylene, spiro[5.5]undecanylene, 4-methylspiro[2.4]heptanylene, or the like.

[0063] In an embodiment of the present disclosure, the LIN is: JPEG0007594757000012.jpg2694, where group A is C(O).

[0064] Particularly preferred are the following compounds of Formula I in Tables 1 and 2 of the present disclosure and salts thereof (especially pharmaceutically acceptable salts).

[0065] Table 1. Structural formulas and names of compounds disclosed herein JPEG0007594757000013.jpg214170JPEG0007594757000014.jpg213170JPEG0007594757000015.jpg214170JPEG0007594757000016.jpg196170JPEG0007594757000017.jpg213170JPEG0007594757000018.jpg215170JPEG0007594757000019.jpg214170JPEG0007594757000020.jpg213170JPEG0007594757000021.jpg209170JPEG0007594757000022.jpg214170JPEG0007594757000023.jpg213170JPEG0007594757000024.jpg200170JPEG0007594757000025.jpg212170JPEG0007594757000026.jpg200170JPEG0007594757000027.jpg213170JPEG0007594757000028.jpg213170JPEG0007594757000029.jpg213170JPEG0007594757000030.jpg213170JPEG0007594757000031.jpg205170JPEG0007594757000032.jpg215170JPEG0007594757000033.jpg213170JPEG0007594757000034.jpg204170JPEG0007594757000035.jpg214170JPEG0007594757000036.jpg213170JPEG0007594757000037.jpg213170JPEG0007594757000038.jpg213170JPEG0007594757000039.jpg191170JPEG0007594757000040.jpg214170JPEG0007594757000041.jpg214170JPEG0007594757000042.jpg214170JPEG0007594757000043.jpg216170JPEG0007594757000044.jpg215170JPEG0007594757000045.jpg213170JPEG0007594757000046.jpg214170JPEG0007594757000047.jpg200170JPEG0007594757000048.jpg200170JPEG0007594757000049.jpg199170JPEG0007594757000050.jpg201170JPEG0007594757000051.jpg215170JPEG0007594757000052.jpg214170JPEG0007594757000053.jpg213170JPEG0007594757000054.jpg205170JPEG0007594757000055.jpg214170JPEG0007594757000056.jpg186170JPEG0007594757000057.jpg212170JPEG0007594757000058.jpg213170JPEG0007594757000059.jpg213170JPEG0007594757000060.jpg214170JPEG0007594757000061.jpg213170JPEG0007594757000062.jpg214170JPEG0007594757000063.jpg200170JPEG0007594757000064.jpg213170JPEG0007594757000065.jpg204170JPEG0007594757000066.jpg212170JPEG0007594757000067.jpg196170JPEG0007594757000068.jpg213170JPEG0007594757000069.jpg213170JPEG0007594757000070.jpg213170JPEG0007594757000071.jpg196170JPEG0007594757000072.jpg191170JPEG0007594757000073.jpg213170JPEG0007594757000074.jpg205170JPEG0007594757000075.jpg209170JPEG0007594757000076.jpg201170JPEG0007594757000077.jpg201170JPEG0007594757000078.jpg213170JPEG0007594757000079.jpg210170JPEG0007594757000080.jpg191170JPEG0007594757000081.jpg215170JPEG0007594757000082.jpg213170JPEG0007594757000083.jpg214170JPEG0007594757000084.jpg214170JPEG0007594757000085.jpg213170JPEG0007594757000086.jpg213170JPEG0007594757000087.jpg214170JPEG0007594757000088.jpg214170JPEG0007594757000089.jpg196170JPEG0007594757000090.jpg191170JPEG0007594757000091.jpg191170JPEG0007594757000092.jpg214170JPEG0007594757000093.jpg214170JPEG0007594757000094.jpg214170JPEG0007594757000095.jpg214170JPEG0007594757000096.jpg205170JPEG0007594757000097.jpg215170JPEG0007594757000098.jpg215170JPEG0007594757000099.jpg201170JPEG0007594757000100.jpg213170JPEG0007594757000101.jpg206170JPEG0007594757000102.jpg192170JPEG0007594757000103.jpg204170JPEG0007594757000104.jpg213170JPEG0007594757000105.jpg212170JPEG0007594757000106.jpg214170JPEG0007594757000107.jpg214170JPEG0007594757000108.jpg205170JPEG0007594757000109.jpg200170JPEG0007594757000110.jpg200170JPEG0007594757000111.jpg214170JPEG0007594757000112.jpg214170JPEG0007594757000113.jpg205170JPEG0007594757000114.jpg213170JPE G0007594757000115.jpg214170JPEG0007594757000116.jpg213170JPEG0007594757000117.jpg214170JPEG000759475700 0118.jpg197170JPEG0007594757000119.jpg204170JPEG0007594757000120.jpg215170JPEG0007594757000121.jpg2131 70JPEG0007594757000122.jpg214170JPEG0007594757000123.jpg202170JPEG0007594757000124.jpg214170JPEG0007594 757000125.jpg206170JPEG0007594757000126.jpg214170JPEG0007594757000127.jpg214170JPEG0007594757000128.jp g200170JPEG0007594757000129.jpg214170JPEG0007594757000130.jpg214170JPEG0007594757000131.jpg215170JPEG00 07594757000132.jpg214170JPEG0007594757000133.jpg213170JPEG0007594757000134.jpg205170JPEG00075947570001 35.jpg215170JPEG0007594757000136.jpg212170JPEG0007594757000137.jpg214170JPEG0007594757000138.jpg196170.

[0066] Table 2. Structural formulas and names of compounds disclosed herein JPEG0007594757000139.jpg241170JPEG0007594757000140.jpg241170JPEG00075947570 00141.jpg241170JPEG0007594757000142.jpg241170JPEG0007594757000143.jpg241170 JPEG0007594757000144.jpg241170JPEG0007594757000145.jpg241170JPEG00075947570 00146.jpg241170JPEG0007594757000147.jpg241170JPEG0007594757000148.jpg241170 JPEG0007594757000149.jpg241170JPEG0007594757000150.jpg241170JPEG00075947570 00151.jpg241170JPEG0007594757000152.jpg241170JPEG0007594757000153.jpg241170 JPEG0007594757000154.jpg241170JPEG0007594757000155.jpg241170JPEG00075947570 00156.jpg241170JPEG0007594757000157.jpg241170JPEG0007594757000158.jpg241170

[0067] It should be understood that the compounds of formula (I) of the present disclosure may have a stereochemistry and thus may exist as one or more stereoisomers. The present disclosure further relates to compounds of formula (I) in pure or substantially pure isomeric form, e.g., having a stereochemistry of about 90% or greater enantiomeric / diastereomeric excess ("ee"), e.g., about 95% ee or 97% ee or greater, or about 99% ee or greater, and mixtures thereof, including racemic mixtures. Purification of said isomers and separation of said isomeric mixtures can be achieved by standard techniques known in the art, such as asymmetric synthesis (e.g., via chiral intermediates) and / or chiral resolution.

[0068] The present disclosure further provides a pharmaceutical composition comprising a compound of formula (I) according to the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present disclosure further comprise at least one additional medicament for treating or preventing cancer.

[0069] In another aspect of the present disclosure, the compounds of formula (I) or pharmaceutically acceptable salts thereof according to the present disclosure are used as medicines. In another aspect of the present disclosure, the compounds of formula (I) or pharmaceutically acceptable salts thereof according to the present disclosure are used to prevent and / or treat cancer.

[0070] Cancers include, but are not limited to, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer, ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, EGFR-mutated non-small cell lung cancer, lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), colorectal cancer, brain tumor, glioma, glioblastoma, acute myeloid leukemia (AML), and ovarian cancer. In one embodiment of the present disclosure, the compounds of formula (I) or pharmaceutically acceptable salts thereof according to the present disclosure are used to prevent and / or treat lung cancer.

[0071] In one embodiment of the present disclosure, the lung cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), such as anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC), ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, and EGFR-mutated non-small cell lung cancer.

[0072] Another aspect of the present disclosure provides the use of a compound of formula (I) according to the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for preventing and / or treating cancer.

[0073] In one embodiment of the use of the compounds of formula (I) of the present disclosure, the cancer includes, but is not limited to, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer, ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, EGFR-mutated non-small cell lung cancer, lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), colorectal cancer, brain tumor, glioma, glioblastoma, acute myeloid leukemia (AML), and ovarian cancer.

[0074] In one embodiment, the lung cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), such as, for example, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC), ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, and EGFR-mutated non-small cell lung cancer.

[0075] Another aspect of the present disclosure further provides a method for treating or preventing cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present disclosure.

[0076] In the method for treating or preventing cancer according to the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical composition according to the present disclosure is administered to a subject by at least one administration form selected from the group consisting of nasal administration, inhalation administration, topical administration, oral administration, buccal administration, rectal administration, pleural administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration and intravenous administration.

[0077] In one embodiment of the method for treating or preventing cancer according to the present disclosure, the cancer includes, but is not limited to, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer, ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, EGFR-mutated non-small cell lung cancer, lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), colorectal cancer, brain tumor, glioma, glioblastoma, acute myeloid leukemia (AML), and ovarian cancer.

[0078] In one embodiment of the method for treating or preventing cancer according to the present disclosure, the lung cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), such as anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC), ROS1 mutation-positive non-small cell lung cancer, MET-mutated or amplified lung cancer, and EGFR-mutated non-small cell lung cancer.

[0079] definition As used herein, the compounds of formula (I) of the present disclosure may also be referred to, and used interchangeably, as PROTAD (small) molecules, PROTAD compounds that are ALK protein degraders, PROTAD compounds, degraders, ALK PROTAD (compounds) or ALK protein modulators.

[0080] As used herein, the structure of formula (Ia) above is a monovalent chemical moiety formed or derived from crizotinib by removing the single hydrogen atom on the piperidinyl nitrogen. The structure of formula (Ib) above is a monovalent chemical moiety derived from ceritinib by removing the single hydrogen atom on the piperidinyl nitrogen. JPEG0007594757000159.jpg47170

[0081] In this specification, the structures represented by formulas (Ic), (Id) and (Ie) above are all analogs of alectinib. JPEG0007594757000160.jpg62137

[0082] In the present specification, the structures represented by the above formulas (If), (Ig) and (Ih) are all analogs of brigatinib. JPEG0007594757000161.jpg56136

[0083] As used herein, the structure represented by formula (Ii) is a monovalent chemical moiety derived from TAE684 (NVP-TAE684) by removal of the methyl on the piperazinyl nitrogen. JPEG0007594757000162.jpg64143

[0084] As used herein, the structure represented by formula (Ij) is a monovalent chemical moiety derived from ASP3026 by removal of the methyl on the piperazinyl nitrogen. JPEG0007594757000163.jpg64145

[0085] As used herein, the structure represented by formula (Ik) is a monovalent chemical moiety derived from GSK1838705A by removing one or two methyls on the dimethylamino. JPEG0007594757000164.jpg70135

[0086] As used herein, the structure represented by formula (Il) is a monovalent chemical moiety derived from AZD3463 by removing a single hydrogen atom from the primary amino (-NH2). JPEG0007594757000165.jpg51128

[0087] As used herein, the structure represented by formula (Im) is a monovalent chemical moiety derived from Entrectinib (RXDX-101) by removal of the methyl on the piperazinyl nitrogen. JPEG0007594757000166.jpg75162

[0088] As used herein, the structure represented by formula (In) is a monovalent chemical moiety derived from Ensartinib (X-396) by removing the single hydrogen atom on the piperazinyl nitrogen. JPEG0007594757000167.jpg48131

[0089] As used herein, bonds interrupted by wavy lines indicate the attachment points of the groups illustrated. For example, the groups illustrated below are JPEG0007594757000168.jpg39141(Ia) A chemical moiety of formula (Ia) which is connected to the rest of the compound of formula (I) by the piperidinyl N atom.

[0090] As used herein, ULM may represent the structure of formula (II): JPEG0007594757000169.jpg68123

[0091] wherein X represents CH or C(O), Y represents CH, NH, or O, and Z represents carbonyl or is absent. The structure of formula (II) is a derivative of thalidomide, lenalidomide, or pomalidomide. JPEG0007594757000170.jpg35170

[0092] As used herein, ULM may represent the structure of formula (III): JPEG0007594757000171.jpg121116

[0093] wherein Z represents a carbonyl or is absent. The structure of formula (III) is a derivative of VHL-1. JPEG0007594757000172.jpg126167

[0094] As used herein, the terms "LIN" and "linker" may be used interchangeably and both refer to a linking group in a compound of formula (I).

[0095] As used herein, the term "intermediate LM" refers to an intermediate compound in the following process for synthesizing the target compound of the present disclosure by reacting with an ALK-TKI (e.g., a brigatinib derivative, an erlotinib derivative, a ceritinib or a crizotinib derivative).

[0096] As used herein, the terms "halogen atom" or "halogen", alone or in combination, refer to fluoro, chlorine, bromine or iodine, with F, Cl or Br being preferred.

[0097] As used herein, the term "alkyl," alone or in combination, refers to a straight or branched chain alkyl. x -C y ) alkyl" or "C x-y The term "alkyl" (where x and y are each integers) refers to a straight or branched chain alkyl containing x to y carbon atoms. 1~10 "Alkyl" refers to a straight or branched chain alkyl containing 1 to 10 carbon atoms. 1~10 Alkyl is C 1-9 Alkyl or C 1-8 Alkyl or C 2-8 Alkyl or C 1-7 Alkyl or C 1-6 Alkyl, C 1-5 Alkyl or C 1-4 Preferably, it is alkyl. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. In the present disclosure, the term "C 1-3 "Alkyl" refers to alkyl containing 1 to 3 carbon atoms, representative examples of which include methyl, ethyl, n-propyl, and isopropyl.

[0098] As used herein, "alkyl" is optionally substituted, and the substituents include halogen, cyano, C 1-3 Alkyl, C 1-3 It may be one or more selected from the group consisting of alkoxy, trifluoromethyl, heterocyclyl, or any combination thereof.

[0099] As used herein, the term "alkylene" (which may be used interchangeably with "alkylene chain"), alone or in combination, refers to a straight or branched chain divalent saturated hydrocarbon group composed of carbon and hydrogen atoms. x -C y Alkylene" or "C x-y The term "alkylene" (where x and y are each integers) refers to a straight or branched chain alkylene containing x to y carbon atoms. 1- C 30 Alkylene is C1-C 29 Alkylene, C1-C 28 Alkylene, C1-C 27 Alkylene, C1-C 26 Alkylene, C1-C 25 Alkylene, C1-C 24 Alkylene, C1-C 23 Alkylene, C1-C 22 Alkylene, C1-C 21 Alkylene, C1-C 20 Alkylene, C1-C 19 Alkylene, C1-C 18 Alkylene, C1-C 17 Alkylene, C1-C 16 Alkylene, C1-C 15 Alkylene, C1-C 14 Alkylene, C1-C 13 Alkylene, C1-C 12 Alkylene, C1-C 11 Alkylene, C1-C 10It is preferably alkylene, C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene or C1-C2 alkylene. Representative examples include, but are not limited to, methylene, ethylene, propylene, isopropylidene, butylene, isobutylene, sec-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, tert-pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tetradecylene, pentadecylene, hexadecylene, heptadecylene, octadecylene, nonadecylene, eicosylene, heneicosylene, docosylene, tricosylene, tetracosylene, pentacosylene, hexacosylene, heptacosylene, octacosylene, nonacosylene, and triacontylene.

[0100] As used herein, the term "aryl," used alone or in combination, refers to an aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenyl, naphthyl, or fluorenyl. In the present disclosure, "aryl" refers to an optionally substituted aryl. Substituted aryl refers to any group including C 1-3 Alkyl, C 1-3 refers to aryl optionally substituted 1 to 3 times with a substituent selected from the group consisting of alkoxy, halogen, amino, or hydroxyl.

[0101] As used herein, the term "arylene," used alone or in combination, refers to a divalent aromatic hydrocarbon group containing 5 to 14 carbon atoms and optionally one or more fused rings, such as phenylene, naphthylene, or fluorenylene. In the present disclosure, "arylene" refers to an optionally substituted arylene. Substituted arylene refers to any of C 1-3 Alkyl, C 1-3 refers to an arylene optionally substituted 1 to 3 times with a substituent selected from the group consisting of alkoxy, halogen, amino, or hydroxyl.

[0102] As used herein, the term "C" used alone or in combination 1-3 "Alkoxy" refers to a straight or branched chain alkoxy containing 1 to 3 carbon atoms. 1-3 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, and isopropoxy, with methoxy and ethoxy being preferred.

[0103] As used herein, the term "cycloalkyl," alone or in combination, refers to a saturated or partially unsaturated (e.g., not having a fully conjugated π-electron system and containing one or more double bonds) monovalent monocyclic or bicyclic hydrocarbon radical having 3 to 12 carbon atoms. Representative examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decalinyl, octahydropentalenyl, octahydro-1H-indenyl, and spiro-cycloalkyl.

[0104] As used herein, the term "cycloalkylene," used alone or in combination, refers to a saturated or partially unsaturated (e.g., not having a fully conjugated π-electron system and containing one or more double bonds) divalent monocyclic or bicyclic hydrocarbon group having 3 to 12 carbon atoms. Representative examples include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decalinylene, octahydropentalenylene, octahydro-1H-indenylene, and spiro-cycloalkylene.

[0105] As used herein, the term "heteroaryl," used alone or in combination, refers to a 5- to 10-membered monocyclic or bicyclic aromatic ring containing one or more (e.g., 1 to 6, 1 to 5, 1 to 4, or 1 to 3) heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Representative examples of such heteroaryls include furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3] Heteroaryls include, but are not limited to, oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolyl, isoquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 4H-fluoro[3,2-b]pyrrolyl, pyrrolo[2,1-b]thiazolyl, and imidazo[2,1-b]thiazolyl. By definition, heteroaryls may be unsubstituted or substituted. Substituted heteroaryls are preferably C 1-3 Alkyl, C 1-3 refers to heteroaryl optionally substituted 1 to 3 times with substituents selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0106] As used herein, the term "heteroarylene," used alone or in combination, refers to a 5-10 membered monocyclic or bicyclic divalent aromatic ring group containing one or more (e.g., 1 to 6, 1 to 5, 1 to 4, or 1 to 3) heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Representative examples of such heteroarylenes include furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, triazolylene, pyridylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1, 3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolylene, isoquinolylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridylene, 1H-pyrrolo[3,2-b]pyridylene, 1H-pyrrolo[2,3-b]pyridylene, 4H-fluoro[3,2-b]pyrrolylene, pyrrolo[2,1-b]thiazolylene, and imidazo[2,1-b]thiazolylene. By definition, heteroarylene may be unsubstituted or substituted. Substituted heteroarylene is preferably C 1-3 Alkyl, C 1-3 refers to heteroarylene optionally substituted 1 to 3 times with substituents selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0107] As used herein, the term "heterocyclyl," used alone or in combination, refers to a 4-6-membered saturated monocyclic monovalent hydrocarbon group containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Examples of heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidyl, triazolyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and dioxanyl. Heterocyclyl may be unsubstituted or substituted, as specifically defined. Substituted heterocyclyl is preferably C 1-3 Alkyl, C 1-3 refers to a heterocyclyl optionally substituted 1 to 3 times with a substituent selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0108] As used herein, the term "heterocyclylene," used alone or in combination, refers to a 4-6-membered saturated monocyclic divalent hydrocarbon group containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Examples of heterocyclylene include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidine, triazolylene, tetrahydrofuranylene, tetrahydrothienylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, and dioxanylene. Heterocyclylene may be unsubstituted or substituted, as specifically defined. Substituted heterocycloalkylene is preferably C 1-3 Alkyl, C 1-3 refers to heterocycloalkylene optionally substituted 1 to 3 times with substituents selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0109] As used herein, the term "spiro-cycloalkylene," used alone or in combination, refers to a divalent alicyclic hydrocarbon group derived by removing two hydrogen atoms from one or two free valence carbon atoms of an alicyclic hydrocarbon group in which two rings share one common carbon atom. A representative example is spiro[3.3]heptanylene. JPEG0007594757000173.jpg32143Includes, but is not limited to, spiro[4.5]decanylene, spiro[5.5]undecanylene, 4-methylspiro[2.4]heptanylene, and the like.

[0110] As used herein, the term "alkynyl," alone or in combination, refers to a straight- or branched-chain hydrocarbon group containing one or more carbon-carbon triple bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and 1,3-dialkynyl.

[0111] As used herein, the term "alkynylene," alone or in combination, refers to a straight- or branched-chain divalent hydrocarbon group containing one or more carbon-carbon triple bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkynylene include, but are not limited to, ethynylene, 1-propynylene, 1-butynylene, and 1,3-diynylene.

[0112] As used herein, the term "alkenyl," used alone or in combination, refers to a straight- or branched-chain hydrocarbon group containing one or more carbon-carbon double bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, and 1-butenyl.

[0113] As used herein, the term "alkenylene," used alone or in combination, refers to a straight- or branched-chain divalent hydrocarbon group containing one or more carbon-carbon double bonds and containing 2 to 10 (e.g., 2 to 6 or 2 to 4) carbon atoms. Examples of alkenylene include, but are not limited to, vinylidene (e.g., -CH=CH-), 1-propenylene, and 1-butenylene. Salts or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, and crystalline polymorphs of the compounds of Formula I according to the present disclosure are also within the scope of the present invention.

[0114] In all embodiments of the present disclosure, salts or pharmaceutically acceptable salts of compounds of Formula I refer to non-toxic inorganic or organic acid and / or base addition salts, including, but not limited to, sulfate, hydrochloride, citrate, maleate, sulfonate or paratoluenesulfonate salts, etc.

[0115] A "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable substance, such as a filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or sealant. A useful compound according to the present disclosure can be carried or transported into a patient's body or administered to a patient together with a pharmaceutically acceptable carrier to perform its desired function. Typically, such structures are carried or transported from one organ or part of the body to another organ or part of the body. A carrier must be "acceptable" in the sense of being compatible with the other ingredients of a formulation containing a compound useful in the present disclosure and not harmful to the patient. Some examples of substances used as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate, excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter, and suppository waxes, oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil, glycols such as propylene glycol, polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, buffers such as magnesium hydroxide and aluminum hydroxide, surfactants, phosphate buffers, and other commonly used non-toxic compatible substances used in pharmaceuticals.

[0116] A "therapeutically effective amount" of a compound of the present disclosure will depend on the age, sex, and weight of the patient, the patient's current medical condition, and the progression of the cancer in the patient being treated. One of ordinary skill in the art will be able to determine the appropriate dosage based on these and other factors. The term "room temperature" as used herein refers to ambient temperature, for example, a temperature of 20 to 30°C.

[0117] The compounds developed in this invention are specific proteolytic agents consisting of three parts: a target protein anchoring moiety, a proteolytic system (e.g., E3 ligase) recruitment moiety, and a linker. In this disclosure, we developed a degrader that targets ALK protein by using an ALK protein-targeting inhibitor as the anchoring moiety and attaching an E3 ligase ligand to the ALK protein inhibitor via a linker. By specifically recognizing the target protein, ALK-TKI inhibits ALK protein phosphorylation, and E3 ligase specifically ubiquitinates ALK protein for degradation and elimination, ultimately resulting in the removal of the target protein from tumor cells. Because ALK mutation-positive lung cancer cells are highly dependent on the presence and activity of ALK protein, completely degrading ALK protein and suppressing remaining ALK activity may not only inhibit tumor development and progression but also overcome resistance to targeted drugs. Furthermore, the degraders designed and developed in this invention can target and inhibit other tyrosine kinase receptors, including ROS1, c-MET, insulin receptor, IGFIR, and EGFR, which harbor mutations that drive lung cancer. The compounds developed in this study offer potential alternative treatments for cancers positive for these targets. This research offers a new therapeutic strategy for lung cancer patients with precision medicine. Example

[0118] In order to provide a thorough understanding of the present invention, numerous specific details are set forth below. The present invention may be practiced without some or all of these specific details. In other instances, well-known process operations have not been described in detail so as not to unnecessarily obscure the present invention. While the present invention will be described with reference to certain examples, it should be understood that the present invention is not intended to be limited by these examples.

[0119] The following abbreviations are used throughout the descriptions and examples: JPEG0007594757000174.jpg156170

[0120] In the present disclosure, 1The H NMR spectrum was measured on a Bruker 500 MHz nuclear magnetic resonance spectrometer using CD3OD containing 0.1% TMS as the solvent. 1 For H NMR spectra, CD3OD (δ = 3.31 ppm) was used as the internal standard. Alternatively, when CDCl3 containing 0.1% TMS was used as the solvent, 1 For H NMR spectra, CDCl3 (δ = 7.26 ppm) was used as the internal standard. Alternatively, when DMSO-d6 containing 0.03% TMS was used as the solvent, 1 1 H NMR spectra were measured using DMSO-d (δ = 2.50 ppm) as an internal standard. LRMS spectra were measured using an AB Triple 4600 mass spectrometer, HPLC purity was measured using a Shimadzu LC-20AP, and HPLC purity was measured using a Shimadzu LC-30AP or a Waters 1525. Unless otherwise specified, all reactions were carried out in an air atmosphere and followed by TLC or LC-MS. The solvents and reagents are as follows:

[0121] Solvents used in the reaction: DCM, DMF, absolute EtOH and absolute MeOH purchased from Chinese Sinopharm Group. Preparative grade CH3CN and deionized water were used for HPLC preparations.

[0122] Unless otherwise stated, alectinib, alectinib analog A, crizotinib, ceritinib, brigatinib, TAE684 (NVP-TAE684), ASP3026, GSK1838705A, AZD3463, entrectinib (RXDX-101), ensartinib (X-396) and the various carbon chain linking units (linker groups of the compounds of formula (I) of the present disclosure) may be purchased directly. Other reagents and medicines were purchased from the manufacturers and used as received unless otherwise stated.

[0123] General synthetic procedure General synthetic procedure for brigatinib analogues A, B and C (ALK inhibitors) JPEG0007594757000175.jpg93170 where groups X and Y are as shown in Scheme 1.

[0124] General synthesis procedure for alectinib analogues B and C (ALK inhibitors): JPEG0007594757000176.jpg51170 where groups X and Y are as shown in Scheme 2.

[0125] Alectinib analog A (9-ethyl-6,6-dimethyl-11-oxo-8-(piperazin-1-yl)-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile) may also be purchased directly. General procedure for the synthesis of intermediate LM (pomalidomide PEG linker): JPEG0007594757000177.jpg35170 where n is an integer from 1 to 5, as shown in Scheme 3.

[0126] General procedure for the synthesis of intermediate LM (pomalidomide alkyl carbon chain linker) JPEG0007594757000178.jpg35170 where n is an integer from 0 to 5, as shown in Scheme 4.

[0127] General procedure for the synthesis of intermediate LM (VHL-1 PEG linker): JPEG0007594757000179.jpg37170 where n is an integer from 0 to 10, as shown in Scheme 5.

[0128] General procedure for the synthesis of intermediate LM (VHL-1 alkyl carbon chain linker): JPEG0007594757000180.jpg38170 where n is an integer from 0 to 7, as shown in Scheme 6.

[0129] General procedure for the synthesis of intermediate LM (lenalidomide carbonyl alkyl carbon chain linker): JPEG0007594757000181.jpg49170 where n is an integer from 1 to 5, as shown in Scheme 7.

[0130] General synthetic procedure for intermediate LM (lenalidomide alkyl carbon chain linker) JPEG0007594757000182.jpg49170 where n is an integer from 1 to 20, as shown in Scheme 8.

[0131] General procedure for the synthesis of special intermediate LM (SIAIS151103): JPEG0007594757000183.jpg63170

[0132] General procedure for the synthesis of special intermediate LM (SIAIS164119): JPEG0007594757000184.jpg52170

[0133] General procedure for the synthesis of special intermediate LM (SIAIS164050): JPEG0007594757000185.jpg80170

[0134] General procedure for the synthesis of special intermediate LM (SIAIS164128): JPEG0007594757000186.jpg67170

[0135] General synthetic procedure for special intermediate LM (SIAIS219048): JPEG0007594757000187.jpg41170 where n is 7, as shown in Scheme 13.

[0136] General synthetic procedure for special intermediate LM (SIAIS172147): JPEG0007594757000188.jpg74170

[0137] General procedure for the synthesis of compounds in this patent: JPEG0007594757000189.jpg113170

[0138] Intermediate example Intermediate Example 1: Synthesis of Brigatinib Analogue A (SIAIS1197135) Brigatinib analog A (SIAIS1197135) was synthesized according to Scheme 1.

[0139] Synthesis of tert-butyl 4-(3-methoxy-4-nitrophenyl)piperazine-1-carboxylate (SIAIS1197111): To a solution of 5-fluoro-2-nitroanisole (7 g, 40.9 mmol) in DMF (60 mL) was added K2CO3 (8.4 g, 60.8 mmol) and piperazine-1-tert-butylcarboxylate (9.1 g, 48.9 mmol) at room temperature under air. After stirring overnight at the same temperature, the reaction mixture was quenched with water, extracted with ethyl acetate, washed with brine, and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the residue was purified by recrystallization (eluent: petroleum ether / ethyl acetate = 5:1) to give SIAIS1197111 as a yellow solid in 80% yield (11.1 g). 1 H NMR (500 MHz, DMSO) δ 7.89 (d, J = 9.3 Hz, 1H), 6.57 (d, J = 9.5 Hz, 1H), 6.52 (s, 1H), 3.90 (s, 3H), 3.46 (s, 8H), 1.42 (s, 9H). HRMS (ESI) C 16 H 24 N3O5 + [M+H] + Calculated value: 338.1710, measured value: 338.1610. Synthesis of tert-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate (SIAIS1197129):

[0140] To a stirred solution of SIAIS1197111 (10 g, 29.6 mmol) in EtOH (90 mL) and HO (30 mL) was added NH4Cl (6.3 g, 118.6 mmol) and iron powder (8.3 g, 148.2 mmol). The resulting mixture was then refluxed at 80 °C under a nitrogen atmosphere for 2 h. After the reaction was complete, the crude mixture was cooled to room temperature, filtered through silica, and the solvent was evaporated and extracted with DCM (3 × 50 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo to give SIAIS1197129 as a gray solid in 85% yield (7.7 g). 1 H NMR (500 MHz, MeOD) δ 6.72 (d, J = 8.3 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 6.47 (d, J = 7.0 Hz, 1H), 3.86 (s, 3H), 3.57 (s, 4H), 2.99 (s, 4H), 1.50 (s, 9H). HRMS (ESI) C 16 H 26 N3O3 + [M+H] + Calculated value: 308.1969, measured value: 308.1882.

[0141] Synthesis of (2-((5-chloro-2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (SIAIS1197135):

[0142] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (2 g, 6.3 mmol) in DMF (30 mL) was added SIAIS1197129 (2.4 g, 7.8 mmol), Pd(OAc) (176 mg, 0.78 mmol), Xantphos (810 mg, 1.4 mmol), and CsCO (6.4 g, 19.6 mmol) in a microwave tube. The solution was purged and refilled with nitrogen three times. The mixture was then stirred in a microwave oven at 110 °C for 2 h. After the starting material was consumed, the reaction mixture was filtered through a silica gel pad, and most of the solvent in the filtrate was removed under reduced pressure. The mixture was then quenched with water, extracted with ethyl acetate, washed with water and brine, and dried over anhydrous NaSO. The solvent was evaporated under reduced pressure and the residue purified by reverse phase ISCO (C18) to give the title compound (900 mg) as a brown solid.

[0143] To a solution of the above compound (900 mg) in DCM (6 mL) was added TFA (2 mL) under air. The resulting solution was stirred at room temperature for 1 h. Afterwards, most of the solvent was removed under reduced pressure, and the pH of the solution was adjusted to 8-9 with saturated NaHCO3 solution. The extract was then extracted with DCM and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the residue was purified by reverse-phase ISCO (C18) using MeOH / water (v / v) in a ratio of 10% to 100% to give a yellow solid, SIAIS1197135 (701 mg, 23% yield for two steps). 1 H NMR (500 MHz, MeOD) δ 8.32 (dd, J = 8.2, 4.4 Hz, 1H), 8.04 (s, 1H), 7.70 (d, J = 8.7 Hz, 1H), 7.61 (dd, J = 14.1, 7.7 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 7.26 (t, J = 7.5, 1H), 6.67 (d, J = 2.5 Hz, 1H), 6.45 (dd, J = 8.8, 2.5 Hz, 1H), 3.86 (s, 3H), 3.24 - 3.17 (m, 4H), 3.17 - 3.11 (m, 4H), 1.83 (d, J = 13.5 Hz, 6H). HRMS (ESI) C23 H 29 ClN6O2P + [M+H] + Calculated value: 487.1773, Measured value: 487.1773. Intermediate Example 2: Synthesis of Brigatinib Analogue B

[0144] Brigatinib analog B was synthesized in a similar manner to the preparation of brigatinib analog A in Intermediate Example 1 according to Scheme 1. The synthesis data and structural property data are as follows: JPEG0007594757000190.jpg68165

[0145] tert-Butyl (1-(3-methoxy-4-nitrophenyl)piperazin-4-yl)carbamate (SIAIS151054). (yellow solid, 1.81 g, 88%) 1 H NMR (500 MHz, CDCl3) δ 7.99 (t, J = 8.9 Hz, 1H), 6.41 (dd, J = 9.4, 2.5 Hz, 1H), 6.30 (d, J = 2.5 Hz, 1H), 4.49 (s, 1H), 3.94 (s, 3H), 3.86 - 3.82 (m, 2H), 3.71 (s, 1H), 3.09 - 3.00 (m, 2H), 2.11 - 2.03 (m, 2H), 1.89 - 1.75 (m, 2H), 1.45 (s, 9H). JPEG0007594757000191.jpg42139

[0146] tert-Butyl (1-(4-amino-3-methoxyphenyl)piperazin-4-yl)carbamate (SIAIS151062). (Gray solid, 411.6 mg, 90%) 1H NMR (500 MHz, DMSO) δ 6.82 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.48 (d, J = 2.5 Hz, 1H), 6.28 (dd, J = 8.4, 2.4 Hz, 1H), 4.20 (s, 2H), 3.73 (s, 3H), 3.33 - 3.26 (m, 3H), 2.56 - 2.50 (m, 2H), 1.77 (d, J = 11.4 Hz, 2H), 1.53 - 1.45 (m, 2H), 1.39 (s, 9H). JPEG0007594757000192.jpg47123

[0147] (2-((2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (SIAIS151101). (Yellow solid, 330 mg, 33% yield over two steps) 1 H NMR (500 MHz, DMSO) δ 8.49 (s, 1H), 8.08 (s, 1H), 8.06 (s, 1H), 7.53 (ddd, J = 14.0, 7.7, 1.3 Hz, 1H), 7.38 - 7.32 (m, 2H), 7.10 (t, J = 7.1 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.46 (dd, J = 8.7, 2.5 Hz, 1H), 3.75 (s, 3H), 3.65 - 3.61 (m, 2H), 2.78 - 2.67 (m, 3H), 1.82 - 1.79 (m, 2H), 1.78 (s, 3H), 1.75 (s, 3H), 1.42 - 1.34 (m, 2H). HRMS (ESI) C 24 H 31 ClN6O2P [M+H] + Calculated value: 501.1913, measured value: 501.1900. Intermediate Example 3: Synthesis of Brigatinib Analogue C

[0148] Brigatinib analog C was synthesized in a similar manner to the preparation of brigatinib analog A in Intermediate Example 1 according to Scheme 1. The synthesis data and structural property data are as follows: JPEG0007594757000193.jpg49138

[0149] tert-Butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (SIAIS151059). (yellow solid, 1.02 g, 83%) 1 H NMR (500 MHz, MeOD) δ 7.93 (d, J = 9.4 Hz, 1H), 6.55 (dt, J = 13.4, 6.7 Hz, 1H), 6.50 (d, J = 2.5 Hz, 1H), 4.10 (s, 1H), 4.07 (s, 1H), 3.94 (d, J = 6.6 Hz, 3H), 3.43 (s, 4H), 3.02 - 2.93 (m, 2H), 2.60 - 2.55 (m, 5H), 2.02 - 1.95 (m, 2H), 1.57 (qd, J = 12.4, 4.0 Hz, 2H), 1.46 (s, 9H). HRMS (ESI) C 21 H 33 N4O5[M+H] + Calculated value: 421.2445, measured value: 421.2442. JPEG0007594757000194.jpg47116

[0150] tert-Butyl 4-(1-(4-amino-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (SIAIS164003). (Gray solid, 745 mg, 79%). 1H NMR (500 MHz, MeOD) δ 6.59 (t, J = 56.8 Hz, 3H), 3.78 (s, 3H), 3.46 (s, 6H), 2.62 (d, J = 4.3 Hz, 6H), 2.42 (s, 1H), 1.98 (s, 2H), 1.69 (d, J = 9.7 Hz, 2H), 1.46 (s, 9H). HRMS (ESI) C 21 H 35 N4O3[M+H] + Calculated value: 391.2704, measured value: 391.3048. JPEG0007594757000195.jpg56154

[0151] (2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide. (SIAIS164005). (Yellow solid, 350 mg, 37% yield over two steps). 1 H NMR (500 MHz, MeOD) δ 8.33 (dd, J = 8.2, 4.4 Hz, 1H), 8.03 (s, 1H), 7.69 - 7.64 (m, 1H), 7.60 (ddd, J = 14.0, 7.7, 1.4 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.26 (td, J = 7.6, 1.2 Hz, 1H), 6.66 (d, J = 2.4 Hz, 1H), 6.45 (dd, J = 8.8, 2.5 Hz, 1H), 3.85 (s, 3H), 3.73 - 3.63 (m, 2H), 3.11 - 3.02 (m, 4H), 2.79 - 2.66 (m, 6H), 2.48-2.43 (m, 1H), 1.99 (d, J = 12.5 Hz, 2H), 1.84 (d, J = 13.5 Hz, 6H), 1.72-1.63 (m, 2H). HRMS (ESI) C 28 H 38 ClNOP [M+H] + Calculated value: 570.2508, measured value: 570.2498. Intermediate Example 4: Synthesis of Alectinib Analogue B (SIAIS184193)

[0152] Alectinib analog B, 8-(4-aminopiperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile (SIAIS184193), was synthesized according to Scheme 2. JPEG0007594757000196.jpg41130

[0153] A 25 mL egg-shaped flask was charged with 9-ethyl-8-iodo-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile (440 mg, 1 mmol), 4-tert-butoxycarbonylaminopiperidine (377 mg, 1.4 mmol), Pd(dba) (45.8 mg, 0.05 mmol), Sphos (82.1 mg, 0.2 mmol), and dioxane (10 mL) at room temperature. The mixture was evacuated and purged with argon. NaHMDS (4 mL, 4 mmol, 1.0 M in THF) was added, and the mixture was heated to 60 °C and stirred for 5 h. When the reaction was complete as determined by TLC, the resulting solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (eluent: hexane / EA = 1:1) to give a brown solid.

[0154] To a solution of the brown solid (350 mg) in DCM (6 mL) was added TFA (2 mL) under air. The resulting solution was stirred at room temperature for 1 h. Afterwards, most of the solvent was removed under reduced pressure, and the pH of the solution was adjusted to 8-9 with saturated NaHCO3 solution. The extract was then extracted with DCM and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by reverse-phase ISCO (C18) using MeOH / water (v / v) 10%-100% to give the desired product SIAIS184193 (310 mg, 60% yield for two steps) as a yellow solid. 1H NMR (500 MHz, DMSO) δ 12.91 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 4.2 Hz, 2H), 8.05 (d, J = 8.2 Hz, 1H), 8.01 (s, 1H), 7.61 (dd, J = 8.1, 1.3 Hz, 1H), 7.38 (s, 1H), 3.22 (d, J = 12.2 Hz, 3H), 2.86 (t, J = 11.4 Hz, 2H), 2.70 (q, J = 7.5 Hz, 2H), 2.06 (d, J = 10.0 Hz, 2H), 1.81 - 1.73 (m, 8H), 1.28 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 26 H 29 NO [M+H] + Calculated value: 413.2336, measured value 413.2339. Intermediate Example 5: Synthesis of Alectinib Analogue C

[0155] According to Scheme 2, Alectinib analog C was synthesized by a similar procedure to prepare Alectinib analog B in Intermediate Example 4. The structural property data are as follows: JPEG0007594757000197.jpg45124

[0156] 9-Ethyl-6,6-dimethyl-11-oxo-8-(4-(piperazin-1-yl)piperidin-1-yl)-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS184192) (yellow solid, 280 mg, 48%) 1H NMR (500 MHz, DMSO) δ 12.76 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.01 (s, 1H), 7.61 (d, J = 9.0 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 3.94 (s, 8H), 3.61 (s, 1H), 3.49 - 3.29 (m, 4H), 2.70 (q, J = 7.8 Hz, 2H), 1.76 (s, 6H), 1.61 (s, 4H), 1.28 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 30 H 36 NO [M+H] + Calculated value: 482.2914, measured value 482.2911.

[0157] Intermediate Example 6: Synthesis of 3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoic acid (SIAIS151001)

[0158] According to Scheme 3, a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (5 mmol, 1 equiv.), tert-butyl 3-(2-aminoethoxy)propionate (6 mmol, 1.2 equiv.), and DIPEA (25 mmol, 5 equiv.) in NMP (8 mL) was stirred at room temperature for 10 minutes in a 30 mL microwave tube, then filled with argon and heated to 110 °C for 2 hours in a microwave reactor. After cooling to RT, the reaction mixture was poured into 90% saline and extracted with EA (4 × 50 mL). The combined organic phases were washed with water (2 × 30 mL), brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent: hexane / EA = 1:1) to give the desired tert-butyl ester intermediate. This intermediate was treated with 88% formic acid (20 mL) at room temperature overnight. After concentration under reduced pressure and lyophilization, the desired product SIAIS151001 (1.0 g, 48% yield) was obtained as a yellow solid. 1H NMR (500 MHz, DMSO) δ 12.17 (s, 1H), 11.09 (s, 1H), 7.57 (dd, J = 8.5, 7.5 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.59 (t, J = 5.7 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.65 (t, J = 6.3 Hz, 2H), 3.59 (t, J = 5.5 Hz, 2H), 3.46 (q, J = 5.5 Hz, 2H), 2.91 - 2.83 (m, 1H), 2.61 - 2.52 (m, 2H), 2.46 (t, J = 6.3 Hz, 2H), 2.05 - 2.00 (m, 1H). HRMS (ESI) C 18 H 20 N3O7 + [M + H] + Calculated value: 390.1301, measured value: 390.1261.

[0159] Intermediate Example 7: Synthesis of 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoic acid (SIAIS151004)

[0160] Following the procedure for preparing Intermediate Example 6, tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propionate was used to prepare SIAIS151004 (yellow solid, 0.95 g, 51% yield). 1H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 7.58 (dd, J = 8.0, 7.5 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.60 (t, J = 5.7 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.62 - 3.58 (m, 4H), 3.56 - 3.54 (m, 2H), 3.52 - 3.49 (m, 2H), 3.46 (dd, J = 11.1, 5.5 Hz, 2H), 2.92 - 2.84 (m, 1H), 2.66 - 2.51 (m, 2H), 2.42 (t, J = 6.4 Hz, 2H), 2.06 - 1.98 (m, 1H). HRMS (ESI) C 20 H 24 N3O8 + [M + H] + Calculated value: 434.1558, measured value: 434.1445.

[0161] Intermediate Example 8: Synthesis of 3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoic acid (SIAIS151005)

[0162] SIAIS151005 (yellow solid, 0.95 g, 61% yield) was prepared using tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propionate in the procedure for preparing Intermediate Example 6. 1H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 7.58 (dd, J = 8.0, 7.0 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.61 (t, J = 5.8 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.63 - 3.48 (m, 14H), 2.92 - 2.83 (m, 1H), 2.64 - 2.52 (m, 2H), 2.18 (t, J = 8.1 Hz, 2H), 2.07 - 1.99 (m, 1H). HRMS (ESI) C 22 H 28 N3O9 + [M + H] + Calculated value: 478.1820, measured value: 478.1159.

[0163] Intermediate Example 9: Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid (SIAIS151006)

[0164] SIAIS151006 (yellow solid, 0.87 g, 53% yield) was prepared using tert-butyl 1-amino-3,6,9,12-tetraoxapentadecan-15-oate following the procedure for preparing Intermediate Example 6. 1 H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 7.58 (dd, J = 8.5, 7.5 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.60 (t, J = 5.7 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.63 - 3.48 (m, 18H), 2.92 - 2.84 (m, 1H), 2.63 - 2.52 (m, 2H), 2.41 (t, J = 6.4 Hz, 2H), 2.07 - 1.98 (m, 1H). HRMS (ESI) C 24 H32 N3O 10 + [M + H] + Calculated value: 522.2082, measured value: 522.2178.

[0165] Intermediate Example 10: Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecanoic-18-oic acid (SIAIS151007)

[0166] SIAIS151007 (yellow solid, 0.8 g, 51%) was prepared using tert-butyl 1-amino-3,6,9,12,15-pentaoxaoctadecanoate following the procedure for preparing Intermediate Example 6. 1 H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.60 (t, J = 5.7 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.63 - 3.54 (m, 8H), 3.54 - 3.48 (m, 12H), 3.30 (dd, J = 7.0 Hz, 4H), 2.92 - 2.84 (m, 1H), 2.63 - 2.52 (m, 2H), 2.06 - 1.99 (m, 1H). HRMS (ESI) C 26 H 36 N3O 11 + [M + H] + Calculated value: 566.2344, measured value: 566.2679. Intermediate Example 11: Synthesis of (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine (SIAIS151025)

[0167] According to Scheme 4, a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (7 mmol, 1 equiv.), tert-butyl 3-(2-aminoethoxy)propionate (8.4 mmol, 1.2 equiv.), and DIPEA (35 mmol, 5 equiv.) in NMP (8 mL) was stirred at room temperature for 10 minutes in a microwave tube, then filled with argon and heated to 110 °C for 2 hours in a microwave reactor. After cooling to RT, the reaction mixture was poured into 90% saline and extracted with ethyl acetate (4 × 50 mL). The combined organic phases were washed with water (2 × 30 mL), brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent (v / v): hexane / EA = 1:1) to give the desired tert-butyl ester intermediate. This intermediate was treated with 88% formic acid (20 mL) at room temperature overnight. After concentration under reduced pressure and lyophilization, the desired product SIAIS151025 (1.2 g, 48% yield) was obtained as a yellow solid. 1 H NMR (500 MHz, DMSO) δ 11.10 (s, 1H), 7.59 (dd, J = 15.9, 8.5 Hz, 1H), 7.07 (d, J = 7.0 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H), 6.86 (t, J = 5.7 Hz, 1H), 5.06 (dt, J = 15.1, 7.6 Hz, 1H), 4.08 (d, J = 5.7 Hz, 2H), 2.92 - 2.84 (m, 1H), 2.63 - 2.52 (m, 2H), 2.07 - 2.02 (m, 1H). HRMS (ESI) C 18 H 20 N3O6 + [M + H] + Calculated value: 332.0877, measured value: 332.0720.

[0168] Intermediate Example 12: Synthesis of 3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoic acid (SIAIS151026)

[0169] Following the procedure for preparing Intermediate Example 11, tert-butyl 3-amino-propionate was used to prepare SIAIS151026 (yellow solid, 0.93 g, 39% yield). 1 H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 7.59 (dd, J = 8.0, 7.5 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.67 (t, J = 6.0 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.53 (dd, J = 12.6, 6.3 Hz, 2H), 2.92 - 2.84 (m, 1H), 2.65 - 2.53 (m, 4H), 2.08 - 1.98 (m, 1H). HRMS (ESI) C 16 H 16 N3O6 + [M + H] + Calculated value: 346.1034, measured value: 346.0868.

[0170] Intermediate Example 13: Synthesis of 4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoic acid (SIAIS151019)

[0171] Following the procedure for preparing Intermediate Example 11, tert-butyl 4-amino-butanoate was used to prepare SIAIS151019 (yellow solid, 0.8 g, 61% yield). 1H NMR (500 MHz, DMSO) δ 12.14 (s, 1H), 11.09 (s, 1H), 7.58 (dd, J = 8.4, 7.3 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.65 (t, J = 6.0 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.32 (dd, J = 13.7, 6.7 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.66 - 2.51 (m, 2H), 2.30 (t, J = 7.2 Hz, 2H), 2.05 - 2.00 (m, 1H), 1.82 - 1.75 (m, 2H). HRMS (ESI) C 17 H 18 N3O6 + [M + H] + Calculated value: 360.1190, measured value: 360.1223.

[0172] Intermediate Example 14: Synthesis of 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoic acid (SIAIS151020)

[0173] Following the procedure for preparing Intermediate Example 11, tert-butyl 5-amino-pentanoate was used to prepare SIAIS151020 (yellow solid, 0.9 g, 50% yield). 1H NMR (500 MHz, DMSO) δ 12.05 (s, 1H), 11.11 (s, 1H), 7.57 (dd, J = 8.3, 7.4 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.56 (t, J = 5.9 Hz, 1H), 5.05 (dd, J = 12.7, 5.4 Hz, 1H), 3.32 - 3.28 (m, 2H), 2.94 - 2.82 (m, 1H), 2.62 - 2.51 (m, 2H), 2.27 - 2.25 (m, 2H), 2.06 - 1.99 (m, 1H), 1.62 - 1.53 (m, 4H). HRMS (ESI) C 18 H 20 N3O6 + [M + H] + Calculated value: 374.1347, measured value: 374.1384.

[0174] Intermediate Example 15: Synthesis of 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoic acid (SIAIS151027)

[0175] Following the procedure for preparing Intermediate Example 11, tert-butyl 6-amino-hexanoate was used to prepare SIAIS151027 (yellow solid, 1.26 g, 61% yield). 1H NMR (500 MHz, DMSO) δ 12.00 (s, 1H), 11.09 (s, 1H), 7.58 (dd, J = 8.3, 7.4 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.54 (t, J = 5.9 Hz, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.30 - 3.27 (m, 2H), 2.92 - 2.84 (m, 1H), 2.63 - 2.51 (m, 2H), 2.21 (t, J = 7.5Hz, 2H), 2.08 - 1.98 (m, 1H), 1.60 - 1.50 (m, 4H), 1.38 - 1.31 (m, 2H). HRMS (ESI) C 19 H 22 N3O6 + [M + H] + Calculated value: 388.1503, measured value: 388.1119.

[0176] Intermediate Example 16: Synthesis of 7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoic acid (SIAIS151086)

[0177] Following the procedure for preparing Intermediate Example 11, tert-butyl 7-amino-heptanoate was used to prepare SIAIS151086 (yellow solid, 1.3 g, 64% yield). 1H NMR (500 MHz, DMSO) δ 12.04 (s, 1H), 11.09 (s, 1H), 7.58 (dd, J = 8.3, 7.3 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.53 (t, J = 5.9 Hz, 1H), 5.05 (dd, J = 12.7, 5.4 Hz, 1H), 3.28 (dd, J = 13.4, 6.7 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.65 - 2.51 (m, 2H), 2.19 (t, J = 7.3 Hz, 2H), 2.05 - 2.00 (m, 1H), 1.60 - 1.53 (m, 2H), 1.53 - 1.46 (m, 2H), 1.37 - 1.28 (m, 4H). HRMS (ESI) C 20 H 24 N3O6 + [M + H] + Calculated value: 402.1660, measured value: 402.1643.

[0178] Intermediate Example 17: Synthesis of 2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)acetic acid (SIAIS151010)

[0179] According to Scheme 5, NMM (10.0 mmol, 5 equiv.), VHL-1 (2 mmol, 1 equiv.), HOAt (2.4 mmol, 1.2 equiv.), and EDCI (2.4 mmol, 1.2 equiv.) were added to a solution of the diacid (2,2'-(ethane-1,2-diylbis(oxy))diacetic acid, 5.0 mmol, 2.5 equiv.) in anhydrous DMF (10 mL) and anhydrous DCM (150 mL) at 0 °C. The resulting reaction solution was stirred at 0 °C for 5 h and then at room temperature overnight. After complete consumption of VHL-1, the reaction was quenched with water (1 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography using acetonitrile / (water + 0.1% TFA) as an eluent (v / v) from 10% to 100% to give the desired product SIAIS151010 (0.2 g, 23%) as a white solid. 1 H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.60 (t, J = 5.9 Hz, 1H), 7.48 (d, J = 9.5 Hz, 1H), 7.40 (s, 4H), 4.57 (d, J = 9.6 Hz, 1H), 4.47 - 4.37 (m, 2H), 4.35 (s, 1H), 4.29 - 4.22 (m, 1H), 4.07 (d, J = 12.5 Hz, 1H), 3.97 (s, 2H), 3.69 - 3.59 (m, 8H), 2.44 (s, 3H), 2.07 - 2.03 (m, 1H), 1.93 - 1.87 (m, 1H), 0.94 (s, 9H). HRMS (ESI) C 28 H 39 N4O8S + [M + H] + Calculated value: 591.2483, measured value: 591.2365.

[0180] Intermediate Example 18: Synthesis of 3-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)propanoic acid (SIAIS151002)

[0181] SIAIS151002 (white solid, 0.53 g, 44% yield) was prepared using the procedure for preparing Intermediate Example 17, using 3,3'-(ethane-1,2-diylbis(oxy))dipropionic acid. 1 H NMR (500 MHz, DMSO) δ 12.17 (s, 1H), 8.99 (s, 1H), 8.57 (t, J = 6.0 Hz, 1H), 7.92 (d, J = 9.3 Hz, 1H), 7.41 (dd, J = 18.5, 8.2 Hz, 4H), 4.55 (d, J = 9.5 Hz, 1H), 4.46 - 4.40 (m, 2H), 4.36 (s, 1H), 4.23 (dd, J = 15.8, 5.4 Hz, 1H), 3.69 - 3.56 (m, 7H), 3.49 - 3.46 (m, 4H), 2.58 - 2.53 (m, 1H), 2.47 - 2.42 (m, 2H), 2.45 (s, 3H), 2.39 - 2.32 (m, 1H), 2.06 - 2.01 (m, 1H), 1.95 - 1.88 (m, 1H), 0.94 (s, 9H). HRMS (ESI) C 30 H 43 N4O8S + [M + H] + Calculated value: 619.2796, measured value: 619.2973.

[0182] Intermediate Example 19: Synthesis of (S)-15-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-16,16-dimethyl-13-oxo-4,7,10-trioxa-14-azaheptadecanoic acid (SIAIS151003)

[0183] SIAIS151003 (white solid, 0.63 g, 59% yield) was prepared using the procedure for preparing Intermediate Example 17 and 3,3′-((oxybis(ethane-2,1-diyl))bis(oxy))dipropionic acid. 1H NMR (500 MHz, DMSO) δ 8.99 (s, 1H), 8.57 (t, J = 6.0 Hz, 1H), 7.92 (d, J = 9.4 Hz, 1H), 7.41 (dd, J = 18.5, 8.2 Hz, 4H), 4.56 (d, J = 9.4 Hz, 1H), 4.47 - 4.41 (m, 2H), 4.36 (s, 1H), 4.23 (dd, J = 15.9, 5.5 Hz, 1H), 3.70 - 3.57 (m, 8H), 3.51 - 3.47 (m, 7H), 2.58 - 2.52 (m, 1H), 2.47 - 2.42 (m, 2H), 2.45 (s, 3H), 2.39 - 2.32 (m, 1H), 2.08 - 2.00 (m, 1H), 1.94 - 1.88 (m, 1H), 0.94 (s, 9H). HRMS (ESI) C 32 H 47 N4O9S + [M + H] + Calculated value: 663.3058, measured value: 663.3008.

[0184] Intermediate Example 20: Synthesis of (S)-18-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-19,19-dimethyl-16-oxo-4,7,10,13-tetraoxa-17-azaicosanoic acid (SIAIS151008)

[0185] SIAIS151008 (white solid, 0.53 g, 51% yield) was prepared using 4,7,10,13-tetraoxahexadecanedioic acid following the procedure for preparing Intermediate Example 17. 1H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.56 (t, J = 6.0 Hz, 1H), 7.91 (d, J = 9.4 Hz, 1H), 7.40 (dd, J = 18.8, 8.3 Hz, 4H), 4.55 (d, J = 9.4 Hz, 1H), 4.45 - 4.40 (m, 2H), 4.35 (s, 1H), 4.22 (dd, J = 15.8, 5.5 Hz, 1H), 3.69 - 3.54 (m, 10H), 3.48 (d, J = 2.7 Hz, 9H), 2.56 - 2.52 (m, 1H), 2.45 - 2.41 (m, 2H), 2.45 (s, 3H), 2.38 - 2.32 (m, 1H), 2.06 - 2.00 (m, 1H), 1.94 - 1.88 (m, 1H), 0.93 (s, 9H). HRMS (ESI) C 34 H 51 N4O 10 S + [M + H] + Calculated value: 707.3320, measured value: 707.2945.

[0186] Intermediate Example 21: Synthesis of (S)-21-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-22,22-dimethyl-19-oxo-4,7,10,13,16-pentaoxa-20-azatricosanoic acid (SIAIS151009)

[0187] SIAIS151009 (white solid, 0.82 g, 85% yield) was prepared using 4,7,10,13,16-pentaoxanonadecanedioic acid following the procedure for preparing Intermediate Example 17. 1H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.56 (d, J = 5.7 Hz, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.40 (dd, J = 18.6, 7.9 Hz, 4H), 4.55 (d, J = 9.3 Hz, 1H), 4.47 - 4.40 (m, 2H), 4.35 (s, 1H), 4.22 (dd, J = 15.7, 5.2 Hz, 1H), 3.68 - 3.56 (m, 11H), 3.51 - 3.49 (s, 9H), 2.56 - 2.53 (m, 1H), 2.45 - 2.41 (m, 5H), 2.44 (s, 3H), 2.36 (dd, J = 13.4, 7.0 Hz, 1H), 2.08 - 2.00 (m, 1H), 1.94 - 1.86 (m, 1H), 0.93 (s, 9H). HRMS (ESI) C 36 H 55 N4O 11 S + [M + H] + Calculated value: 751.3583, measured value: 751.3199.

[0188] Intermediate Example 22: Synthesis of 4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid (SIAIS074011)

[0189] According to Scheme 6, NMM (10.0 mmol, 5 equiv.), VHL-1 (2 mmol, 1 equiv.), HOAt (2.4 mmol, 1.2 equiv.), and EDCI (2.4 mmol, 1.2 equiv.) were added to a solution of the diacid (succinic acid, 5.0 mmol, 2.5 equiv.) in anhydrous DMF (10 mL) and anhydrous DCM (150 mL) at 0 °C. The resulting reaction solution was stirred at 0 °C for 5 h and then at room temperature overnight. After complete consumption of VHL-1, the reaction was quenched with water (1 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography using acetonitrile / (water + 0.1% TFA) as an eluent (v / v) from 10% to 100% to give the desired product SIAIS074011 (0.82 g, 65%) as a white solid. 1 H NMR (500 MHz, CDCl3) δ 11.88 (s, 1H), 8.85 (s, J = 11.2 Hz, 1H), 7.69 (s, 1H), 7.37 - 7.29 (m, 4H), 6.09 (br, 1H), 4.67 - 4.54 (m, 3H), 4.49 (s, 1H), 4.29 (dd, J = 15.0, 5.0Hz, 1H), 4.05 (d, J = 11.3 Hz, 1H), 3.73 - 3.63 (m, 1H), 2.73 - 2.58 (m, 1H), 2.57 - 2.41 (m, 3H), 2.50 (s, 3H), 2.31 - 2.14 (m, 2H), 0.96 (s, 9H). HRMS (ESI) C 26 H 35 N4O6S + [M + H] + Calculated value: 531.2272, measured value: 531.2275.

[0190] Intermediate Example 23: Synthesis of 5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentanoic acid (SIAIS074012)

[0191] SIAIS074012 (white solid, 0.85 g, 67% yield) was prepared using glutaric acid following the procedure for preparing Intermediate Example 22. 1 H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.65 (br, 1H), 8.10 (s, 1H), 7.38 - 7.29 (m, 4H), 4.72 - 4.64 (m, 3H), 4.52 (s, 1H), 4.25 (dd, J = 15.4, 5.0 Hz, 1H), 4.09 (d, J = 10.5 Hz, 1H), 3.73 (d, J = 10.0 Hz, 1H), 2.48 (s, 3H), 2.39 - 2.13 (m, 6H), 1.92 - 1.74 (m, 2H), 0.96 (s, 9H). HRMS (ESI) C 27 H 37 N4O6S + [M + H] + Calculated value: 545.2428, Measured value: 545.2428.

[0192] Intermediate Example 24: Synthesis of 6-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexanoic acid (SIAIS074013)

[0193] SIAIS074013 (white solid, 0.79 g, 55% yield) was prepared using adipic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.99 (s, 1H), 7.66 (s, 1H), 7.39 - 7.33 (m, 4H), 7.30 (d, J = 7.5 Hz, 1H). 7.14 (br, 1H), 4.67 - 4.61 (m, 3H), 4.52 (s, 1H). 4.28 (dd, J = 15.4, 5.0 Hz, 1H), 4.09 (d, J = 11.4 Hz, 1H), 3.74 - 3.63 (m, 1H), 2.52 (s, 3H), 2.31 - 2.17 (m, 6H), 1.65 - 1.53 (m, 4H), 0.96 (s, 9H). HRMS (ESI) C 28 H 40 N4O6S + [M + H] + Calculated value: 559.2585, measured value: 559.3632.

[0194] Intermediate Example 25: Synthesis of 7-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptanoic acid (SIAIS074014)

[0195] SIAIS074014 (white solid, 0.8 g, 57% yield) was prepared using pimelic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.90 (s, 1H), 7.42 - 7.38 (m, 1H), 7.41 - 7.33 (m, 4H), 7.31 (d, J = 9.0 Hz, 1H), 6.38 (br, 1H), 4.79 - 4.46 (m, 3H), 4.55 (s, 1H), 4.28 (dd, J = 15.2, 5.1 Hz, 1H), 4.12 (d, J = 11.3 Hz, 1H), 3.72 - 3.63 (m, 1H), 2.51 (s, 3H), 2.38 - 2.33 (m, 1H), 2.28 - 2.21 (m, 4H), 2.18 - 2.12 (m, 1H), 1.62 - 1.52 (m, 3H), 1.33 - 1.23 (m, 3H), 0.96 (s, 9H). HRMS (ESI) C 29 H 41 N4O6S + [M + H] + Calculated value: 573.2741, measured value: 573.3804.

[0196] Intermediate Example 26: Synthesis of 8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctanoic acid (SIAIS074015)

[0197] SIAIS074015 (white solid, 0.95 g, 68% yield) was prepared using suberic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H), 7.43 (t, J = 6.0 Hz, 1H), 7.34 (s, 4H), 6.98 (d, J = 8.5 Hz, 1H), 6.10 (s, 1H), 4.69 - 4.65 (m, 1H), 4.63 - 4.51 (m, 2H), 4.55 - 4.50 (m, 1H), 4.38 - 4.27 (m, 1H), 4.11 (d, J = 16.7 Hz, 1H), 3.72 - 3.62 (m, 1H), 2.51 (s, 3H), 2.39 - 2.13 (m, 6H), 1.58 - 1.54 (m, 4H), 1.33 - 1.21 (m, 4H), 0.95 (s, 9H). HRMS (ESI) C 30 H 43 N4O6S + [M + H] + Calculated value: 587.2898, measured value: 587.2917.

[0198] Intermediate Example 27: Synthesis of 9-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-9-oxononanoic acid (SIAIS074016)

[0199] SIAIS074016 (white solid, 0.92 g, 64% yield) was prepared using azelaic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H), 7.35 (s, 4H), 7.02 (t, J = 14.3 Hz, 1H), 5.99 (s, 1H), 4.74 - 4.49 (m, 4H), 4.30 (dd, J = 15.2, 5.1 Hz, 1H), 4.13 (d, J = 11.3 Hz, 1H), 3.67 (dd, J = 11.5, 3.5 Hz, 1H), 2.51 (s, 3H), 2.42 - 2.36 (m, 1H), 2.28 (t, J = 7.5 Hz, 2H), 2.24 - 2.12 (m, 3H), 1.67 - 1.48 (m, 4H), 1.35 - 1.22 (m, 6H), 0.95 (s, 9H). HRMS (ESI) C 31 H 45 N4O6S + [M + H] + Calculated value: 601.3054, measured value: 601.3150.

[0200] Intermediate Example 28: Synthesis of 10-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecanoic acid (SIAIS074019)

[0201] SIAIS074019 (white solid, 0.96 g, 66% yield) was prepared using sebacic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.79 (s, 1H), 7.39 - 7.36 (m, 1H), 7.35 (s, 4H), 7.01 (d, J = 9.0 Hz, 1H), 5.80 (s, 1H), 4.68 - 4.52 (m, 4H), 4.29 (dd, J = 15.2, 5.0 Hz, 1H), 4.12 (d, J = 11.2 Hz, 1H), 3.72 - 3.62 (m, 1H), 2.51 (s, 3H), 2.41 - 2.33 (m, 1H), 2.32 - 2.23 (m, 2H), 2.23 - 2.11 (m, 3H), 1.65 - 1.48 (m, 4H), 1.32 - 1.21 (m, 8H), 0.95 (s, 9H). HRMS (ESI) C 32 H 47 N4O6S + [M + H] + Calculated value: 615.3211, measured value: 615.4391.

[0202] Intermediate Example 29: Synthesis of 11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoic acid (SIAIS074020)

[0203] SIAIS074020 (white solid, 1 g, 67% yield) was prepared using 1,11-undecanedioic acid following the procedure for preparing Intermediate Example 22. 1H NMR (500 MHz, CDCl3) δ 8.77 (s, 1H), 7.39 - 7.32 (m, 4H), 7.30 (m, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.52 (br, 1H), 4.69 - 4.59 (m, 3H), 4.53 (s, 1H), 4.29 (dd, J = 15.2, 5.0 Hz, 1H), 4.14 (d, J = 11.3 Hz, 1H), 3.68 - 3.64 (m, 1H), 2.51 (s, 3H), 2.44 - 2.40 (m, 1H), 2.29 (t, J = 7.1 Hz, 2H), 2.26 - 2.12 (m, 3H), 1.68 - 1.48 (m, 4H), 1.30 - 1.20 (m, 10H), 0.95 (s, 9H). HRMS (ESI) C 33 H 49 N4O6S + [M + H] + Calculated value: 629.3367, Measured value: 629.4540.

[0204] Intermediate Example 30: Synthesis of 3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropanoic acid (SIAIS171004)

[0205] According to Scheme 7, NMM (10.0 mmol, 5 equiv.), lenalidomide (2 mmol, 1 equiv.), HOAt (2.4 mmol, 1.2 equiv.), and EDCI (2.4 mmol, 1.2 equiv.) were added to a solution of diacid (malonic acid, 5.0 mmol, 2.5 equiv.) in anhydrous DMF (10 mL) and anhydrous DCM (150 mL) at 0 °C. The resulting reaction solution was then stirred overnight at room temperature. After complete consumption of lenalidomide, the reaction was quenched with water (1 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography using acetonitrile / (water + 0.1% TFA) as an eluent (v / v) from 10% to 100% to afford the desired product SIAIS171004 (0.32 g, 24%) as a white solid. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.03 (s, 1H), 7.86 (d, J = 7.1 Hz, 1H), 7.62 - 7.43 (m, 2H), 5.15 (dd, J = 13.4, 4.9 Hz, 1H), 4.36 (dd, J = 35.5, 17.5 Hz, 2H), 3.42 (s, 2H), 2.95 - 2.87 (m, 1H), 2.63 - 2.59 (m, 1H), 2.38 - 2.28 (m, 1H), 2.07 - 2.01 (m, 1H). HRMS (ESI) C 16 H 16 N3O6 + [M+H] + Calculated value: 346.1034, measured value: 346.1015.

[0206] Intermediate Example 31: Synthesis of 4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-4-oxobutanoic acid (SIAIS164084)

[0207] SIAIS164084 (white solid, 0.11 g, 44% yield) was prepared using succinic acid following the procedure for preparing Intermediate Example 30. 1 H NMR (500 MHz, DMSO) δ 12.16 (s, 1H), 11.02 (s, 1H), 9.86 (s, 1H), 7.81 (dd, J = 7.1, 1.7 Hz, 1H), 7.57 - 7.40 (m, 2H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (dd, J = 35.5, 17.5 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.65 - 2.58 (m, 3H), 2.55 - 2.53 (m, 2H), 2.37 - 2.29 (m, 1H), 2.06 - 2.00 (m, 1H). HRMS (ESI) C 17 H 18 N3O6 + [M+H] + Calculated value: 360.1190, measured value: 360.1198.

[0208] Intermediate Example 32: Synthesis of 5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-5-oxopentanoic acid (SIAIS171005)

[0209] SIAIS171005 (white solid, 0.52 g, 35% yield) was prepared using glutaric acid following the procedure for preparing Intermediate Example 30. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 9.80 (s, 1H), 7.81 (d, J = 5.8 Hz, 1H), 7.54 - 7.46 (m, 2H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (dd, J = 35.5, 17.5 Hz, 2H), 2.97 - 2.85 (m, 1H), 2.77 - 2.75 (m, 2H), 2.66 - 2.57 (m, 1H), 2.42 - 2.39 (m, 1H), 2.35 (dd, J = 13.1, 4.4Hz, 1H), 2.30 - 2.27 (m, 1H), 2.03 - 1.97 (m, 1H), 1.85 - 1.79 (m, 2H). HRMS (ESI) C 18 H 20 N3O6 + [M+H] + Calculated value: 374.1347, measured value: 374.1526.

[0210] Intermediate Example 33: Synthesis of 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-6-oxohexanoic acid (SIAIS164101)

[0211] SIAIS164101 (white solid, 0.4 g, 27% yield) was prepared using adipic acid following the procedure for preparing Intermediate Example 30. 1H NMR (500 MHz, MeOD) δ 7.70 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 7.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 5.16 (dd, J = 13.4, 5.2 Hz, 1H), 4.53 - 4.43 (m, 2H), 2.95 - 2.87 (m, 1H), 2.81 - 2.76 (m, 1H), 2.55 - 2.48 (m, 1H), 2.46 (t, J = 7.2 Hz, 2H), 2.36 (t, J = 7.0 Hz, 2H), 2.22 - 2.16 (m, 1H), 1.79 - 1.66 (m, 4H). HRMS (ESI) C 19 H 22 N3O6 + [M+H] + Calculated value: 388.1503, measured value: 388.1714.

[0212] Intermediate Example 34: Synthesis of 7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-7-oxoheptanoic acid (SIAIS164102)

[0213] SIAIS164102 (white solid, 0.45 g, 28% yield) was prepared using pimelic acid following the procedure for preparing Intermediate Example 30. 1H NMR (500 MHz, MeOD) δ 7.70 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 7.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 5.16 (dd, J = 13.4, 5.2 Hz, 1H), 4.49 (t, J = 10.1 Hz, 2H), 2.94 - 2.87 (m, 1H), 2.81 - 2.76 (m, 1H), 2.54 - 2.48 (m, 1H), 2.45 (t, J = 7.5 Hz, 2H), 2.32 (t, J = 7.0 Hz, 2H), 2.22 - 2.16 (m, 1H), 1.77 - 1.72 (m, 2H), 1.70 - 1.63 (m, 2H), 1.48 - 1.42 (m, 2H). HRMS (ESI) C 20 H 24 N3O6 + [M+H] + Calculated value: 402.1660, measured value: 402.1890. Intermediate Example 35: Synthesis of (2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)aminoacetic acid (SIAIS1204057) JPEG0007594757000198.jpg46122

[0214] According to Scheme 8, tert-butyl 2-bromoacetate (2.4 mmol, 1.2 equiv.) and DIPEA (6 mmol, 3 equiv.) were added to a solution of lenalidomide (2 mmol, 1 equiv.) in NMP (8 mL) and the mixture was stirred at 110 °C overnight. After cooling to room temperature, the resulting solution was purified by reverse-phase chromatography using an eluent (v / v): acetonitrile / (water + 0.1% TFA) = 10% to 100% to afford the desired tert-butyl ester intermediate. This intermediate was treated with TFA (2 mL) / DCM (6 mL) at room temperature for 1 h. After concentration under reduced pressure and lyophilization, the desired product SIAIS1204057 (1.0 g, 48%) was obtained as a yellow solid. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 5.94 (s, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.26 (d, J = 17.0 Hz, 1H), 4.16 (d, J = 17.0 Hz, 1H), 3.92 (s, 2H), 2.98 - 2.85 (m, 1H), 2.62 (d, J = 17.3 Hz, 1H), 2.39-2.26 (m, 1H), 2.08-1.99 (m, 1H). HRMS (ESI) C 15 H 16 N3O5 + [M+H] + Calculated value: 318.1084, measured value: 318.1098.

[0215] Intermediate Example 36: Synthesis of 4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butanoic acid (SIAIS1204085)

[0216] SIAIS1204085 (yellow solid, 215 mg, 62% yield) was prepared using tert-butyl 4-bromobutanoate in the procedure for preparing Intermediate Example 35. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.93 (d, J = 7.3 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.23 (d, J = 17.0 Hz, 1H), 4.13 (d, J = 17.0 Hz, 1H), 4.01 (s, 1H), 3.14 (t, J = 7.0 Hz, 2H), 2.98 - 2.86 (m, 1H), 2.66 - 2.58 (d, J = 17.6 Hz, 1H), 2.34 (t, J = 7.3 Hz, 2H), 2.32 - 2.24 (m, 1H), 2.08 - 1.98 (m, 1H), 1.85 - 1.75 (m, 2H). HRMS (ESI) C 17 H 20 N3O5 + [M+H] + Calculated value: 346.1379, measured value: 346.1414.

[0217] Intermediate Example 37: Synthesis of 5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentanoic acid (SIAIS1210133)

[0218] SIAIS1210133 (yellow solid, 215 mg, 60% yield) was prepared using tert-butyl 5-bromopentanoate following the procedure for preparing Intermediate Example 35. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.92 (t, J = 10.9 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 5.07 (s, 1H), 4.23 (d, J = 17.2 Hz, 1H), 4.13 (d, J = 17.1 Hz, 1H), 3.13 (d, J = 6.4 Hz, 2H), 2.97 - 2.87 (m, 1H), 2.61 (d, J = 16.7 Hz, 1H), 2.38 - 2.21 (m, 3H), 2.06 - 1.98 (m, 1H), 1.67 - 1.55 (m, 4H). HRMS (ESI) C 18 H 22 N3O5 + [M+H] + Calculated value: 360.1554, measured value: 360.1551.

[0219] Intermediate Example 38: Synthesis of 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanoic acid (SIAIS1204061)

[0220] SIAIS1204061 (yellow solid, 268 mg, 72% yield) was prepared using tert-butyl 6-bromohexanoate following the procedure for preparing Intermediate Example 35. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.29 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 7.4 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.24 (d, J = 17.0 Hz, 1H), 4.14 (d, J = 17.0 Hz, 1H), 4.05 (s, 1H), 3.12 (t, J = 7.0 Hz, 2H), 2.98 - 2.87 (m, 1H), 2.66 - 2.58 (m, 1H), 2.35 - 2.25 (m, 1H), 2.22 (t, J = 7.0 Hz, 2H), 2.07 - 2.00 (m, 1H), 1.63 - 1.50 (m, 4H), 1.43 - 1.37 (m, 2H). HRMS (ESI) C 19 H 24 N3O5 + [M+H] + Calculated value: 374.1710, measured value: 374.1720.

[0221] Intermediate Example 39: Synthesis of 7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)heptanoic acid (SIAIS1204063)

[0222] Following the procedure for preparing Intermediate Example 35, tert-butyl 7-bromoheptanoate was used to prepare SIAIS1204063 (yellow solid, 252 mg, 65% yield). 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.93 (d, J = 7.3 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 1H), 4.13 (d, J = 17.0 Hz, 1H), 3.11 (t, J = 7.0 Hz, 2H), 2.98 - 2.84 (m, 1H), 2.67 - 2.57 (m, 1H), 2.35 - 2.25 (m, 1H), 2.20 (t, J = 7.3 Hz, 2H), 2.07 - 1.99 (m, 1H), 1.63 - 1.46 (m, 4H), 1.42 - 1.27 (m, 4H). HRMS (ESI) C 20 H 26 N3O5 + [M+H] + Calculated value: 388.1867, measured value: 388.1878.

[0223] Intermediate Example 40: Synthesis of 4-((2-aminoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (SIAIS151103)

[0224] According to Scheme 9, a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (7.2 mmol, 1 equiv.), tert-butyl (2-aminoethyl)carbamate (8.1 mmol, 1.2 equiv.), and DIPEA (36.4 mmol, 5 equiv.) in NMP (10 mL) was stirred at room temperature for 10 minutes in a microwave tube, then filled with argon and heated to 110 °C for 2 hours in a microwave reactor. After cooling to RT, the reaction mixture was poured into 90% saline and extracted with EA (4 × 50 mL). The combined organic phases were washed with water (2 × 30 mL), brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent (v / v): hexane / EA = 1:1) to give the desired tert-butyl ester intermediate. This intermediate was treated with 88% formic acid (20 mL) at room temperature overnight. After concentration under reduced pressure and lyophilization, the desired product SIAIS151103 (1.1 g, 48% yield) was obtained as a yellow solid. 1 H NMR (500 MHz, DMSO) δ 8.36 (s, 2H), 7.64 - 7.58 (m, 1H), 7.18 (t, J = 6.2 Hz, 1H), 7.07 (d, J = 7.1 Hz, 1H), 6.84 (t, J = 6.2 Hz, 1H), 5.06 (dd, J = 12.7, 5.4 Hz, 1H), 3.56 (dd, J = 12.2, 6.0 Hz, 2H), 2.96 (t, J = 6.1 Hz, 2H), 2.93 - 2.85 (m, 1H), 2.61 - 2.51 (m, 2H), 2.06 - 2.00 (m, 1H). HRMS (ESI) C 15 H 17 N4O4 + [M+H] + Calculated value: 317.1244, measured value: 317.1236.

[0225] Intermediate Example 41: Synthesis of 4-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)amino)-4-oxobutanoic acid (SIAIS164119)

[0226] According to Scheme 10, NMM (1.01 g, 10.0 mmol, 10 equiv), SIAIS151103 (316.3 mg, 1 mmol, 1 equiv), HOAt (163.3 mg, 1.2 mmol, 1.2 equiv), and EDCI (230 mg, 1.2 mmol, 1.2 equiv) were added to a solution of succinic acid (295.2 mg, 2.5 mmol, 2.5 equiv) in anhydrous DMF (5 mL) and anhydrous DCM (50 mL) at 0° C. The resulting reaction solution was stirred at 0° C. for 5 hours and then at room temperature overnight. After the reaction was completed, the resulting solution was quenched with water (1 mL), then concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography with an eluent (v / v): acetonitrile / (water + 0.1% TFA) = 10% to 100% to give the desired product SIAIS164119 (170 mg, 41%) as a yellow solid. 1 H NMR (500 MHz, MeOD) δ 7.55 - 7.50 (m, 1H), 7.10 (d, J = 8.6 Hz, 1H), 7.04 (t, J = 6.3 Hz, 1H), 5.05 (dd, J = 12.4, 5.5 Hz, 1H), 3.47-3.39 (m, 4H), 2.89-2.82 (m, 1H), 2.79 - 2.65 (m, 2H), 2.58 (t, J = 7.0 Hz, 2H), 2.45 (t, J = 7.0 Hz, 2H), 2.16 - 2.05 (m, 1H). HRMS (ESI) C 19 H 21 N4O7 + [M+H] + Calculated value: 417.1405, measured value: 417.0916.

[0227] Intermediate Example 42: Synthesis of (2S,4R)-1-((S)-2-(4-azidobutyrylamino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (SIAIS164050)

[0228] According to Scheme 11, HOAt (54.4 mg, 0.4 mmol, 0.2 equiv.), EDCI (766.8 mg, 4 mmol, 2 equiv.), and NMM (2.02 g, 20 mmol, 10 equiv.) were added to a solution of VHL-1 (934 mg, 2 mmol, 1 equiv.) and 4-azidobutanoic acid (258.2 mg, 2 mmol, 1 equiv.) in DMF (5 mL) and DCM (20 mL) at room temperature. The resulting reaction solution was stirred overnight at room temperature. After completion of the reaction was confirmed by LC-MS, the resulting solution was concentrated under reduced pressure, and the residue was poured into 90% saline and extracted with EA (4 × 50 mL). The combined organic phases were washed with water (2 × 30 mL), brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography (eluent (v / v): DCM / MeOH=40:1) to give the desired product SIAIS164050 (734 mg, 68%) as a pale yellow liquid. 1 H NMR (500 MHz, MeOD) δ 8.87 (s, 1H), 7.48 - 7.41 (m, 4H), 4.62 (s, 1H), 4.58-4.50 (m, 3H), 4.38 - 4.33 (m, 1H), 3.91 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 10.9, 3.9 Hz, 1H), 3.33 (t, J = 5.0 Hz, 2H), 2.48 (d, J = 5.3 Hz, 3H), 2.41 - 2.32 (m, 2H), 2.22 (dd, J = 13.1, 7.6 Hz, 1H), 2.11-2.06 (m, 1H), 1.90 - 1.82 (m, 2H), 1.04 (s, 9H). HRMS (ESI) C 26 H 36 N7O4S + [M+H] + Calculated value: 542.2544, measured value: 542.2256.

[0229] Intermediate Example 43: Synthesis of 4-(1-(4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobut-2-yl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butanoic acid (SIAIS164128):

[0230] According to Scheme 12, CuSO4 (31.9 mg, 0.2 mmol, 1 equiv.) and sodium ascorbate (39.6 mg, 0.2 mmol, 1 equiv.) were added to a solution of 5-hexynoic acid (22.4 mg, 0.2 mmol, 1 equiv.) and SIAIS164050 (108.3 mg, 0.2 mmol, 1 equiv.) in DMF (1 mL), tBuOH (1 mL), and water (1 mL) at room temperature. The resulting reaction solution was stirred at room temperature for 2 h. After completion of the reaction was confirmed by LC-MS, the resulting solution was purified by reverse-phase chromatography (eluent (v / v): acetonitrile / (water + 0.1% TFA) = 10% to 100%) to give the desired product SIAIS164128 (100 mg, 76%) as a white solid. 1 H NMR (500 MHz, MeOD) δ 9.19 (d, J = 3.4 Hz, 1H), 7.87 (s, 1H), 7.51 - 7.42 (m, 4H), 4.60 (s, 1H), 4.59-4.54 (m, 2H), 4.51 (s, 1H), 4.43 (t, J = 6.8 Hz, 2H), 4.36 (d, J = 15.3 Hz, 1H), 3.93 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.8 Hz, 1H), 2.77 (t, J = 7.6 Hz, 2H), 2.51 (d, J = 3.8 Hz, 3H), 2.36 (t, J = 7.3 Hz, 2H), 2.32-2.28 (m, 2H), 2.25 - 2.15 (m, 3H), 2.11-2.06 (m, 1H), 2.00-1.94 (m, 2H), 1.04 (s, 9H). HRMS (ESI) C 32 H 44 N7O6S+ [M+H] + Calculated value: 654.3068, measured value: 654.2990.

[0231] Intermediate Example 44: Synthesis of 11-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoic acid (SIAIS219048):

[0232] According to Scheme 13, NMM (0.5 mmol, 5 equiv.), trans-VHL-1 (0.1 mmol, 1 equiv.), HOAt (0.15 mmol, 1.5 equiv.), and EDCI (0.15 mmol, 1.5 equiv.) were added to a solution of the diacid (1,11-undecanedioic acid, 0.25 mmol, 2.5 equiv.) in anhydrous DMF (4 mL) and anhydrous DCM (10 mL) at 0 °C. The resulting reaction solution was stirred at 0 °C for 2 h and then at room temperature overnight. After complete consumption of trans-VHL-1, the reaction was quenched with water (1 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase chromatography using acetonitrile / (water + 0.1% TFA) as an eluent (v / v) from 10% to 100% to give the desired product SIAIS219048 (48 mg, 76%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.78 (s, 1H), 7.38 - 7.31 (m, 4H), 7.31-7.28 (m, 1H), 7.00 (d, J = 8.8 Hz, 1H), 5.50 (br, 1H), 4.67 - 4.56 (m, 3H), 4.51 (s, 1H), 4.26 (dd, J = 15.2, 5.0 Hz, 1H), 4.13 (d, J = 11.3 Hz, 1H), 3.64 - 3.62 (m, 1H), 2.50 (s, 3H), 2.43 - 2.40 (m, 1H), 2.27 (t, J = 7.1 Hz, 2H), 2.25 - 2.11 (m, 3H), 1.67 - 1.46 (m, 4H), 1.30 - 1.21 (m, 10H), 0.93 (s, 9H). HRMS (ESI) C 33 H 49 N4O6S + [M + H] + Calculated value: 629.3367, measured value: 629.3377.

[0233] Intermediate Example 45: Synthesis of 3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propionic acid (SIAIS172147): Synthesis of 4-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (SIAIS172136):

[0234] According to Scheme 14, 4-bromoisobenzofuran-1,3-dione (500 mg, 2.20 mmol), 3-aminopiperidine-2,6-dione (400 mg, 2.42 mmol), and anhydrous sodium acetate were added to a 100 mL egg-shaped flask, followed by glacial acetic acid (10 mL). The resulting reaction solution was gradually heated to 140 °C and stirred for 12 hours. After the reaction was completed, the reaction solution was cooled to room temperature, and a large amount of white solid precipitated. After filtration, the cake, water (10 mL), and methanol (2 mL) were added to the flask and stirred for 0.5 hours. After filtration, the cake was washed with water and concentrated under reduced pressure to obtain the desired product SIAIS172136 (700 mg, 94%) as a white solid. 1 H NMR (500 MHz, DMSO) δ 11.14 (s, 1H), 8.14 (d, J = 1.4 Hz, 1H), 8.09 (dd, J = 7.9, 1.7 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 5.16 (dd, J = 12.9, 5.4 Hz, 1H), 2.93 - 2.85 (m, 1H), 2.65 - 2.50 (m, 2H), 2.08 - 2.04 (m, 1H). HRMS (ESI) C 13 H 10 BrN2O4 + [M+H] + Calculated value: 336.9818, measured value: 336.9810.

[0235] Synthesis of tert-butyl (E)-3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acrylate (SIAIS172145):

[0236] According to Scheme 14, tri-tert-butylphosphine tetrafluoroborate (110 mg, 0.38 mmol), N-methyldicyclohexylamine (250 mg, 1.28 mmol), Pd2(dba)3 (163 mg, 0.64 mmol), and anhydrous dioxane were added to a 50 mL egg-shaped flask and stirred at room temperature for 30 minutes. Then, SIAIS172136 (300 mg, 0.89 mmol) and tert-butyl acrylate were added. The resulting reaction solution was gradually heated to 55 °C under a nitrogen atmosphere and stirred for 12 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (eluent (v / v): EA / PE = 2:3) to obtain the desired product SIAIS172145 (270 mg, 79%) as a pale yellow liquid. 1 H NMR (500 MHz, CDCl3) δ 8.11 (s, 1H), 8.02 (s, 1H), 7.89 (d, J = 7.7 Hz, 1H), 7.84 (dd, J = 7.8, 1.2 Hz, 1H), 7.65 (d, J = 16.0 Hz, 1H), 6.54 (d, J = 16.0 Hz, 1H), 5.00 (dd, J = 12.5, 5.3 Hz, 1H), 2.94 - 2.72 (m, 3H), 2.20 - 2.13 (m, 1H), 1.54 (s, 9H). HRMS (ESI) C 20 H 21 N2O6 + [M+H] + Calculated value: 385.1394, measured value: 385.1389. Synthesis of 3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propionic acid (SIAIS172147):

[0237] According to Scheme 14, SIAIS172145 (250 mg, 0.65 mmol) was added to a 100 mL egg-shaped flask, followed by dioxane (20 mL) and 10% wet Pd / C. After extraction and replenishment with H2 (25 psi) three times, the reaction solution was stirred at room temperature overnight. After completion of the reaction, the reaction solution was filtered and washed with dioxane. The filtrate was concentrated under reduced pressure to give a pale yellow oil, which was used in subsequent reactions without further purification. The crude material, TFA (1 mL), and anhydrous DCM were added to a 50 mL egg-shaped flask and stirred at room temperature for 2 hours. After completion of the reaction, the resulting solution was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography using an eluent (v / v): acetonitrile / (water + 0.1% TFA) = 10% to 100%. After concentration and lyophilization, the desired product SIAIS172147 (white solid, 180 mg, 84% yield for two steps) was obtained. 1 H NMR (500 MHz, DMSO) δ 12.22 (s, 1H), 11.12 (s, 1H), 7.86 - 7.79 (m, 2H), 7.77 - 7.70 (m, 1H), 5.13 (dd, J = 12.8, 5.4 Hz, 1H), 3.01 (t, J = 7.4 Hz, 2H), 2.93 - 2.85 (m, 1H), 2.64 (t, J = 7.4 Hz, 2H), 2.62 - 2.50 (m, 2H), 2.08 - 2.02(m, 1H). HRMS (ESI) C 16 H 15 N2O6 + [M+H] + Calculated value: 331.0925, measured value: 331.0919. Compound example

[0238] Compound Example 1: Synthesis of 4-((2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197065)

[0239] According to Scheme 15, HOAt (0.04 mmol, 2 equiv.), EDCI (0.04 mmol, 2 equiv.), and NMM (0.2 mmol, 10 equiv.) were sequentially added to a stirred solution of the corresponding ALK inhibitor (brigatinib analog A, 0.02 mmol, 1 equiv.) and intermediate LM (SIAIS151001, 0.02 mmol, 1 equiv.) in DMF (1 mL) and DCM (5 mL) at RT. The resulting reaction mixture was stirred overnight at room temperature. After completion of the reaction was confirmed by LC-MS, the resulting solution was purified by preparative HPLC using an eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% to 100%, and after concentration under reduced pressure and lyophilization, the desired product SIAIS1197065 (16.2 mg, 60%) was obtained as a yellow solid. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.05 (s, 1H), 7.65 (dd, J = 13.8, 7.7 Hz, 1H), 7.54 (s, 1H), 7.50 (dd, J = 8.4, 7.2 Hz, 1H), 7.35 (t, J = 7.3 Hz, 1H), 7.26 (s, 1H), 7.04 (d, J = 8.6 Hz, 1H), 7.00 (d, J = 7.1 Hz, 1H), 6.65 (s, 1H), 6.46 (d, J = 7.9 Hz, 1H), 4.97 (dd, J = 12.4, 5.4 Hz, 1H), 3.84 (t, J = 5.8 Hz, 4H), 3.80 (s, 3H), 3.72 (t, J = 5.0 Hz, 4H), 3.48 (t, J = 5.0 Hz, 2H), 3.20 (s, 4H), 2.80 - 2.68 (m, 3H), 2.66 - 2.58 (m, 2H), 2.04 - 1.96 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 41 H 46 ClN9O8P + [M+H] + Calculated value: 858.2890, measured value: 858.3506.

[0240] Compound Example 2: Synthesis of 4-((2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197067)

[0241] SIAIS1197067 (yellow solid, 16.7 mg, yield 62%) was prepared using brigatinib analog A and intermediate LM (SIAIS151004) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.37 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 13.9, 7.7 Hz, 1H), 7.55 (s, 1H), 7.50 (dd, J = 8.5, 7.2 Hz, 1H), 7.37 (t, J = 7.0 Hz, 1H), 7.28 (d, J = 6.7 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 7.00 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 6.51 (d, J = 6.4 Hz, 1H), 5.02 (dd, J = 12.5, 5.5 Hz, 1H), 3.82 (s, 3H), 3.79 (t, J = 6.1 Hz, 2H), 3.74 (d, J = 4.2 Hz, 4H), 3.68 (t, J = 5.3 Hz, 2H), 3.66 - 3.59 (m, 4H), 3.43 (t, J = 5.2 Hz, 2H), 3.28 - 3.18 (m, 4H), 2.86 - 2.76 (m, 1H), 2.75 - 2.61 (m, 4H), 2.11 - 2.03 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 43 H 50 ClN9O9P + [M+H] + Calculated value: 902.3152, measured value: 902.3791.

[0242] Compound Example 3: Synthesis of 4-((2-(2-(2-(3-(4-(4-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197069)

[0243] SIAIS1197069 (yellow solid, 13.7 mg, yield 51%) was prepared using brigatinib analog A and intermediate LM (SIAIS151005) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.36 (s, 1H), 8.03 (s, 1H), 7.66 (dd, J = 14.0, 7.7 Hz, 1H), 7.55 (s, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.30 (s, 1H), 7.03 (d, J = 8.7 Hz, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.70 (s, 1H), 6.56 (s, 1H), 5.02 (dd, J = 12.6, 5.5 Hz, 1H), 3.83 (s, 3H), 3.80 - 3.71 (m, 6H), 3.68 - 3.57 (m, 10H), 3.44 (t, J = 5.0 Hz, 2H), 3.28 (s, 2H), 3.23 (s, 2H), 2.87 - 2.78 (m, 1H), 2.75 - 2.62 (m, 4H), 2.12 - 2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 45 H 54 ClNO 10 P + [M+H] + Calculated value: 946.3961, measured value: 946.1771.

[0244] Compound Example 4: Synthesis of 4-((15-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197071)

[0245] SIAIS1197071 (yellow solid, 4.8 mg, 18% yield) was prepared using brigatinib analog A and intermediate LM (SIAIS151006) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.03 (s, 1H), 7.66 (dd, J = 15.0, 7.4 Hz, 1H), 7.58 - 7.49 (m, 2H), 7.37 (t, J = 8.4 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.07 - 7.00 (m, 2H), 6.72 (s, 1H), 6.56 (s, 1H), 5.02 (dd, J = 12.6, 5.5 Hz, 1H), 3.84 (s, 3H), 3.80 - 3.73 (m, 6H), 3.64 - 3.55 (m, 14H), 3.46 (t, J = 5.5 Hz, 2H), 3.24 (s, 4H), 2.87 - 2.78 (m, 1H), 2.74 - 2.67 (m, 4H), 2.10 - 2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 47 H 58 ClNO 11 P + [M+H] + Calculated value: 990.3676, measured value: 990.4374.

[0246] Compound Example 5: Synthesis of 4-((18-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197073)

[0247] SIAIS1197073 (yellow solid, 4.5 mg, 17% yield) was prepared using brigatinib analog A and intermediate LM (SIAIS151007) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.66 (dd, J = 14.0, 7.5 Hz, 1H), 7.59 - 7.48 (m, 2H), 7.38 (t, J = 7.1 Hz, 1H), 7.29 (s, 1H), 7.06 (d, J = 8.7 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.73 (s, 1H), 6.57 (s, 1H), 5.02 (dd, J = 12.6, 5.5 Hz, 1H), 3.84 (s, 3H), 3.80 - 3.72 (m, 6H), 3.71 - 3.54 (m, 18H), 3.46 (t, J = 5.5 Hz, 2H), 3.24 (s, 4H), 2.86 - 2.77 (m, 1H), 2.76 - 2.62 (m, 4H), 2.11 - 2.04 (m, 1H), 1.88 (d, J = 13.6Hz, 6H). HRMS (ESI) C 49 H 62 ClNO 12 P + [M+H] + Calculated value: 1034.3939, measured value: 1034.3055.

[0248] Compound Example 6: Synthesis of 4-((2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197055)

[0249] SIAIS1197055 (yellow solid, 18.8 mg, yield 69%) was prepared using brigatinib analog A and intermediate LM (SIAIS151025) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, DMSO) δ 11.12 (s, 1H), 8.43 (s, 1H), 8.11 (s, 1H), 7.64 (dd, J = 8.4, 7.2 Hz, 1H), 7.59 - 7.54 (m, 1H), 7.43 (d, J = 9.4 Hz, 1H), 7.39 (s, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.09 (d, J = 7.1 Hz, 1H), 6.73 (d, J = 2.1 Hz, 1H), 6.55 (dd, J = 8.5, 2.2 Hz, 1H), 5.08 (dd, J = 12.9, 5.1 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 4H), 3.28 (s, 2H), 3.20 (s, 4H), 1.78 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 38 H 40 ClN9O7P + [M+H] + Calculated value: 800.2471, measured value: 800.2478.

[0250] Compound Example 7: Synthesis of 4-((3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197057)

[0251] SIAIS1197057 (yellow solid, 13.5 mg, 50% yield) was prepared using brigatinib analog A and intermediate LM (SIAIS151026) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.37 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 14.0, 7.6 Hz, 1H), 7.58 (t, J = 7.8 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.14 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 7.1 Hz, 1H), 6.68 (s, 1H), 6.54 (d, J = 7.5 Hz, 1H), 4.99 (dd, J = 12.8, 5.5 Hz, 1H), 3.83 (s, 3H), 3.78 - 3.68 (m, 6H), 3.18 (s, 4H), 2.84 - 2.74 (m, 3H), 2.71 - 2.59 (m, 2H), 2.02 - 1.94 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 39 H 42 ClN9O7P + [M+H] + Calculated value: 814.2628, measured value: 814.3219.

[0252] Compound Example 8: Synthesis of 4-((4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197059)

[0253] SIAIS1197059 (yellow solid, 14.4 mg, yield 53%) was prepared using brigatinib analog A and intermediate LM (SIAIS151019) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 13.8, 7.3 Hz, 1H), 7.54 (dd, J = 8.5, 7.1 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.69 (s, 1H), 6.54 (d, J = 7.5 Hz, 1H), 5.03 (dd, J = 12.6, 5.5 Hz, 1H), 3.84 (s, 3H), 3.78 - 3.65 (m, 4H), 3.44 (t, J = 6.6 Hz, 2H), 3.18 (s, 4H), 2.89 - 2.77 (m, 1H), 2.75 - 2.63 (m, 2H), 2.58 (t, J = 7.0 Hz, 2H), 2.11 - 2.04 (m, 1H), 2.04 - 1.97 (m, 2H), 1.88(d, J = 13.6 Hz, 6H). HRMS (ESI) C 40 H 44 ClN9O7P + [M+H] + Calculated value: 828.2784, measured value: 828.2783.

[0254] Compound Example 9: Synthesis of 4-((5-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197061)

[0255] SIAIS1197061 (yellow solid, 12.6 mg, yield 45%) was prepared using brigatinib analog A and intermediate LM (SIAIS151020) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.37 (s, 1H), 8.04 (s, 1H), 7.64 (dd, J = 14.1, 7.8 Hz, 1H), 7.54 (t, J = 7.8 Hz, 2H), 7.41 - 7.30 (m, 2H), 7.07 (d, J = 8.5 Hz, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.69 (s, 1H), 6.53 (s, 1H), 5.00 (dd, J = 12.6, 5.5 Hz, 1H), 3.85 (s, 3H), 3.78 - 3.66 (m, 4H), 3.39 (t, J = 5.6 Hz, 2H), 3.19 (s, 4H), 2.85 - 2.74 (m, 1H), 2.73 - 2.60 (m, 2H), 2.53 (t, J = 6.6 Hz, 2H), 2.07 -2.00 (m, 1H), 1.87 (d, J = 13.5 Hz, 6H), 1.81 - 1.71 (m, 4H). HRMS (ESI) C 41 H 46 ClN9O7P + [M+H] + Calculated value: 842.2941, measured value: 842.2951.

[0256] Compound Example 10: Synthesis of 4-((6-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197063)

[0257] SIAIS1197063 (yellow solid, 15.6 mg, yield 58%) was prepared using brigatinib analog A and intermediate LM (SIAIS151027) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 13.5, 7.0 Hz, 1H), 7.53 (dd, J = 8.6, 7.1 Hz, 2H), 7.36 (t, J = 6.8 Hz, 1H), 7.32 (d, J = 6.8 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 7.00 (d, J = 6.9 Hz, 1H), 6.71 (s, 1H), 6.55 (d, J = 7.7 Hz, 1H), 5.01 (dd, J = 12.5, 5.4 Hz, 1H), 3.85 (s, 3H), 3.78 - 3.68 (m, 4H), 3.36 (t, J = 6.8 Hz, 2H), 3.22 (s, 4H), 2.86 - 2.74 (m, 1H), 2.74 - 2.62 (m, 2H), 2.49 (t, J = 7.4 Hz, 2H), 2.10 - 2.03 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.76 - 1.66 (m, 4H), 1.54 - 1.46 (m, 2H). HRMS (ESI) C 42 H 48 ClN9O7P + [M+H] + Calculated value: 856.3097, measured value: 856.3109.

[0258] Compound Example 11: Synthesis of 4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS1197077)

[0259] SIAIS1197077 (yellow solid, 17.6 mg, yield 65%) was prepared using brigatinib analog A and intermediate LM (SIAIS151086) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 13.8, 7.7 Hz, 1H), 7.53 (dd, J = 8.6, 7.1 Hz, 2H), 7.37 (t, J = 7.1 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.72 (s, 1H), 6.56 (d, J = 8.5 Hz, 1H), 5.03 (dd, J = 12.5, 5.5 Hz, 1H), 3.85 (s, 3H), 3.79 - 3.67 (m, 4H), 3.34 (t, J = 6.9 Hz, 2H), 3.24 (d, J = 14.7 Hz, 4H), 2.87 - 2.77 (m, 1H), 2.75 - 2.64 (m, 2H), 2.46 (t, J = 7.5 Hz, 2H), 2.12 - 2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.74 - 1.62 (m, 4H), 1.54 - 1.40 (m, 4H). HRMS (ESI) C 43 H 50 ClN9O7P + [M+H] + Calculated value: 870.3254, measured value: 870.3009.

[0260] Compound Example 12: Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197087)

[0261] SIAIS1197087 (white solid, 15.7 mg, 58%) was prepared using brigatinib analog A and intermediate LM (SIAIS151010) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.85 (s, 1H), 8.37 (s, 1H), 8.04 (s, 1H), 7.65 (dd, J = 14.1, 7.4 Hz, 1H), 7.54 (s, 1H), 7.44 - 7.32 (m, 5H), 6.69 (s, 1H), 6.55 (s, 1H), 4.71 (d, J = 9.4 Hz, 1H), 4.60 - 4.44 (m, 2H), 4.50 (s, 1H), 4.41 - 4.31 (m, 3H), 4.07 (d, J = 10.4 Hz, 2H), 3.87 (d, J = 9.8 Hz, 1H), 3.83 (s, 3H), 3.80 - 3.64 (m, 9H), 3.25 (s, 4H), 2.44 (s, 3H), 2.27 - 2.17 (m, 1H), 2.13 - 2.04 (m, 1H), 1.87 (d, J = 13.5 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 51 H 65 ClN 10 O9PS + [M+H] + Calculated value: 1059.4077, measured value: 1059.4091.

[0262] Compound Example 13: Synthesis of (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197079)

[0263] SIAIS1197079 (white solid, 14.9 mg, 55%) was prepared using brigatinib analog A and intermediate LM (SIAIS151002) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.89 (s, 1H), 8.40 (s, 1H), 8.03 (s, 1H), 7.66 (dd, J = 14.0, 7.7 Hz, 1H), 7.55 (s, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.42 - 7.33 (m, 3H), 7.29 (d, J = 7.8 Hz, 1H), 6.72 (s, 1H), 6.58 (d, J = 8.5 Hz, 1H), 4.64 (s, 1H), 4.60 - 4.52 (m, 2H), 4.49 (s, 1H), 4.34 (d, J = 15.5 Hz, 1H), 3.88 (d, J = 10.9 Hz, 1H), 3.84 (s, 3H), 3.81 - 3.66 (m, 9H), 3.62 - 3.58 (m, 4H), 3.31 (s, 2H), 3.21 (s, 2H), 2.77 - 2.66 (m, 2H), 2.46 (s, 3H), 2.51 - 2.43 (m, 1H), 2.43 - 2.36 (m, 1H), 2.25 - 2.18 (m, 1H), 2.12 - 2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 53 H 69 ClN 10 O9PS + [M+H] + Calculated value: 1087.4390, measured value: 1087.3478.

[0264] Compound Example 14: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197081)

[0265] SIAIS1197081 (white solid, 17.1 mg, 63%) was prepared using brigatinib analog A and intermediate LM (SIAIS151003) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.91 (s, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 14.1, 7.8 Hz, 1H), 7.54 (s, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.44 - 7.35 (m, 3H), 7.29 (d, J = 8.2 Hz, 1H), 6.73 (d, J = 2.1 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 4.64 (s, 1H), 4.59 - 4.51 (m, 2H), 4.49 (s, 1H), 4.35 (d, J = 15.5 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.85 (s, 3H), 3.82 - 3.73 (m, 7H), 3.72 - 3.65 (m, 2H), 3.63 - 3.54 (m, 8H), 3.44 (t, J = 7.0 Hz, 1H), 3.31 (s, 2H), 3.24 (s, 2H), 2.71 (t, J = 6.2 Hz, 2H), 2.60 - 2.50 (m, 1H), 2.47 (s, 3H), 2.49 - 2.40 (m, 1H), 2.25 - 2.18 (m, 1H), 2.11 - 2.05 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 55 H 73 ClN 10 O 10 PS + [M+H] + Calculated value: 1131.4652, measured value: 1131.4651.

[0266] Compound Example 15: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197083)

[0267] SIAIS1197083 (white solid, 16.7 mg, 62%) was prepared using brigatinib analog A and intermediate LM (SIAIS151008) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.89 (s, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 7.66 (dd, J = 13.5, 8.1 Hz, 1H), 7.54 (s, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.42 - 7.35 (m, 3H), 7.31 (d, J = 8.6 Hz, 1H), 6.73 (s, 1H), 6.58 (d, J = 7.5 Hz, 1H), 4.64 (s, 1H), 4.59 - 4.50 (m, 2H), 4.49 (s, 1H), 4.35 (d, J = 15.5 Hz, 1H), 3.87 (d, J = 12.2 Hz, 1H), 3.85 (s, 3H), 3.82 - 3.72 (m, 7H), 3.73 - 3.65 (m, 2H), 3.64 - 3.53 (m, 12H), 3.31 (s, 2H), 3.24 (s, 2H), 2.72 (t, J = 6.2 Hz, 2H), 2.59 - 2.51 (m, 1H), 2.46 (s, 3H), 2.49 - 2.40 (m, 1H), 2.25 - 2.16 (m, 1H), 2.11 -2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 57 H 77 ClN10 O 11 PS + [M+H] + Calculated value: 1175.4915, measured value: 1175.4981.

[0268] Compound Example 16: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197085)

[0269] SIAIS1197085 (white solid, 16.5 mg, 61%) was prepared using brigatinib analog A and intermediate LM (SIAIS151009) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.90 (s, 1H), 8.39 (s, 1H), 8.03 (s, 1H), 7.67 (dd, J = 14.0, 6.9 Hz, 1H), 7.55 (s, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.44 - 7.34 (m, 3H), 7.30 (d, J = 8.5 Hz, 1H), 6.74 (s, 1H), 6.59 (d, J = 8.1 Hz, 1H), 4.64 (s, 1H), 4.59 - 4.51 (m, 2H), 4.49 (s, 1H), 4.35 (d, J = 15.6 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.85 (s, 3H), 3.82 - 3.4 (m, 7H), 3.74 - 3.67 (m, 2H), 3.65 - 3.54 (m, 16H), 3.31 (s, 2H), 3.25 (s, 2H), 2.72 (t, J = 6.1 Hz, 2H), 2.60 - 2.51 (m, 1H), 2.47 (s, 3H), 2.50 - 2.40 (m, 1H), 2.25 - 2.17 (m, 1H), 2.11 - 2.04 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 59 H 81 ClN 10 O 12 PS + [M+H] + Calculated value: 1219.5177, measured value: 1219.5229.

[0270] Compound Example 17: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197145)

[0271] SIAIS1197145 (white solid, 10.1 mg, 37%) was prepared using brigatinib analog A and intermediate LM (SIAIS074011) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.98 (s, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 7.80 - 7.45 (m, 8H), 7.39 (s, 1H), 7.13 (d, J = 8.5 Hz, 1H), 4.66 - 4.35 (m, 5H), 4.05 (s, 4H), 3.96 (s, 3H), 3.89 (d, J = 10.7 Hz, 1H), 3.80 (d, J = 8.1 Hz, 1H), 3.70 (s, 2H), 3.61 (s, 2H), 2.91 - 2.63 (m, 4H), 2.61 (s, 3H), 2.23 (s, 1H), 2.07 (s, 1H), 1.87 (d, J = 13.4 Hz, 6H), 1.05 (s, 9H). HRMS (ESI) C 49 H 61 ClN 10 O7PS + [M+H] + Calculated value: 999.3866, measured value: 999.1918.

[0272] Compound Example 18: Synthesis of (2S,4R)-1-((S)-2-(5-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197147)

[0273] SIAIS1197147 (white solid, 9.4 mg, 35%) was prepared using brigatinib analog A and intermediate LM (SIAIS074012) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 10.00 (s, 1H), 8.25 (s, 1H), 8.14 (s, 1H), 7.79 - 7.63 (m, 3H), 7.61 - 7.46 (m, 6H), 7.22 (d, J = 8.6 Hz, 1H), 4.65 - 4.47 (m, 4H), 4.41 (d, J = 15.7 Hz, 1H), 4.07 (s, 4H), 3.97 (s, 3H), 3.93 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.6 Hz, 1H), 3.74 (s, 2H), 3.66 (s, 2H), 2.60 (s, 3H), 2.53 (t, J = 7.4 Hz, 2H), 2.40 (t, J = 7.1 Hz, 2H), 2.28 - 2.20 (m, 1H), 2.11 - 2.02 (m, 1H), 2.01 - 1.92 (m, 2H), 1.87 (d, J = 13.6 Hz, 6H), 1.05 (s, 9H). HRMS (ESI) C 50 H 63 ClN 10 O7PS + [M+H] + Calculated value: 1013.4023, measured value: 1013.2012.

[0274] Compound Example 19: Synthesis of (2S,4R)-1-((S)-2-(6-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-6-oxohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197149)

[0275] SIAIS1197149 (white solid, 11.4 mg, 42%) was prepared using brigatinib analog A and intermediate LM (SIAIS074013) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 10.02 (d, J = 2.9 Hz, 1H), 8.26 (s, 1H), 8.13 (m 1H), 7.80 - 7.63 (m, 3H), 7.60 - 7.49 (m, 6H), 7.25 (d, J = 8.8 Hz, 1H), 4.64 - 4.46 (m, 4H), 4.40 (dd, J = 15.7, 3.7 Hz, 1H), 4.10 (s, 4H), 3.97 (s, 3H), 3.90 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.9 Hz, 1H), 3.76 (s, 2H), 3.68 (s, 2H), 2.61 (s, 3H), 2.59 - 2.48 (m, 2H), 2.38 - 2.32 (m, 2H), 2.27 - 2.21(m, 1H), 2.10 - 2.03 (m, 1H), 1.87 (d, J = 13.6 Hz, 6H), 1.77 - 1.64 (m, 4H), 1.04 (s, 9H). HRMS (ESI) C 51 H 65 ClN 10 O7PS + [M+H] + Calculated value: 1027.4179, measured value: 1027.2037.

[0276] Compound Example 20: Synthesis of (2S,4R)-1-((S)-2-(7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197151)

[0277] SIAIS1197151 (white solid, 12.7 mg, 47%) was prepared using brigatinib analog A and intermediate LM (SIAIS074014) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 10.03 (d, J = 1.2 Hz, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 7.78 - 7.65 (m, 3H), 7.61 - 7.48 (m, 6H), 7.25 (d, J = 8.6 Hz, 1H), 4.63 (d, J = 7.6 Hz, 1H), 4.59 - 4.53 (m, 2H), 4.50 (s, 1H), 4.40 (dd, J = 15.8, 6.4 Hz, 1H), 4.11 (s, 4H), 3.98 (s, 3H), 3.90 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 11.0, 3.7 Hz, 1H), 3.77 - 3.60 (m, 4H), 2.61 (s, 3H), 2.52 (t, J = 7.5 Hz, 2H), 2.36 - 2.19 (m, 3H), 2.12 - 2.04 (m, 1H), 1.87 (d, J = 13.6 Hz, 6H), 1.72 - 1.57 (m, 4H), 1.47 - 1.29 (m, 2H), 1.03 (s, 9H). HRMS (ESI) C 52 H 67 ClN 10 O7PS + [M+H] + Calculated value: 1041.4336, measured value: 1041.2125.

[0278] Compound Example 21: Synthesis of (2S,4R)-1-((S)-2-(8-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197153)

[0279] SIAIS1197153 (white solid, 6.8 mg, 25%) was prepared using brigatinib analog A and intermediate LM (SIAIS074015) in the procedure for preparing Compound Example 1.1 H NMR (500 MHz, MeOD) δ 9.99 (d, J = 4.4 Hz, 1H), 8.23 ​​(s, 1H), 8.18 (s, 1H), 7.74 (dd, J = 13.0, 7.6 Hz, 1H), 7.66 (t, J = 7.5 Hz, 2H), 7.60 - 7.46 (m, 5H), 7.40 (s, 1H), 7.14 (d, J = 8.7 Hz, 1H), 4.63 (d, J = 6.1 Hz, 1H), 4.60 -- 4.52 (m, 2H), 4.50 (s, 1H), 4.40 (dd, J = 15.8, 7.7 Hz, 1H), 4.05 (s, 4H), 3.96 (s, 3H), 3.91 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 11.1, 3.7 Hz, 1H), 3.68 (s, 2H), 3.62 (s, 2H), 2.61 (s, 3H), 2.51 (t, J = 7.5 Hz, 2H), 2.40 - 2.17 (m, 3H), 2.11 - 2.03 (m, 1H), 1.87 (d, J = 13.5 Hz, 6H), 1.70 - 1.55 (m, 4H), 1.45 - 1.30 (m, 4H), 1.04 (s, 9H). HRMS (ESI) C 53 H 69 ClN 10 O7PS + [M+H] + Calculated value: 1055.4492, measured value: 1055.2208.

[0280] Compound Example 22: Synthesis of (2S,4R)-1-((S)-2-(9-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197155)

[0281] SIAIS1197155 (white solid, 8.3 mg, 31%) was prepared using brigatinib analog A and intermediate LM (SIAIS074016) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.96 (s, 1H), 8.19 (d, J = 14.1 Hz, 2H), 7.73 (dd, J = 14.0, 6.8 Hz, 1H), 7.67 - 7.45 (m, 6H), 7.31 (s, 1H), 7.07 (d, J = 8.7 Hz, 1H), 4.64 (s, 1H), 4.60 - 4.52 (m, 2H), 4.50 (s, 1H), 4.41 (d, J = 15.8 Hz, 1H), 4.00 (s, 4H), 3.95 (s, 3H), 3.91 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.8 Hz, 1H), 3.63 (s, 2H), 3.57 (s, 2H), 2.60 (s, 3H), 2.50 (t, J = 7.6 Hz, 2H), 2.37 - 2.18 (m, 3H), 2.11 - 2.03 (m, 1H), 1.87 (d, J = 13.6 Hz, 6H), 1.70 - 1.55 (m, 4H), 1.45 - 1.30 (m, 6H), 1.02 (s, 9H). HRMS (ESI) C 54 H 71 ClN 10 O7PS + [M+H] + Calculated value: 1069.4649, measured value: 1069.2386.

[0282] Compound Example 23: Synthesis of (2S,4R)-1-((S)-2-(10-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS1197157)

[0283] In the procedure for preparing Compound Example 1, brigatinib analog A and intermediate LM (SIAIS074019) were used to prepare SIAIS1197157 (white solid, 10.6 mg, 39%). 1 H NMR (500 MHz, MeOD) δ 9.56 (d, J = 4.2 Hz, 1H), 8.35 (s, 1H), 8.08 (s, 1H), 7.70 (s, 1H), 7.62 - 7.30 (m, 6H), 6.86 (s, 1H), 6.71 (s, 1H), 4.64 (d, J = 3.5 Hz, 1H), 4.60 - 4.47 (m, 3H), 4.39 (dd, J = 15.7, 3.2 Hz, 1H), 4.00 - 3.69 (m, 9H), 3.36 (s, 4H), 2.55 (d, J = 3.8 Hz, 3H), 2.51 - 2.40 (m, 2H), 2.38 - 2.18 (m, 3H), 2.12 - 2.02 (m, 1H), 1.89 (dd, J = 13.6, 3.5 Hz, 6H), 1.62 (s, 4H), 1.35 (s, 8H), 1.03 (t, J = 5.8 Hz, 9H). HRMS (ESI) C 55 H 73 ClN 10 O7PS + [M+H] + Calculated value: 1083.4805, measured value: 1083.2486.

[0284] Compound Example 24: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propenamide. (SIAIS151113)

[0285] SIAIS151113 (yellow solid, 10.4 mg, 60%) was prepared using brigatinib analog B and intermediate LM (SIAIS151001) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.29 (dd, J = 8.1, 3.8 Hz, 1H), 8.13 (s, 1H), 7.74 - 7.67 (m, 2H), 7.63 - 7.59 (m, 1H), 7.55 (dd, J = 8.6, 7.1 Hz, 1H), 7.41 - 7.31 (m, 1H), 7.09 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 6.8 Hz, 1H), 7.00 (d, J = 1.9 Hz, 1H), 6.81 (dd, J = 8.8, 2.4 Hz, 1H), 5.03 (dd, J = 12.5, 5.5 Hz, 1H), 4.10 - 3.85 (m, 2H), 3.92 (s, 3H), 3.79 (t, J = 5.9 Hz, 2H), 3.71 (t, J = 5.1 Hz, 2H), 3.68 - 3.64 (m, 2H), 3.50 (t, J = 5.0 Hz, 2H), 2.93 - 2.61 (m, 4H), 2.48 (t, J = 5.9 Hz, 2H), 2.10 - 2.01 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.83 - 1.75 (m, 2H). HRMS (ESI) C 42 H 48 ClN9O8P + [M+H] + Calculated value: 872.3047, measured value: 872.2645.

[0286] Compound Example 25: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propenamide. (SIAIS151114)

[0287] SIAIS151114 (yellow solid, 9.8 mg, 53%) was prepared using brigatinib analog B and intermediate LM (SIAIS151004) in the procedure for preparing Compound Example 1.1 H NMR (500 MHz, MeOD) δ 8.29 (dd, J = 7.5, 3.5 Hz, 1H), 8.13 (s, 1H), 7.72 - 7.67 (m, 2H), 7.62 - 7.59 (m, 1H), 7.52 (dd, J = 8.5, 7.1 Hz, 1H), 7.41 - 7.37 (m, 1H), 7.07 (d, J = 8.5 Hz, 1H), 7.01 (d, J = 6.9 Hz, 1H), 6.99 (s, 1H), 6.79 (d, J = 8.8 Hz, 1H), 5.04 (dd, J = 12.6, 5.5 Hz, 1H), 4.00 - 3.94 (m, 1H), 3.90 (s, 3H), 3.76 (t, J = 6.1 Hz, 2H), 3.72 (t, J = 5.3 Hz, 2H), 3.70 - 3.62 (m, 8H), 3.48 (t, J = 5.3 Hz, 2H), 2.87 - 2.80 (m, 1H), 2.75 - 2.67 (m, 2H), 2.46 (t, J = 6.0 Hz, 2H), 2.13 - 2.07 (m, 3H), 1.88 (s, 3H), 1.86 (s, 3H), 1.84 - 1.77 (m, 2H). HRMS (ESI) C 44 H 52 ClN9O9P + [M+H] + Calculated value: 916.3309, measured value: 916.2857.

[0288] Compound Example 26: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propenamide. (SIAIS151115)

[0289] Compound Example 1 was prepared using SIAIS 151115 (yellow solid, 16.8 mg, 87%). 1 H NMR (500 MHz, MeOD) δ 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.12 (s, 1H), 7.73 - 7.66 (m, 2H), 7.61 (t, J = 7.8 Hz, 1H), 7.52 (dd, J = 8.5, 7.1 Hz, 1H), 7.39 (t, J = 7.1 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 7.00 (s, 1H), 6.81 (d, J = 6.9 Hz, 1H), 5.04 (dd, J = 12.7, 5.5 Hz, 1H), 4.02 - 3.96 (m, 1H), 3.90 (s, 3H), 3.75 - 3.67 (m, 7H), 3.65 (s, 3H), 3.64 - 3.63 (m, 3H), 3.61 - 3.59 (m, 2H), 3.48 (t, J = 5.2 Hz, 2H), 3.38 - 3.35 (m, 1H), 2.89 - 2.81 (m, 1H), 2.76 - 2.67 (m, 2H), 2.45 (t, J = 6.0 Hz, 2H), 2.16 - 2.07 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.84 - 1.78 (m, 2H). HRMS (ESI) C 46 H 56 ClN9O 10 P + [M+H] + Calculated value: 960.3571, measured value: 960.3920.

[0290] Compound Example 27: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide. (SIAIS151116)

[0291] SIAIS151116 (yellow solid, 13.5 mg, 67%) was prepared using brigatinib analog B and intermediate LM (SIAIS151006) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.12 (s, 1H), 7.75 - 7.66 (m, 2H), 7.60 (t, J = 7.8 Hz, 1H), 7.51 (dd, J = 8.5, 7.1 Hz, 1H), 7.38 (dd, J = 7.0, 6.0 Hz, 1H), 7.05 - 6.99 (m, 3H), 6.82 (d, J = 8.2 Hz, 1H), 5.03 (dd, J = 12.7, 5.5 Hz, 1H), 4.03 - 3.96 (m, 1H), 3.90 (s, 3H), 3.75 - 3.68 (m, 6H), 3.65 - 3.59 (m, 12H), 3.45 (t, J = 5.3 Hz, 2H), 3.39 - 3.34 (m, 2H), 2.88 - 2.81 (m, 1H), 2.77 - 2.62 (m, 2H), 2.45 (t, J = 6.0 Hz, 2H), 2.16 - 2.12 (m, 2H), 2.11 - 2.06 (m, 1H), 1.88 (s, 3H), 1.85 (s, 3H), 1.85 - 1.78 (m, 2H). HRMS (ESI) C 48 H 60 ClNO 11 P + [M+H] + Calculated value: 1004.3833, measured value: 1004.4184.

[0292] Compound Example 28: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-amide. (SIAIS151117)

[0293] SIAIS151117 (yellow solid, 15.8 mg, 75%) was prepared using brigatinib analog B and intermediate LM (SIAIS151007) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.24 (dd, J = 7.5, 3.5 Hz, 1H), 8.16 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.69 (ddd, J = 13.9, 7.7, 1.4 Hz, 1H), 7.63 - 7.59 (m, 1H), 7.52 (dd, J = 8.5, 7.1 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.16 - 7.11 (m, 1H), 7.03 (dd, J = 15.1, 7.8 Hz, 2H), 6.92 (d, J = 8.7 Hz, 1H), 5.03 (dd, J = 12.8, 5.5 Hz, 1H), 4.06 - 4.00 (m, 1H), 3.92 (s, 3H), 3.75 - 3.71 (m, 4H), 3.69 (t, J = 5.3 Hz, 2H), 3.64 - 3.60 (m, 16H), 3.53 - 3.48 (m, 2H), 3.45 (t, J = 5.3 Hz, 2H), 2.88 - 2.80 (m, 1H), 2.75 - 2.64 (m, 2H), 2.46 (t, J = 6.0 Hz, 2H), 2.20 - 2.17 (m, 2H), 2.11 - 2.06 (m, 1H), 1.95 - 1.89 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H). HRMS (ESI) C 50H 64 ClNO 12 P + [M+H] + Calculated value: 1049.5400, measured value: 1049.4482.

[0294] Compound Example 29: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide. (SIAIS151120)

[0295] SIAIS151120 (yellow solid, 11.1 mg, 68%) was prepared using brigatinib analog B and intermediate LM (SIAIS151025) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.31 (dd, J = 7.5, 3.5 Hz, 1H), 8.10 (s, 1H), 7.72-7.66 (m, 2H), 7.62 - 7.57 (m, 2H), 7.40 - 7.36 (m, 1H), 7.13 (d, J = 7.0 Hz, 1H), 6.97 (s, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 5.08 (dd, J = 12.6, 5.5 Hz, 1H), 4.07 - 4.01 (m, 3H), 3.90 (s, 3H), 3.74 - 3.69 (m, 2H), 3.38 - 3.31 (m, 2H), 2.88 - 2.83 (m, 1H), 2.78 - 2.76 (m, 1H), 2.75 - 2.71 (m, 1H), 2.15 - 2.08 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.85 - 1.78 (m, 2H). HRMS (ESI) C 39 H 42 ClN9O7P + [M+H] + Calculated value: 814.2628, measured value: 814.3211.

[0296] Compound Example 30: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propenamide. (SIAIS151121)

[0297] SIAIS151121 (yellow solid, 14 mg, 85%) was prepared using brigatinib analog B and intermediate LM (SIAIS151026) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 8.29 (dd, J = 7.5, 3.5 Hz, 1H), 8.12 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 7.69 (ddd, J = 13.9, 7.8, 1.4 Hz, 1H), 7.62 - 7.57 (m, 2H), 7.41 - 7.36 (m, 1H), 7.14 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 6.9 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.83 (dd, J = 8.8, 2.4 Hz, 1H), 5.03 (dd, J = 12.4, 5.5 Hz, 1H), 4.02 - 3.96 (m, 1H), 3.92 (s, 3H), 3.71 - 3.67 (m, 4H), 3.40 - 3.34 (m, 2H), 2.86 - 2.79 (m, 1H), 2.75 - 2.65 (m, 2H), 2.56 (dd, J = 6.9, 5.3 Hz, 2H), 2.12 - 2.05 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.81 - 1.72 (m, 2H). HRMS (ESI) C 40 H 44 ClN9O7P + [M+H] + Calculated value: 828.2784, measured value: 828.3370.

[0298] Compound Example 31: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanamide. (SIAIS151118)

[0299] SIAIS151118 (yellow solid, 13.2 mg, 78%) was prepared using brigatinib analog B and intermediate LM (SIAIS151019) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.11 (s, 1H), 7.75 - 7.73 (m, 1H), 7.69 (ddd, J = 13.9, 7.7, 1.4 Hz, 1H), 7.62 - 7.58 (m, 1H), 7.56 (dd, J = 9.0, 7.5 Hz, 1H), 7.41 - 7.36 (m, 1H), 7.09 (d, J = 8.5 Hz, 1H), 7.05 (d, J = 6.8 Hz, 1H), 6.99 (s, 1H), 6.81 (d, J = 8.4 Hz, 1H), 5.06 (dd, J = 12.6, 5.5 Hz, 1H), 3.96 - 3.89 (m, 1H), 3.91 (s, 3H), 3.71 - 3.68 (m, 2H), 3.41 (t, J = 6.7 Hz, 2H), 3.37 - 3.33 (m, 2H), 2.89 - 2.81 (m, 1H), 2.77 - 2.69 (m, 2H), 2.34 (t, J = 7.0 Hz, 2H), 2.14 - 2.05 (m, 3H), 2.03 - 1.97 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H), 1.81 - 1.72 (m, 2H). HRMS (ESI) C 41 H 46 ClN9O7P + [M+H] +Calculated value: 842.2941, measured value: 842.3294.

[0300] Compound Example 32: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanamide. (SIAIS151119)

[0301] SIAIS151119 (yellow solid, 12 mg, 70%) was prepared using brigatinib analog B and intermediate LM (SIAIS151020) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.11 (s, 1H), 7.71 - 7.66 (m, 2H), 7.61 (t, J = 7.9 Hz, 1H), 7.55 (dd, J = 8.6, 7.1 Hz, 1H), 7.41 - 7.37 (m, 1H), 7.05 (dd, J = 9.8, 7.8 Hz, 2H), 7.00 (d, J = 2.0 Hz, 1H), 6.82 (dd, J = 8.8, 2.3 Hz, 1H), 5.05 (dd, J = 12.5, 5.5 Hz, 1H), 4.00 - 3.94 (m, 1H), 3.92 (s, 3H), 3.75 - 3.70 (m, 2H), 3.39 - 3.33 (m, 4H), 2.88 - 2.80 (m, 1H), 2.76 - 2.66 (m, 2H), 2.28 (t, J = 7.1 Hz, 2H), 2.15 - 2.08 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.83 - 1.68 (m, 6H). HRMS (ESI) C 42 H 48 ClN9O7P + [M+H] + Calculated value: 856.3097, measured value: 856.3403.

[0302] Compound Example 33: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanamide. (SIAIS151122)

[0303] SIAIS151122 (yellow solid, 4.5 mg, 30%) was prepared using brigatinib analog B and intermediate LM (SIAIS151027) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.32 (dd, J = 7.5, 3.5 Hz, 1H), 8.10 (s, 1H), 7.69 (ddd, J = 14.0, 7.8, 1.4 Hz, 2H), 7.61 (t, J = 7.8 Hz, 1H), 7.55 (dd, J = 8.6, 7.1 Hz, 1H), 7.40 - 7.36 (m, 1H), 7.05 (dd, J = 10.9, 7.7 Hz, 2H), 6.96 (s, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.04 (dd, J = 12.5, 5.5 Hz, 1H), 3.97 - 3.93 (m, 1H), 3.91 (s, 3H), 3.72 - 3.68 (m, 2H), 3.36 (t, J = 6.8 Hz, 2H), 3.30 - 3.23 (m, 2H), 2.85 - 2.76 (m, 1H), 2.75 - 2.65 (m, 2H), 2.24 (t, J = 7.2 Hz, 2H), 2.11 - 2.05 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.79 - 1.73 (m, 2H), 1.73 - 1.67 (m, 4H), 1.51 - 1.43 (m, 2H). HRMS (ESI) C 43 H 50 ClN9O7P + [M+H] + Calculated value: 870.3254, measured value: 870.3881.

[0304] Compound Example 34: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanamide. (SIAIS151123)

[0305] SIAIS151123 (yellow solid, 12.3 mg, 70%) was prepared using brigatinib analog B and intermediate LM (SIAIS151086) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.11 (s, 1H), 7.75 - 7.66 (m, 2H), 7.61 (t, J = 7.9 Hz, 1H), 7.55 (dd, J = 8.6, 7.1 Hz, 1H), 7.41 - 7.37 (m, 1H), 7.04 (t, J = 7.5 Hz, 2H), 7.00 (s, 1H) 6.82 (d, J = 7.7 Hz, 1H), 5.05 (dd, J = 12.5, 5.5 Hz, 1H), 4.01 - 3.93 (m, 1H), 3.92 (s, 3H), 3.72 - 3.70 (m, 2H), 3.37 - 3.32 (m, 4H), 2.89 - 2.79 (m, 1H), 2.76 - 2.69 (m, 2H), 2.22 (t, J = 7.4 Hz, 2H), 2.14 - 2.05 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.84 - 1.76 (m, 2H), 1.72 - 1.64 (m, 4H), 1.50 - 1.40 (m, 4H). HRMS (ESI) C 44 H 52 ClN9O7P + [M+H] + Calculated value: 884.3410, measured value: 884.3420.

[0306] Compound Example 35: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)acetamide. (SIAIS219151)

[0307] SIAIS219151 (yellow solid, 7.2 mg, 45%) was prepared using brigatinib analog B and intermediate LM (SIAIS1204057) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.19 (s, 2H), 7.72 (dd, J = 13.7, 7.6 Hz, 2H), 7.63 (t, J = 7.6 Hz, 1H), 7.44 (s, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.26 (s, 1H), 7.17 (d, J = 7.5 Hz, 1H), 6.99 (s, 1H), 6.72 (d, J = 8.1 Hz, 1H), 5.18 (dd, J = 13.3, 5.1 Hz, 1H), 4.44 (d, J = 16.8 Hz, 1H), 4.39 (d, J = 16.9 Hz, 1H), 4.15 (s, 1H), 3.95 (s, 3H), 3.73 - 3.68 (m, 2H), 3.63 - 3.50 (m, 4H), 2.97-2.90 (m, 1H), 2.85 - 2.77 (m, 1H), 2.55-2.46 (m, 1H), 2.22-2.15 (m, 3H), 2.00 (s, 2H), 1.86 (d, J = 13.5 Hz, 6H). HRMS (ESI) C39H44ClN9O7P+ [M+H]+Calculated value: 800.2835, Actual value: 800.2831.

[0308] Compound Example 36: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butanamide. (SIAIS219128)

[0309] SIAIS219128 (yellow solid, 10 mg, 40%) was prepared using brigatinib analog B and intermediate LM (SIAIS1204085) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 8.24 (s, 1H), 8.12 (s, 1H), 7.79 - 7.71 (m, 2H), 7.67 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.1 Hz, 1H), 7.44 (s, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.21 - 7.15 (m, 2H), 7.00 (d, J = 8.1 Hz, 1H), 5.20 (dd, J = 13.3, 5.0 Hz, 1H), 4.44 (d, J = 17.0 Hz, 1H), 4.37 (d, J = 17.0 Hz, 1H), 3.98 (s, 4H), 3.82 - 3.62 (m, 4H), 3.41-3.37 (m, 2H), 3.01 - 2.89 (m, 1H), 2.83 (d, J = 16.7 Hz, 1H), 2.58 - 2.48 (m, 1H), 2.41 (t, J = 6.7 Hz, 2H), 2.28 - 2.13 (m, 2H), 2.07-1.96 (m, 4H), 1.87 (d, J = 13.5 Hz, 6H), 1.77 (d, J = 14.2 Hz, 1H). HRMS (ESI) C 41 H 48 ClN9O6P + [M+H] + Calculated value: 828.3148, measured value: 828.3141.

[0310] Synthesis of Compound Example 37: N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentanamide (SIAIS219152)

[0311] SIAIS219152 (yellow solid, 8.0 mg, 47%) was prepared using brigatinib analog B and intermediate LM (SIAIS1210133) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 8.13 (s, 1H), 7.80 - 7.71 (m, 2H), 7.68 (t, J = 7.7 Hz, 1H), 7.55 - 7.41 (m, 3H), 7.37 - 7.25 (m, 1H), 7.22-7.17 (m, 1H), 7.14-7.08 (m, 1H), 5.17 (dd, J = 13.2, 5.1 Hz, 1H), 4.53 - 4.38 (m, 2H), 4.08 (s, 1H), 3.99 (s, 3H), 3.73 (s, 4H), 3.35-3.32 (m, 2H), 2.93-2.90 (m, 1H), 2.83-2.81 (m, 1H), 2.59 - 2.46 (m, 1H), 2.32 (s, 2H), 2.23-2.07 (m, 5H), 1.87 (d, J = 13.6 Hz, 6H), 1.81 - 1.71 (m, 4H). HRMS (ESI) C 42 H 50 ClN9O6P + [M+H] + Calculated value: 842.3305, measured value: 842.3301.

[0312] Compound Example 38: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanamide. (SIAIS219153)

[0313] SIAIS219153 (yellow solid, 8.2 mg, 48%) was prepared using brigatinib analog B and intermediate LM (SIAIS1204061) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 8.14 (s, 1H), 7.80 - 7.71 (m, 2H), 7.68 (t, J = 7.4 Hz, 1H), 7.54 - 7.40 (m, 3H), 7.31-7.25 (m 1H), 7.21-7.17 (m, 1H), 7.15 - 7.03 (m, 1H), 5.17 (dd, J = 13.3, 5.1 Hz, 1H), 4.48-4.38 (m, 2H), 4.06 (s, 1H), 3.99 (s, 3H), 3.72 (s, 4H), 3.33-3.31 (m, 2H), 2.93-2.90 (m, 1H), 2.82-2.81 (m, 1H), 2.58 - 2.47 (m, 1H), 2.27 (t, J = 6.7 Hz, 2H), 2.24-2.16 (m, 2H), 2.05-2.04 (m, 3H), 1.87 (d, J = 13.5 Hz, 6H), 1.76 - 1.68 (m, 4H), 1.52-1.45 (m, 2H). HRMS (ESI) C 43 H 52 ClN9O6P + [M+H] + Calculated value: 856.3461, measured value: 856.3449.

[0314] Compound Example 39: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)heptanamide. (SIAIS219154)

[0315] SIAIS219154 (yellow solid, 7.9 mg, 45%) was prepared using brigatinib analog B and intermediate LM (SIAIS1204063) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.22 (s, 1H), 8.17 (s, 1H), 7.79 - 7.70 (m, 2H), 7.66 (t, J = 7.8 Hz, 1H), 7.47 (t, J = 7.1 Hz, 1H), 7.39 (dd, J = 16.2, 8.4 Hz, 2H), 7.20 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 5.17 (dd, J = 13.3, 5.2 Hz, 1H), 4.42 (d, J = 17.0 Hz, 1H), 4.37 (d, J = 17.0 Hz, 1H), 4.06 (t, J = 10.9 Hz, 1H), 3.98 (s, 3H), 3.69-3.62 (m, 4H), 3.30 - 3.26 (m, 2H), 2.99 - 2.89 (m, 1H), 2.85 - 2.76 (m, 1H), 2.58 - 2.46 (m, 1H), 2.26-2.15 (m, 5H), 2.04-2.00 (m, 2H), 1.87 (d, J = 13.5 Hz, 6H), 1.74 - 1.65 (m, 4H), 1.51-1.46 (m, 2H), 1.44-1.40 (m, 2H). HRMS (ESI) C 44 H 54 ClN9O6P + [M+H] + Calculated value: 870.3618, measured value: 870.3611.

[0316] Compound Example 40: Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151128)

[0317] SIAIS151128 (white solid, 14.7 mg, 68%) was prepared using brigatinib analog B and intermediate LM (SIAIS151010) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.92 (s, 1H), 8.30 (dd, J = 8.0, 4.1 Hz, 1H), 8.11 (s, 1H), 7.71 - 7.64 (m, 2H), 7.61 - 7.57 (m, 1H), 7.43 - 7.38 (m, 5H), 7.00 (s, 1H), 6.82 (dd, J = 8.5, 2.0 Hz, 1H), 4.72 (s, 1H), 4.59 - 4.56 (m, 1H), 4.53 - 4.46 (m, 2H), 4.38 (d, J = 15.7 Hz, 1H), 4.13 - 4.02 (m, 5H), 3.91 - 3.90 (m, 1H), 3.90 (s, 3H), 3.85 - 3.65 (m, 8H), 3.37 - 3.34 (m, 1H), 2.46 (s, 3H), 2.28 - 2.23 (m, 1H), 2.15 - 2.07 (m, 3H), 1.99 - 1.91 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H), 1.05 (s, 9H). HRMS (ESI) C 52 H 67 ClN 10 O9PS + [M+H] + : 1073.4234, Actual value: 1073.4229.

[0318] Compound Example 41: Synthesis of (2S,4R)-1-((S)-2-(3-(2-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151124)

[0319] SIAIS151124 (white solid, 6.1 mg, 28%) was prepared using brigatinib analog B and intermediate LM (SIAIS151002) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.30 (dd, J = 7.5, 3.5 Hz, 1H), 8.12 (s, 1H), 7.73 - 7.66 (m, 2H), 7.63 - 7.59 (m, 1H), 7.47 - 7.45 (m, 2H), 7.43 - 7.38 (m, 3H), 7.03 (d, J = 2.0 Hz, 1H), 6.84 (dd, J = 8.8, 2.4 Hz, 1H), 4.66 (s, 1H), 4.60 - 4.54 (m, 1H), 4.51 - 4.47 (m, 2H), 4.39 - 4.34 (m, 1H), 4.03 - 3.96 (m, 1H), 3.91 - 3.87 (m, 1H), 3.92 (s, 3H), 3.80 (dd, J = 11.0, 3.8 Hz, 1H), 3.75 - 3.70 (m, 6H), 3.64 - 3.60 (m, 4H), 3.40 - 3.34 (m, 2H), 2.61 - 2.53 (m, 1H), 2.49 - 2.44 (m, 3H), 2.47 (s, 3H), 2.25 - 2.20 (m, 1H), 2.16 - 2.05 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H), 1.84 - 1.78 (m, 2H), 1.04 (s, 9H). HRMS (ESI) C 54 H 71 ClN 10 O9PS + [M+H] + Calculated value: 1101.4547, measured value: 1101.4558.

[0320] Compound Example 42: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-16-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151125)

[0321] SIAIS151125 (white solid, 13.2 mg, 58%) was prepared using brigatinib analog B and intermediate LM (SIAIS151003) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.94 (s, 1H), 8.29 (dd, J = 7.5, 3.5 Hz, 1H), 8.12 (s, 1H), 7.73 - 7.67 (m, 2H), 7.62 - 7.58 (m, 1H), 7.47 - 7.44 (m, 2H), 7.43 - 7.37 (m, 3H), 7.04 (s, 1H), 6.86 (d, J = 8.6 Hz, 1H), 4.65 (s, 1H), 4.59 - 4.50 (m, 2H), 4.50 - 4.47 (m, 1H), 4.38 - 4.33 (m, 1H), 4.03 - 3.97 (m, 1H), 3.92 (s, 3H), 3.89 - 3.86 (m, 1H), 3.80 (dd, J = 10.9, 3.9 Hz, 1H), 3.76 - 3.70 (m, 6H), 3.64 - 3.58 (m, 9H), 3.44 - 3.35 (m, 2H), 2.60 - 2.54 (m, 1H), 2.50 - 2.44 (m, 3H), 2.47 (s, 3H), 2.24 - 2.20 (m, 1H), 2.17 - 2.13 (m, 2H), 2.10 - 2.05 (m, 1H), 1.88 (s, 3H), 1.86 - 1.80 (m, 2H), 1.85 (s, 3H), 1.04 (s, 9H). HRMS (ESI) C 56 H 75 ClN 10 O 10 PS + [M+H] + Calculated value: 1145.4809, measured value: 1145.4807.

[0322] Compound Example 43: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N16-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13-tetraoxahexadecanediamide. (SIAIS151126)

[0323] SIAIS151126 (white solid, 13.0 mg, 55%) was prepared using brigatinib analog B and intermediate LM (SIAIS151008) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.99 (s, 1H), 8.25 (dd, J = 8.1, 4.0 Hz, 1H), 8.16 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.70 (dd, J = 13.9, 7.7 Hz, 1H), 7.63 - 7.59 (m, 1H), 7.48 - 7.46 (m, 2H), 7.44 - 7.41 (m, 3H), 7.15 (d, J = 2.3 Hz, 1H), 6.94 (dd, J = 8.8, 2.5 Hz, 1H), 4.64 (s, 1H), 4.59 - 4.51 (m, 2H), 4.50 - 4.47 (m, 1H), 4.36 (d, J = 15.5 Hz, 1H), 4.08 - 4.01 (m, 1H), 3.93 (s, 3H), 3.90 - 3.87 (m, 1H), 3.79 (dd, J = 10.9, 3.7 Hz, 1H), 3.76 - 3.71 (m, 6H), 3.62 - 3.60 (m, 12H), 3.50 (t, J = 11.1 Hz, 2H), 2.58 - 2.53 (m, 1H), 2.49 - 2.45 (m, 3H), 2.48 (s, 3H), 2.24 - 2.16 (m, 3H), 2.11 - 2.05 (m, 1H), 1.94 - 1.90 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H), 1.03 (s, 9H). HRMS (ESI) C 58 H 79 ClN 10 O 11 PS + [M+H] + Calculated value: 1189.5071, measured value: 1189.5091.

[0324] Compound Example 44: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13,16-pentaoxanonadecanediamide. (SIAIS151127)

[0325] SIAIS151127 (white solid, 19.5 mg, 79%) was prepared using brigatinib analog B and intermediate LM (SIAIS151009) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 9.05 (s, 1H), 8.23 ​​(dd, J = 8.0, 4.1 Hz, 1H), 8.17 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.71 (ddd, J = 13.9, 7.8, 1.4 Hz, 1H), 7.64 - 7.59 (m, 1H), 7.50 - 7.46 (m, 2H), 7.44 - 7.40 (m, 3H), 7.19 (d, J = 2.4 Hz, 1H), 6.97 (dd, J = 8.8, 2.5 Hz, 1H), 4.64 (s, 1H), 4.58 - 4.51 (m, 2H), 4.51 - 4.48 (m, 1H), 4.36 (d, J = 15.6 Hz, 1H), 4.09 - 4.03 (m, 1H), 3.94 (s, 3H), 3.90 - 3.87 (m, 1H), 3.80 (dd, J = 11.0, 3.9 Hz, 1H), 3.76 - 3.69 (m, 6H), 3.62 - 3.60 (m, 16H), 3.54 (t, J = 12.0 Hz, 2H), 2.59 - 2.54 (m, 1H), 2.50 - 2.45 (m, 3H), 2.49 (s, 3H), 2.24 - 2.18 (m, 3H), 2.11 - 2.05 (m, 1H), 1.98 - 1.91 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H), 1.03 (s, 9H). HRMS (ESI) C 60 H 83 ClN 10 O 12 PS + [M+H] + Calculated value: 1233.5333, measured value: 1233.5335.

[0326] Compound Example 45: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide. (SIAIS164143)

[0327] SIAIS164143 (white solid, 12.8 mg, 63%) was prepared using brigatinib analog B and intermediate LM (SIAIS074011) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.95 (s, 1H), 8.27 (s, 1H), 8.11 (s, 1H), 7.78 - 7.73 (m, 2H), 7.68 (t, J = 7.5 Hz, 1H), 7.60 - 7.50 (m, 6H), 7.29 (d, J = 8.2 Hz, 1H), 4.62 - 4.47 (m, 4H), 4.41 (d, J = 15.6 Hz, 1H), 4.19 - 4.11 (m, 1H), 4.00 (s, 3H), 3.91 - 3.89 (m, 1H), 3.81 - 3.78 (m, 5H), 2.67 - 2.53 (m, 4H), 2.59 (s, 3H), 2.31 - 2.15 (m, 5H), 2.11 - 2.04 (m, 1H), 1.88 (s, 3H), 1.86 (s, 3H), 1.04 (s, 9H). HRMS (ESI) C 50 H 63 ClN 10 O7PS + [M+H] + Calculated value: 1013.4023, measured value: 1013.3452.

[0328] Compound Example 46: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide. (SIAIS164144)

[0329] SIAIS164144 (white solid, 12.2 mg, 59%) was prepared using brigatinib analog B and intermediate LM (SIAIS074012) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.96 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.78 - 7.73 (m, 2H), 7.68 (t, J = 7.8 Hz, 1H), 7.61 - 7.56 (m, 3H), 7.55 - 7.49 (m, 3H), 7.30 (d, J = 8.7 Hz, 1H), 4.64 (s, 1H), 4.69 - 4.51 (m, 3H), 4.45 - 4.40 (m, 1H), 4.20 - 4.12 (m, 1H), 4.00 (s, 3H), 3.93 (d, J = 11.2 Hz, 1H), 3.86 - 3.73 (m, 5H), 2.60 (s, 3H), 2.38 - 2.17 (m, 9H), 2.11 - 2.05 (m, 1H), 1.96 - 1.91 (m, 2H), 1.88 (s, 3H), 1.85 (s, 3H), 1.05 (s, 9H). HRMS (ESI) C 51 H 65 ClN 10 O7PS + [M+H] + Calculated value: 1027.4179, measured value: 1027.3585.

[0330] Compound Example 47: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide. (SIAIS164145)

[0331] SIAIS164145 (white solid, 13.1 mg, 63%) was prepared using brigatinib analog B and intermediate LM (SIAIS074013) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 10.01 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.78 - 7.74 (m, 2H), 7.69 (t, J = 7.9 Hz, 1H), 7.63 (s, 1H), 7.59 - 7.57 (m, 2H), 7.55 - 7.50 (m, 3H), 7.32 (d, J = 6.9 Hz, 1H), 4.64 (s, 1H), 4.61 - 4.47 (m, 3H), 4.43 - 4.39 (m, 1H), 4.21 - 4.13 (m, 1H), 4.00 (s, 3H), 3.92 (d, J = 11.1 Hz, 1H), 3.85 - 3.71 (m, 5H), 2.61 (s, 3H), 2.36 - 2.17 (m, 9H), 2.10 - 2.04 (m, 1H), 1.88 (s, 3H), 1.86 (s, 3H), 1.70 - 1.62 (m, 4H), 1.04 (s, 9H). HRMS (ESI) C 52 H 67 ClN 10 O7PS + [M+H] + Calculated value: 1041.4336, measured value: 1041.3764.

[0332] Compound Example 48: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N7-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)heptanediamide. (SIAIS164146)

[0333] SIAIS164146 (white solid, 12.3 mg, 58%) was prepared using brigatinib analog B and intermediate LM (SIAIS074014) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.97 (s, 1H), 8.27 (s, 1H), 8.11 (s, 1H), 7.77 - 7.73 (m, 2H), 7.68 (t, J = 7.8 Hz, 1H), 7.61 - 7.50 (m, 6H), 7.29 (d, J = 8.7 Hz, 1H), 4.64 (s, 1H), 4.61 - 4.48 (m, 3H), 4.44 - 4.38 (m, 1H), 4.18 - 4.12 (m, 1H), 4.00 (s, 3H), 3.91 (d, J = 11.1 Hz, 1H), 3.85 - 3.70 (m, 5H), 2.60 (s, 3H), 2.36 - 2.15 (m, 9H), 2.10 - 2.05 (m, 1H), 1.88 (s, 3H), 1.85 (s, 3H), 1.69 - 1.61 (m, 4H), 1.42 - 1.33 (m, 2H), 1.04 (s, 9H). HRMS (ESI) C 53 H 69 ClN 10 O7PS + [M+H] + : Calculated value 1055.4492, measured value: 1055.3854.

[0334] Compound Example 49: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)octanediamide. (SIAIS164147)

[0335] SIAIS164147 (white solid, 14.8 mg, 69%) was prepared using brigatinib analog B and intermediate LM (SIAIS074015) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.91 (s, 1H), 8.27 (s, 1H), 8.11 (s, 1H), 7.77 - 7.73 (m, 2H), 7.69 (t, J = 7.8 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 7.58 - 7.51 (m, 5H), 7.31 (d, J = 8.7 Hz, 1H), 4.64 (s, 1H), 4.60 - 4.49 (m, 3H), 4.43 - 4.38 (m, 1H), 4.20 - 4.13 (m, 1H), 4.00 (s, 3H), 3.92 (d, J = 11.1 Hz, 1H), 3.86 - 3.75 (m, 5H), 2.60 (s, 3H), 2.33 - 2.18 (m, 9H), 2.11 - 2.05 (m, 1H), 1.88 (s, 3H), 1.85 (s, 3H), 1.68 - 1.59 (m, 4H), 1.41 - 1.34 (m, 4H), 1.04 (s, 9H). HRMS (ESI) C 54 H 71 ClN 10 O7PS + [M+H] + Calculated value: 1069.4649, measured value: 1069.4001.

[0336] Compound Example 50: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide. (SIAIS164148)

[0337] SIAIS164148 (white solid, 12.8 mg, 59%) was prepared using brigatinib analog B and intermediate LM (SIAIS074016) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 10.01 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.78 - 7.73 (m, 2H), 7.69 (t, J = 7.9 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.60 - 7.57 (m, 2H), 7.55 - 7.49 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 4.64 (s, 1H), 4.60 - 4.49 (m, 3H), 4.44 - 4.38 (m, 1H), 4.21 - 4.13 (m, 1H), 4.00 (s, 3H), 3.91 (d, J = 11.1 Hz, 1H), 3.85 - 2.73 (m, 5H), 2.61 (s, 3H), 2.33 - 2.18 (m, 9H), 2.10 - 2.04 (m, 1H), 1.88 (s, 3H), 1.86 (s, 3H), 1.66 - 1.59 (m, 4H), 1.36 (s, 6H), 1.04 (s, 9H). HRMS (ESI) C 55 H 73 ClN 10 O7PS + [M+H] + Calculated value: 1083.4805, measured value: 1083.4133.

[0338] Compound Example 51: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide. (SIAIS164149)

[0339] SIAIS164149 (white solid, 10.2 mg, 46%) was prepared using brigatinib analog B and intermediate LM (SIAIS074019) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 10.02 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 7.79 - 7.73 (m, 2H), 7.69 (t, J = 7.9 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.54 - 7.50 (m, 3H), 7.32 (d, J = 8.6 Hz, 1H), 4.64 (s, 1H), 4.60 - 4.49 (m, 3H), 4.44 - 4.38 (m, 1H), 4.20 - 4.14 (m, 1H), 4.00 (s, 3H), 3.91 (d, J = 11.2 Hz, 1H), 3.81 (dd, J = 10.9, 3.9 Hz, 5H), 2.61 (s, 3H), 2.33 - 2.18 (m, 9H), 2.10 - 2.05 (m, 1H), 1.88 (s, 3H), 1.86 (s, 3H), 1.67 - 1.57 (m, 4H), 1.35 (s, 9H), 1.04 (s, 9H). HRMS (ESI) C 56 H 75 ClN 10 O7PS + [M+H] + Calculated value: 1097.4962, measured value: 1097.4296.

[0340] Compound Example 52: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N11-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)undecanediamide. (SIAIS1210117)

[0341] SIAIS1210117 (white solid, 10.6 mg, 48%) was prepared using brigatinib analog B and intermediate LM (SIAIS074020) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.94 (s, 1H), 8.30 (s, 1H), 8.15 (s, 1H), 7.78 (s, 1H), 7.72 (dd, J = 14.0, 6.7 Hz, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.3 Hz, 3H), 7.11 (s, 1H), 6.91 (d, J = 7.8 Hz, 1H), 4.66 (s, 1H), 4.62 - 4.55 (m, 2H), 4.58 - 4.50 (m, 2H), 4.41 - 4.36 (m, 1H), 3.95 (s, 3H), 3.92 (d, J = 11.1 Hz, 1H), 3.82 (dd, J = 11.0, 3.9 Hz, 1H), 3.75 (d, J = 12.6 Hz, 2H), 3.47 - 3.40 (m, 2H), 2.49 (s, 3H), 2.26 - 2.21 (m, 4H), 2.17 (d, J = 12.5 Hz, 2H), 1.90 - 1.85 (m, 8H), 1.68 - 1.57 (m, 6H), 1.39 - 1.33 (m, 10H), 1.05 (s, 9H). HRMS (ESI) C 57 H 77 ClN 10 O7PS + [M+H]+ Calculated value: 1111.5118, measured value: 1111.5109.

[0342] Compound Example 53: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N11-((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)undecanediamide. (SIAIS219050)

[0343] SIAIS219050 (white solid, 8.2 mg, 37%) was prepared using brigatinib analog B and intermediate LM (SIAIS219048) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.34 (s, 1H), 8.23 ​​(s, 1H), 8.15 (s, 1H), 7.82 - 7.71 (m, 2H), 7.67 (t, J = 7.8 Hz, 1H), 7.50 - 7.45 (m, 6H), 7.18 (d, J = 8.6 Hz, 1H), 4.56 - 4.50 (m, 3H), 4.45 - 4.36 (m, 2H), 4.14-4.10 (m, 1H), 4.04 (dd, J = 10.5, 5.1 Hz, 1H), 3.98 (s, 3H), 3.75-3.68 (m, 6H), 2.53 (s, 3H), 2.50 - 2.40 (m, 1H), 2.34 - 2.20 (m, 8H), 2.13-2.08 (m, 2H), 2.01 - 1.94 (m, 1H), 1.87 (d, J = 13.5 Hz, 6H), 1.62 (d, J = 7.3 Hz, 5H), 1.33 (s, 12H), 1.04 (s, 9H). HRMS (ESI) C 57 H 77 ClN 10 O7PS [M+H] + Calculated value: 1111.5118, measured value: 1111.5111.

[0344] Compound Example 54: Synthesis of N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)succinamide. (SIAIS164157)

[0345] SIAIS164157 (yellow solid, 11.0 mg, 61%) was prepared using brigatinib analog B and intermediate LM (SIAIS164119) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.23 ​​(s, 1H), 8.16 (s, 1H), 7.80 - 7.70 (m, 2H), 7.66 (t, J = 7.8 Hz, 1H), 7.55 (dd, J = 8.4, 7.2 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.38 (s, 1H), 7.14 - 7.10 (m, 2H), 7.04 (d, J = 7.1 Hz, 1H), 5.08 - 5.03 (m, 1H), 4.08 - 4.04 (m, 1H), 3.98 (s, 3H), 3.77 - 3.61 (m, 4H), 3.49 - 3.41 (m, 4H), 2.89 - 2.82 (m, 1H), 2.78 - 2.68 (m, 2H), 2.53 - 2.49 (m, 1H), 2.51 (s, 3H), 2.23 - 2.17 (m, 2H), 2.12 - 2.00 (m, 3H), 1.88 (s, 3H), 1.85 (s, 3H). HRMS (ESI) C 43 H 49 ClN 10 O8P + [M+H] + Calculated value: 899.3155, measured value: 899.0580.

[0346] Compound Example 55: Synthesis of N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propenamide. (SIAIS219170)

[0347] SIAIS219170 (white solid, 6.4 mg, 39%) was prepared using brigatinib analog B and intermediate LM (SIAIS172147) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.24 - 8.12 (m, 2H), 7.83 (d, J = 7.7 Hz, 1H), 7.78-7.71 (m, 4H), 7.65 (s, 1H), 7.47 (d, J = 6.7 Hz, 1H), 7.37-7.28 (m, 1H), 7.10-7.04 (m, 1H), 5.12 (dd, J = 12.5, 5.4 Hz, 1H), 4.04 (s, 1H), 3.97 (d, J = 4.3 Hz, 3H), 3.68-3.61 (m, 4H), 3.16 (t, J = 7.2 Hz, 2H), 2.91 - 2.82 (m, 1H), 2.78 - 2.66 (m, 2H), 2.63 (s, 2H), 2.16 - 2.06 (m, 3H), 1.87 (d, J = 13.5 Hz, 6H), 1.89-1.85 (m, 2H). HRMS (ESI) C 40 H 43 ClN8O7P + [M+H] + Calculated value: 813.2675, measured value: 813.2670.

[0348] Compound Example 56: Synthesis of 4-((2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164007)

[0349] SIAIS164007 (yellow solid, 17.5 mg, 71%) was prepared using brigatinib analog C and intermediate LM (SIAIS151001) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.06 (s, 1H), 7.72 - 7.65 (m, 1H), 7.61 - 7.54 (m, 2H), 7.39 (t, J = 7.5 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 7.05 (d, J = 7.0 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 5.10 (dd, J = 12.7, 5.5 Hz, 1H), 3.86 (s, 3H), 3.84-3.75 (m, 6H), 3.53-3.51 (m, 4H), 3.43 - 3.32 (m, 2H), 3.30 - 2.95 (m, 5H), 2.90-2.83 (m, 2H), 2.81 - 2.54 (m, 5H), 2.21 - 2.01 (m, 3H), 1.89 (d, J = 13.6 Hz, 6H), 1.83 - 1.63 (m, 2H). HRMS (ESI) C 46 H 55 ClN 10 O8P [M+H] + Calculated value: 941.3625, measured value: 941.2930.

[0350] Compound Example 57: Synthesis of 4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164008)

[0351] SIAIS164008 (yellow solid, 18.4 mg, 71%) was prepared using brigatinib analog C and intermediate LM (SIAIS151004) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.06 (s, 1H), 7.68 (dd, J = 14.7, 7.1 Hz, 1H), 7.60-7.54 (m, 2H), 7.37 (t, J = 7.0 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 7.06 (d, J = 7.0 Hz, 1H), 6.69 (d, J = 2.4 Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H), 5.07 (dd, J = 12.5, 5.5 Hz, 1H), 3.89 (s, 1H), 3.87 (s, 1H), 3.84 (s, 3H), 3.78 (t, J = 5.8 Hz, 2H), 3.73 (t, J = 5.1 Hz, 2H), 3.69-3.68 (m, 2H), 3.67 - 3.63 (m, 2H), 3.51 (t, J = 5.1 Hz, 3H), 3.38-3.31 (m, 8H), 2.91 - 2.63 (m, 7H), 2.18 (d, J = 10.2 Hz, 2H), 2.15 - 2.05 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.86 - 1.73 (m, 2H). HRMS (ESI) C 48 H 59 ClN 10 O9P [M+H] +Calculated value: 985.3887, measured value: 985.3166.

[0352] Compound Example 58: Synthesis of 4-((2-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164009)

[0353] SIAIS164009 (yellow solid, 20 mg, 74%) was prepared using brigatinib analog C and intermediate LM (SIAIS151005) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.07 (d, J = 14.7 Hz, 1H), 7.67 (dd, J = 14.7, 7.1 Hz, 1H), 7.61 - 7.51 (m, 2H), 7.37 (t, J = 7.1 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 6.2 Hz, 1H), 7.05 (d, J = 7.0 Hz, 1H), 6.70 (d, J = 2.4 Hz, 1H), 6.53 (d, J = 9.0 Hz, 1H), 5.05 (dd, J = 12.5, 5.5 Hz, 1H), 3.91 (d, J = 12.4 Hz, 2H), 3.84 (s, 3H), 3.80 - 3.70 (m, 5H), 3.70 - 3.63 (m, 7H), 3.63 - 3.57 (m, 3H), 3.51-3.49 (m, 3H), 3.46 - 3.35 (m, 2H), 3.32-3.31 (m, 3H), 2.92 - 2.77 (m, 4H), 2.77 - 2.62 (m, 3H), 2.22 (d, J = 12.1 Hz, 2H), 2.12-2.08 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.86 - 1.79 (m, 2H). HRMS (ESI) C 50 H 63 ClN 10 O 10 P [M+H] + Calculated value: 1029.4149, measured value: 1029.3401.

[0354] Compound Example 59: Synthesis of 4-((15-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164016)

[0355] SIAIS164016 (yellow solid, 13 mg, 46%) was prepared using brigatinib analog C and intermediate LM (SIAIS151006) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.06 (s, 1H), 7.68 (dd, J = 13.3, 8.4 Hz, 1H), 7.60-7..51 (m, 2H), 7.37 (t, J = 7.1 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.71 (d, J = 2.4 Hz, 1H), 6.55 (d, J = 7.7 Hz, 1H), 5.04 (dd, J = 12.7, 5.5 Hz, 1H), 3.93 (d, J = 12.7 Hz, 2H), 3.84 (s, 3H), 3.75 (t, J = 5.8 Hz, 3H), 3.71 (t, J = 5.2 Hz, 2H), 3.69 - 3.55 (m, 15H), 3.54 - 3.36 (m, 5H), 2.86-2.80 (m, 4H), 2.77 - 2.63 (m, 3H), 2.25 (d, J = 11.3 Hz, 2H), 2.15 - 2.04 (m, 1H), 1.90-1.86 (m, 8H). HRMS (ESI) C 52 H 67 ClN 10 O 11 P [M+H] + Calculated value: 1073.4411, measured value: 1073.4778.

[0356] Compound Example 60: Synthesis of 4-((18-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164017)

[0357] Compound Example 1 was prepared using SIAIS 164017 (yellow solid, 18.2 mg, 62%). 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.05 (s, 1H), 7.67 (dd, J = 14.2, 6.5 Hz, 1H), 7.60-7.52 (m, 2H), 7.37 (t, J = 6.9 Hz, 1H), 7.32 (d, J = 8.9 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H), 6.57 (d, J = 8.8 Hz, 1H), 5.04 (dd, J = 12.6, 5.5 Hz, 1H), 3.95 (d, J = 12.2 Hz, 2H), 3.85 (s, 3H), 3.75 (dd, J = 12.5, 6.6 Hz, 2H), 3.71 (t, J = 5.2 Hz, 2H), 3.68 - 3.56 (m, 18H), 3.56 - 3.37 (m, 5H), 3.32-3.31 (m, 4H), 2.93 - 2.78 (m, 4H), 2.78 - 2.60 (m, 3H), 2.25 (d, J = 10.6 Hz, 2H), 2.11-2.07 (m, 1H), 1.90-1.87 (m, 8H). HRMS (ESI) C 54 H 71 ClN 10 O 12 P [M+H] + Calculated value: 1117.4674, measured value: 1117.4682.

[0358] Compound Example 61: Synthesis of 4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164018)

[0359] SIAIS164018 (yellow solid, 18.1 mg, 78%) was prepared using brigatinib analog C and intermediate LM (SIAIS151025) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.39 (s, 1H), 8.07 (d, J = 17.8 Hz, 1H), 7.68 (dd, J = 14.1, 7.7 Hz, 1H), 7.61 - 7.53 (m, 2H), 7.37 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 8.9 Hz, 1H), 7.10 (d, J = 7.0 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.60 (d, J = 7.9 Hz, 1H), 5.09 (dd, J = 12.5, 5.5 Hz, 1H), 4.26 (s, 2H), 3.97 (d, J = 12.4 Hz, 2H), 3.86 (s, 3H), 3.71 - 3.32 (m, 9H), 2.98 - 2.81 (m, 3H), 2.79 - 2.68 (m, 2H), 2.27 (d, J = 11.4 Hz, 2H), 2.17 - 2.08 (m, 1H), 2.00 - 1.91 (m, 2H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 43 H 49 ClN 10 O7P [M+H] + Calculated value: 883.3206, measured value: 883.3327.

[0360] Compound Example 62: Synthesis of 4-((3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164019)

[0361] SIAIS164019 (yellow solid, 14.2 mg, 60%) was prepared using brigatinib analog C and intermediate LM (SIAIS151026) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.39 (s, 1H), 8.06 (s, 1H), 7.68 (dd, J = 13.4, 8.4 Hz, 1H), 7.63 - 7.53 (m, 2H), 7.38 (t, J = 6.8 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.10 (d, J = 7.0 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H), 6.57 (d, J = 8.5 Hz, 1H), 5.05 (dd, J = 12.5, 5.4 Hz, 1H), 3.93 (s, 2H), 3.86 (s, 3H), 3.72 (t, J = 5.2 Hz, 2H), 3.40 (t, J = 12.2 Hz, 2H), 3.32-3.31 (m, 6H), 2.86-2.79 (m, 5H), 2.77 - 2.64 (m, 3H), 2.17 (d, J = 12.1 Hz, 2H), 2.14 - 2.06 (m, 1H), 1.90-1.83 (m, 8H). HRMS (ESI) C 44 H 51 ClN 10 O7P [M+H] + Calculated value: 897.3363, measured value: 897.3679.

[0362] Compound Example 63: Synthesis of 4-((4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164020)

[0363] SIAIS164020 (yellow solid, 14.2 mg, 59%) was prepared using brigatinib analog C and intermediate LM (SIAIS151019) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.40 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 13.4, 8.5 Hz, 1H), 7.60-7.57 (m, 2H), 7.39 (t, J = 7.0 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.08 (d, J = 6.9 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 5.07 (dd, J = 12.6, 5.5 Hz, 1H), 3.94 (d, J = 12.4 Hz, 2H), 3.86 (s, 3H), 3.59 - 3.37 (m, 5H), 3.33-3.31 (m, 6H), 2.89 - 2.80 (m, 3H), 2.79 - 2.68 (m, 2H), 2.58 (s, 2H), 2.19 (s, 2H), 2.13-2.11 (m, 1H), 2.08 - 1.97 (m, 2H), 1.97 - 1.80 (m, 8H). HRMS (ESI) C 45 H 53 ClN 10 O7P [M+H] + Calculated value: 911.3519, measured value: 911.3859.

[0364] Compound Example 64: Synthesis of 4-((5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164021)

[0365] SIAIS164021 (yellow solid, 20.6 mg, 85%) was prepared using brigatinib analog C and intermediate LM (SIAIS151020) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.07 (s, 1H), 7.69 (dd, J = 13.9, 7.5 Hz, 1H), 7.61-7.56 (m, 2H), 7.39 (t, J = 7.6 Hz, 1H), 7.34 (s, 1H), 7.09 (d, J = 8.5 Hz, 1H), 7.06 (d, J = 7.1 Hz, 1H), 6.78 (s, 1H), 6.63 (s, 1H), 5.07 (dd, J = 12.7, 5.5 Hz, 1H), 3.95 (s, 2H), 3.86 (s, 3H), 3.66 (m, 3H), 3.52 - 3.37 (m, 5H), 2.97 - 2.80 (m, 4H), 2.80 - 2.66 (m, 2H), 2.54 (s, 2H), 2.36 (t, J = 8.1 Hz, 1H), 2.27 (s, 2H), 2.17 - 2.08 (m, 1H), 2.04 (dt, J = 14.8, 7.5 Hz, 1H), 1.94 (s, 2H), 1.89 (d, J = 13.6 Hz, 6H), 1.75 (s, 4H). HRMS (ESI) C 46 H 55 ClN 10 O7P [M+H] + Calculated value: 925.3676, measured value: 925.4004.

[0366] Compound Example 65: Synthesis of 4-((6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164022)

[0367] SIAIS164022 (yellow solid, 15.5 mg, 63%) was prepared using brigatinib analog C and intermediate LM (SIAIS151027) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.07 (d, J = 17.1 Hz, 1H), 7.68 (dd, J = 13.4, 7.1 Hz, 1H), 7.60-7.55 (m, 2H), 7.38 (t, J = 7.1 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.06 (dd, J = 9.2, 7.9 Hz, 2H), 6.74 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 8.7 Hz, 1H), 5.06 (dd, J = 12.5, 5.5 Hz, 1H), 3.95 (d, J = 11.7 Hz, 2H), 3.86 (s, 3H), 3.77 - 3.39 (m, 4H), 3.37 (t, J = 6.8 Hz, 2H), 3.35 - 3.31 (m, 5H), 2.91 - 2.80 (m, 3H), 2.80 - 2.64 (m, 2H), 2.49 (t, J = 7.3 Hz, 2H), 2.24 (d, J = 12.1 Hz, 2H), 2.19 - 2.04 (m, 1H), 1.90-1.87 (m, 8H), 1.78 - 1.65 (m, 4H), 1.57 - 1.43 (m, 2H). HRMS (ESI) C 47 H 57 ClN 10 O7P [M+H] + Calculated value: 939.3832, measured value: 939.4168.

[0368] Compound Example 66: Synthesis of 4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS164023)

[0369] SIAIS164023 (yellow solid, 14.1 mg, 56%) was prepared using brigatinib analog C and intermediate LM (SIAIS151086) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.39 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 12.8, 7.8 Hz, 1H), 7.56 (dd, J = 8.6, 7.1 Hz, 2H), 7.38 (t, J = 7.0 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.05 (t, J = 7.8 Hz, 2H), 6.74 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 8.3 Hz, 1H), 5.06 (dd, J = 12.5, 5.5 Hz, 1H), 3.96 (d, J = 12.7 Hz, 2H), 3.87 (s, 3H), 3.71-3.46 (m, 4H), 3.40 - 3.31 (m, 7H), 2.93 - 2.80 (m, 3H), 2.80 - 2.65 (m, 2H), 2.45 (t, J = 7.5 Hz, 2H), 2.25 (d, J = 11.5 Hz, 2H), 2.15 - 2.06 (m, 1H), 1.90-1.87 (m, 8H), 1.71-1.62 (m, 4H), 1.58 - 1.39 (m, 4H). HRMS (ESI) C 48 H 59 ClN 10 O7P [M+H] + Calculated value: 953.3989, measured value: 953.4144.

[0370] Compound Example 67: Synthesis of 3-(4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. (SIAIS219073)

[0371] SIAIS219073 (yellow solid, 5.8 mg, 38%) was prepared using brigatinib analog C and intermediate LM (SIAIS1204057) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.33 (s, 1H), 8.11 (s, 1H), 7.74 - 7.68 (m, 1H), 7.60 (s, 1H), 7.45-7.36 (m, 3H), 7.18 (d, J = 7.5 Hz, 1H), 6.99 (s, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.80 (d, J = 7.0 Hz, 1H), 5.19 - 5.15 (m, 1H), 4.44 (d, J = 16.8 Hz, 1H), 4.37 (d, J = 16.8 Hz, 1H), 4.25 (s, 1H), 3.96 (d, J = 12.7 Hz, 2H), 3.90 (s, 3H), 3.64-3.61 (m, 4H), 3.39-3.36 (m, 2H), 3.28 - 3.05 (m, 6H), 2.97 - 2.87 (m, 1H), 2.81 (d, J = 2.5 Hz, 1H), 2.54-2.50 (m, 1H), 2.37 (d, J = 11.1 Hz, 2H), 2.24 - 2.07 (m, 3H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 43 H 51 ClN 10 O6P + [M+H] + Calculated value: 869.3414, measured value: 869.3410.

[0372] Compound Example 68: Synthesis of 3-(4-((4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. (SIAIS219155)

[0373] SIAIS219155 (yellow solid, 7.0 mg, 45%) was prepared using brigatinib analog C and intermediate LM (SIAIS1204085) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.33 (s, 1H), 8.09 (s, 1H), 7.70 (dd, J = 14.0, 7.8 Hz, 1H), 7.60 (s, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.38 (s, 1H), 7.23 (d, J = 5.0 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 6.92 (s, 1H), 6.74 (s, 1H), 5.17 (dd, J = 13.2, 5.0 Hz, 1H), 4.43 (d, J = 17.3 Hz, 1H), 4.34 (d, J = 17.4 Hz, 1H), 3.97 - 3.87 (m, 4H), 3.77 - 3.47 (m, 2H), 3.46 - 3.31 (m, 8H), 3.17-3.05 (m, 4H), 2.97 - 2.89 (m, 1H), 2.85 - 2.78 (m, 1H), 2.58-2.49 (m, 3H), 2.32 - 2.17 (m, 3H), 2.09 - 1.92 (m, 4H), 1.88 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 45 H 55 ClN 10 O6P + [M+H] + Calculated value: 897.3727, measured value: 897.3722.

[0374] Compound Example 69: Synthesis of 3-(4-((5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. (SIAIS219156)

[0375] SIAIS219156 (yellow solid, 7.5 mg, 47%) was prepared using brigatinib analog C and intermediate LM (SIAIS1210133) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.30 (s, 1H), 8.12 (s, 1H), 7.71 (dd, J = 13.4, 7.1 Hz, 1H), 7.61 (t, J = 7.0 Hz, 1H), 7.47 (dt, J = 12.9, 7.1 Hz, 3H), 7.37 (d, J = 7.4 Hz, 1H), 7.16 (d, J = 7.9 Hz, 1H), 7.04 (s, 1H), 6.84 (d, J = 8.7 Hz, 1H), 5.18 (dd, J = 13.3, 5.2 Hz, 1H), 4.50 (d, J = 17.1 Hz, 1H), 4.43 (d, J = 17.1 Hz, 1H), 3.95 (s, 1H), 3.91 (s, 3H), 3.77 - 3.47 (m, 4H), 3.38 (d, J = 3.4 Hz, 2H), 3.30-3.22 (m, 8H), 2.97 - 2.88 (m, 1H), 2.84 - 2.78 (m, 1H), 2.56-2.49 (m, 3H), 2.36 (s, 2H), 2.26 - 2.18 (m, 1H), 2.12-2.10 (m, 2H), 1.88 (d, J = 13.6 Hz, 6H), 1.77 (s, 4H). HRMS (ESI) C 46 H 57 ClN 10 O6P + [M+H] + Calculated value: 911.3883, measured value: 911.3878.

[0376] Compound Example 70: Synthesis of 3-(4-((6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. (SIAIS219157)

[0377] SIAIS219157 (yellow solid, 8.1 mg, 53%) was prepared using brigatinib analog C and intermediate LM (SIAIS1204061) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.28 (s, 1H), 8.13 (s, 1H), 7.71 (dd, J = 14.0, 7.7 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.45 (t, J = 6.5 Hz, 3H), 7.25 (d, J = 7.9 Hz, 1H), 7.08 (s, 1H), 6.87 (d, J = 8.6 Hz, 1H), 5.19 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 (d, J = 17.1 Hz, 1H), 4.47 (d, J = 17.1 Hz, 1H), 3.95 (s, 1H), 3.91 (s, 3H), 3.67-3.57 (m, 4H), 3.38 (t, J = 7.1 Hz, 2H), 3.30-3.17 (m, 8H), 2.99 - 2.88 (m, 1H), 2.85 - 2.77 (m, 1H), 2.59 - 2.44 (m, 3H), 2.39 (d, J = 10.6 Hz, 2H), 2.27 - 2.08 (m, 3H), 1.88 (d, J = 13.6 Hz, 6H), 1.78-1.74 (m, 2H), 1.73 - 1.65 (m, 2H), 1.56 - 1.47 (m, 2H). HRMS (ESI) C 47 H 59 ClN10 O6P + [M+H] + Calculated value: 925.4040, measured value: 925.4031.

[0378] Compound Example 71: Synthesis of 3-(4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. (SIAIS219124)

[0379] SIAIS219124 (yellow solid, 11.2 mg, 48%) was prepared using brigatinib analog C and intermediate LM (SIAIS1204063) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.38 (s, 1H), 8.08 (s, 1H), 7.70 (dd, J = 13.9, 7.9 Hz, 1H), 7.59 (s, 1H), 7.45 - 7.37 (m, 2H), 7.33 (s, 1H), 7.16 (d, J = 7.3 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.79 (s, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.17 (dd, J = 13.2, 5.0 Hz, 1H), 4.38 (d, J = 17.0 Hz, 1H), 4.31 (d, J = 16.9 Hz, 1H), 3.98 (d, J = 12.6 Hz, 2H), 3.89 (d, J = 14.3 Hz, 3H), 3.57 (s, 2H), 3.47 (s, 2H), 3.19 (s, 6H), 2.95-2.89 (m, 4H), 2.82 (d, J = 15.7 Hz, 2H), 2.54 - 2.41 (m, 3H), 2.34 - 2.18 (m, 4H), 1.97 - 1.86 (m, 6H), 1.71-1.64 (m, 4H), 1.48 (s, 4H). HRMS (ESI) C 48 H61 ClN 10 O6P + [M+H] + Calculated value: 939.4196, measured value: 939.4188.

[0380] Compound Example 72: Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164041)

[0381] SIAIS164041 (white solid, 18.2 mg, 61%) was prepared using brigatinib analog C and intermediate LM (SIAIS151010) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.91 (s, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 14.1, 7.7 Hz, 1H), 7.60-7.55 (m, 1H), 7.46 - 7.37 (m, 5H), 7.30 (s, 1H), 6.72 (d, J = 2.5 Hz, 1H), 6.58 (d, J = 8.7 Hz, 1H), 4.72 (s, 1H), 4.60 - 4.49 (m, 3H), 4.48 - 4.23 (m, 5H), 4.14 - 4.00 (m, 3H), 3.95 (d, J = 12.2 Hz, 2H), 3.91 - 3.83 (m, 5H), 3.82-3.74 (m, 7H), 3.48-3.44 (m, 2H), 2.85 (t, J = 12.2 Hz, 2H), 2.46 (s, 3H), 2.29-2.23 (m, 3H), 2.14 - 2.05 (m, 1H), 1.90-1.87 (m, 9H), 1.04 (s, 9H). HRMS (ESI) C 56 H74 ClN 11 O9PS [M+H] + Calculated value: 1142.4812, measured value: 1142.4776.

[0382] Compound Example 73: Synthesis of (2S,4R)-1-((S)-2-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164032)

[0383] SIAIS164032 (white solid, 15.4 mg, 50%) was prepared using brigatinib analog C and intermediate LM (SIAIS151002) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 14.0, 7.6 Hz, 1H), 7.62 - 7.51 (m, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.45 - 7.36 (m, 3H), 7.29 (d, J = 9.4 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 6.60 (d, J = 7.4 Hz, 1H), 4.66 (s, 1H), 4.60-4.50 (m, 3H), 4.37 (d, J = 15.5 Hz, 1H), 3.97 (d, J = 13.1 Hz, 2H), 3.89 (d, J = 11.2 Hz, 1H), 3.85 (s, 3H), 3.84 - 3.80 (m, 1H), 3.80 - 3.67 (m, 5H), 3.66 - 3.51 (m, 6H), 3.51 - 3.36 (m, 2H), 3.30 (s, 5H), 2.91-2.85 (m, 2H), 2.78 - 2.61 (m, 2H), 2.61 - 2.42 (m, 5H), 2.28-2.21 (m, 3H), 2.11-2.04 (m, 1H), 1.93-1.87 (m, 7H), 1.03 (s, 9H). HRMS (ESI) C 58 H 78 ClN 11 O9PS [M+H] + Calculated value: 1170.5125, measured value: 1170.5152.

[0384] Compound Example 74: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164033)

[0385] Compound Example 1 was prepared using SIAIS 164033 (white solid, 24.9 mg, 78%). 1 H NMR (500 MHz, MeOD) δ 8.98 (s, 1H), 8.40 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 14.0, 7.6 Hz, 1H), 7.62 - 7.52 (m, 1H), 7.51 - 7.46 (m, 2H), 7.45-7.42 (m, 2H), 7.39 (t, J = 7.2 Hz, 1H), 7.28 (s, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.61 (d, J = 8.7 Hz, 1H), 4.65 (s, 1H), 4.60 - 4.47 (m, 3H), 4.37 (d, J = 15.6 Hz, 1H), 3.98 (d, J = 12.7 Hz, 2H), 3.89 (d, J = 11.2 Hz, 1H), 3.85 (s, 3H), 3.83 - 3.69 (m, 6H), 3.66 - 3.57 (m, 9H), 3.52 - 3.41 (m, 2H), 3.32-3.31 (m, 5H), 2.92-2.86 (m, 2H), 2.65-2.63 (m, 2H), 2.62 - 2.53 (m, 1H), 2.53 - 2.43 (m, 4H), 2.33 - 2.18 (m, 3H), 2.10-2.05 (m, 1H), 1.94-1.87 (m, 8H), 1.03 (s, 9H). HRMS (ESI) C 60 H 82 ClN 11 O 10 PS [M+H] + Calculated value: 1214.5387, measured value: 1214.5405.

[0386] Compound Example 75: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164034)

[0387] SIAIS164034 (white solid, 23.8 mg, 72%) was prepared using brigatinib analog C and intermediate LM (SIAIS151008) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.94 (d, J = 3.1 Hz, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 7.68 (dd, J = 13.5, 8.4 Hz, 1H), 7.62 - 7.52 (m, 1H), 7.51 - 7.45 (m, 2H), 7.45-7.41 (m, 2H), 7.38 (t, J = 7.8 Hz, 1H), 7.29 (s, 1H), 6.74 (d, J = 2.3 Hz, 1H), 6.60 (d, J = 8.6 Hz, 1H), 4.65 (s, 1H), 4.59-4.50 (m, 3H), 4.36 (d, J = 15.5 Hz, 1H), 3.98 (d, J = 12.7 Hz, 2H), 3.92 - 3.83 (m, 4H), 3.82-3.70 (m, 6H), 3.65 - 3.56 (m, 14H), 3.47-3.44 (m, 2H), 3.32 (s, 6H), 2.87 (t, J = 12.5 Hz, 2H), 2.67 - 2.54 (m, 2H), 2.51 - 2.43 (m, 4H), 2.32 - 2.18 (m, 3H), 2.10-2.04 (m, 1H), 1.93-1.87 (m, 7H), 1.03 (s, 9H). HRMS (ESI) C 62 H 86ClN 11 O 11 PS [M+H] + Calculated value: 1258.5650, measured value: 1258.5713.

[0388] Compound Example 76: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164035)

[0389] SIAIS164035 (white solid, 18.7 mg, 55%) was prepared using brigatinib analog C and intermediate LM (SIAIS151009) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.94 (s, 1H), 8.52 - 8.25 (m, 1H), 8.05 (s, 1H), 7.68 (dd, J = 14.8, 7.1 Hz, 1H), 7.60-7.55 (m, 1H), 7.51 - 7.46 (m, 2H), 7.45-7.41 (m, 2H), 7.39 (t, J = 7.7 Hz, 1H), 7.28 (s, 1H), 6.74 (s, 1H), 6.61 (s, 1H), 4.65 (s, 1H), 4.59 - 4.49 (m, 3H), 4.36 (d, J = 15.5 Hz, 1H), 3.98 (d, J = 13.0 Hz, 2H), 3.92 - 3.83 (m, 4H), 3.82 - 3.67 (m, 7H), 3.62-3.61 (m, 20H), 3.49-3.44 (m, 2H), 3.34-3.31 (m, 2H), 2.87 (t, J = 12.5 Hz, 2H), 2.68 - 2.53 (m, 2H), 2.51 - 2.44 (m, 4H), 2.28-2.20 (m, 3H), 2.10-2.04 (m, 1H), 1.94-1.87 (m, 8H), 1.04 (s, 9H). HRMS (ESI) C 64 H 90 ClN 11 O 12 PS [M+H] + Calculated value: 1302.5912, measured value: 1302.5944.

[0390] Compound Example 77: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164120)

[0391] Compound Example 1 was prepared using SIAIS 164120 (white solid, 9.1 mg, 48%). 1 H NMR (500 MHz, MeOD) δ 9.62 (s, 1H), 8.31 (s, 1H), 8.11 (s, 1H), 7.70 (dd, J = 14.0, 9.1 Hz, 1H), 7.60 (s, 1H), 7.54 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.43 (t, J = 7.7 Hz, 2H), 6.98 (s, 1H), 6.80 (s, 1H), 4.61 (s, 1H), 4.59-4.54 (m, 2H), 4.50 (s, 1H), 4.40 (d, J = 15.8 Hz, 1H), 4.34 - 4.22 (m, 1H), 3.97 (d, J = 11.9 Hz, 2H), 3.92 - 3.86 (m, 4H), 3.81 (dd, J = 11.0, 3.9 Hz, 1H), 3.67-3.60 (m, 5H), 3.17 (s, 4H), 2.84 - 2.57 (m, 5H), 2.56 (s, 3H), 2.37 (d, J = 10.3 Hz, 2H), 2.28 - 2.19 (m, 1H), 2.19 - 2.05 (m, 3H), 1.88 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 54 H 70 ClN 11 O7PS [M+H] + Calculated value: 1082.4601, measured value: 1082.1363.

[0392] Compound Example 78: Synthesis of (2S,4R)-1-((S)-2-(5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164121)

[0393] SIAIS164121 (white solid, 6.3 mg, 33%) was prepared using brigatinib analog C and intermediate LM (SIAIS074012) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.72 (s, 1H), 8.28 (s, 1H), 8.15 (s, 1H), 7.72 (dd, J = 13.9, 7.9 Hz, 1H), 7.67 - 7.60 (m, 1H), 7.59 - 7.35 (m, 6H), 7.14 (s, 1H), 6.91 (s, 1H), 4.69 - 4.49 (m, 5H), 4.41 (d, J = 15.8 Hz, 1H), 4.31 - 4.16 (m, 1H), 3.95-3.92 (m, 6H), 3.81 (d, J = 7.8 Hz, 1H), 3.69 (s, 4H), 3.27 - 3.02 (m, 5H), 2.57 (s, 3H), 2.44-2.37 (m, 6H), 2.24-2.08 (m, 4H), 1.93-1.87 (m, 8H), 1.04 (s, 9H). HRMS (ESI) C 55 H 72 ClN 11 O7PS [M+H] + Calculated value: 1096.4758, measured value: 1096.1472.

[0394] Compound Example 79: Synthesis of (2S,4R)-1-((S)-2-(6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164122)

[0395] SIAIS164122 (white solid, 8.6 mg, 44%) was prepared using brigatinib analog C and intermediate LM (SIAIS074013) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.76 (s, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 7.72 (dd, J = 13.9, 7.8 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.59 - 7.43 (m, 6H), 7.17 (s, 1H), 6.95 (s, 1H), 4.64 (s, 1H), 4.61 - 4.49 (m, 3H), 4.41 (d, J = 15.6 Hz, 1H), 4.25 (s, 1H), 3.99 - 3.88 (m, 6H), 3.81 (dd, J = 10.8, 3.8 Hz, 1H), 3.69 (s, 4H), 3.40-3.31 (m, 3H), 3.17 (s, 3H), 2.58 (s, 3H), 2.50-2.43 (m, 4H), 2.36-2.22 (m, 5H), 2.13 - 2.03 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.67 (s, 4H), 1.05 (s, 9H). HRMS (ESI) C 56 H 74 ClN 11 O7PS [M+H] + Calculated value: 1110.4914, measured value: 1110.1540.

[0396] Compound Example 80: Synthesis of (2S,4R)-1-((S)-2-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164123)

[0397] SIAIS164123 (white solid, 8.4 mg, 43%) was prepared using brigatinib analog C and intermediate LM (SIAIS074014) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.64 (s, 1H), 8.32 (s, 1H), 8.11 (s, 1H), 7.71 (dd, J = 13.9, 7.7 Hz, 1H), 7.61 (s, 1H), 7.55-7.44 (m, 6H), 7.01 (s, 1H), 6.81 (s, 1H), 4.64 (s, 1H), 4.60-4.50 (m, 3H), 4.41 (d, J = 15.7 Hz, 1H), 3.96 (d, J = 10.3 Hz, 2H), 3.92-3.90 (m, 4H), 3.81 (dd, J = 10.9, 3.9 Hz, 1H), 3.69-3.60 (m, 4H), 3.31-3.17 (m, 7H), 2.56 (s, 3H), 2.47 (t, J = 7.3 Hz, 2H), 2.37 (s, 2H), 2.35 - 2.27 (m, 2H), 2.27 - 2.20 (m, 1H), 2.19 - 2.03 (m, 3H), 1.88 (d, J = 13.6 Hz, 6H), 1.70 - 1.59 (m, 4H), 1.43-1.37 (m, 2H), 1.03 (s, 9H). HRMS (ESI) C 57 H 76 ClN 11 O7PS [M+H] + Calculated value: 1124.5071, measured value: 1124.1726.

[0398] Compound Example 81: Synthesis of (2S,4R)-1-((S)-2-(8-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164124)

[0399] SIAIS164124 (white solid, 8.3 mg, 42%) was prepared using brigatinib analog C and intermediate LM (SIAIS074015) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.76 (s, 1H), 8.27 (s, 1H), 8.15 (s, 1H), 7.72 (dd, J = 14.0, 7.9 Hz, 1H), 7.63 (s, 1H), 7.59 - 7.39 (m, 6H), 7.19 (s, 1H), 6.94 (s, 1H), 4.64 (s, 1H), 4.62 - 4.46 (m, 3H), 4.41 (d, J = 15.7 Hz, 1H), 4.26 (s, 1H), 4.03 - 3.86 (m, 6H), 3.81 (dd, J = 10.9, 3.8 Hz, 1H), 3.69 (s, 4H), 3.33 (s, 3H), 3.17 (s, 3H), 2.58 (s, 3H), 2.53 - 2.38 (m, 4H), 2.38 - 2.17 (m, 5H), 2.13 - 2.02 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.64 (d, J = 6.7 Hz, 4H), 1.39 (d, J = 3.5 Hz, 4H), 1.03 (s, 9H). HRMS (ESI) C 58 H 78 ClN 11 O7PS [M+H] + Calculated value: 1138.5227, measured value: 1138.1798.

[0400] Compound Example 82: Synthesis of (2S,4R)-1-((S)-2-(9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164125)

[0401] SIAIS164125 (white solid, 8.9 mg, 44%) was prepared using brigatinib analog C and intermediate LM (SIAIS074016) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.82 - 9.70 (m, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 7.78 - 7.68 (m, 1H), 7.64 (s, 1H), 7.56-7.47 (m, 6H), 7.23 (s, 1H), 6.98 (s, 1H), 4.64 (s, 1H), 4.61 - 4.47 (m, 3H), 4.40 (d, J = 15.7 Hz, 1H), 4.25 (s, 1H), 3.92 (t, J = 8.1 Hz, 6H), 3.81 (dd, J = 11.0, 3.8 Hz, 1H), 3.70 (s, 4H), 3.39-3.32 (m, 3H), 3.30-3.17 (m, 3H), 2.58 (s, 3H), 2.52 - 2.39 (m, 4H), 2.39 - 2.17 (m, 5H), 2.13 - 2.03 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.62 (s, 4H), 1.37 (s, 6H), 1.03 (s, 9H). HRMS (ESI) C 59 H 80 ClN 11 O7PS [M+H] + Calculated value: 1152.5384, measured value: 1152.1936.

[0402] Compound Example 83: Synthesis of (2S,4R)-1-((S)-2-(10-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164126)

[0403] SIAIS164126 (white solid, 7.7 mg, 38%) was prepared using brigatinib analog C and intermediate LM (SIAIS074019) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.88 - 9.79 (m, 1H), 8.19 (s, 2H), 7.73 (dd, J = 13.9, 7.8 Hz, 1H), 7.65 (s, 1H), 7.57-7.48 (m, 6H), 7.33 (s, 1H), 7.06 (s, 1H), 4.64 (s, 1H), 4.61 - 4.46 (m, 3H), 4.44 - 4.37 (m, 1H), 4.27 (s, 1H), 3.95-3.90 (m, 6H), 3.85 - 3.48 (m, 8H), 3.20-3.04 (m, 3H), 2.60 (s, 3H), 2.53 - 2.43 (m, 4H), 2.42 - 2.19 (m, 5H), 2.10-2.05 (m, 1H), 1.88 (d, J = 13.6 Hz, 6H), 1.62 (d, J = 7.0 Hz, 4H), 1.36 (s, 8H), 1.03 (s, 9H). HRMS (ESI) C 60 H 82 ClN 11 O7PS [M+H] + Calculated value: 1166.5540, measured value: 1166.2102.

[0404] Compound Example 84: Synthesis of 4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxobutanamide. (SIAIS164152)

[0405] SIAIS164152 (yellow solid, 10.6 mg, 63%) was prepared using brigatinib analog C and intermediate LM (SIAIS164119) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.23 ​​(s, 1H), 8.17 (s, 1H), 7.74 (dd, J = 13.8, 7.8 Hz, 1H), 7.71 - 7.62 (m, 2H), 7.57 (dd, J = 8.5, 7.2 Hz, 1H), 7.50 (t, J = 7.3 Hz, 1H), 7.45 (s, 1H), 7.15 (t, J = 6.9 Hz, 2H), 7.06 (d, J = 7.1 Hz, 1H), 5.08 (dd, J = 12.7, 5.5 Hz, 1H), 4.72 (s, 1H), 4.27 (s, 1H), 3.97 (s, 3H), 3.93 (d, J = 12.2 Hz, 2H), 3.86 - 3.58 (m, 6H), 3.48 (s, 5H), 3.17 (s, 2H), 2.93-2.85 (m, 1H), 2.80 - 2.65 (m, 3H), 2.65 - 2.40 (m, 7H), 2.16 - 2.07 (m, 1H), 1.87 (d, J = 13.6 Hz, 6H). HRMS (ESI) C 47 H 56 ClN 11 O8P [M+H] + Calculated value: 968.3734, measured value: 968.1075.

[0406] Compound Example 85: Synthesis of 4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS219158)

[0407] SIAIS219158 (white solid, 6.8 mg, 44%) was prepared using brigatinib analog C and intermediate LM (SIAIS172147) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.31 (d, J = 12.2 Hz, 1H), 8.11 (s, 1H), 7.86 - 7.81 (m, 2H), 7.76 (dd, J = 7.8, 1.2 Hz, 1H), 7.74 - 7.67 (m, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.1 Hz, 2H), 6.99 (s, 1H), 6.80 (d, J = 8.4 Hz, 1H), 5.13 (dd, J = 12.6, 5.5 Hz, 1H), 3.94 (d, J = 12.8 Hz, 2H), 3.90 (s, 3H), 3.61-3.55 (m, 4H), 3.19-3.14 (m, 8H), 2.91-2.77 (m, 4H), 2.76-2.73 (m, 2H), 2.35 (d, J = 11.4 Hz, 2H), 2.18 - 2.06 (m, 3H), 1.91 - 1.87 (m, 6H). HRMS (ESI) C 44 H 50 ClN9O7P + [M+H] + Calculated value: 882.3254, measured value: 882.3242.

[0408] Compound Example 86: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164153)

[0409] SIAIS164153 (white solid, 9.2 mg, 44%) was prepared using brigatinib analog C and intermediate LM (SIAIS164128) in the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 9.90 (s, 1H), 8.32 (s, 1H), 8.21 (s, 2H), 7.74 (dd, J = 13.7, 7.7 Hz, 1H), 7.69 - 7.58 (m, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.54 - 7.46 (m, 3H), 7.38 (s, 1H), 7.10 (s, 1H), 4.64 - 4.48 (m, 6H), 4.44-4.41 (m, 1H), 4.26 (s, 1H), 3.96-3.92 (m, 6H), 3.88 - 3.53 (m, 8H), 3.17 (s, 2H), 2.92 (s, 2H), 2.61-2.59 (m, 5H), 2.52 (s, 2H), 2.48 - 2.13 (m, 8H), 2.12 - 2.01 (m, 3H), 1.87 (d, J = 13.6 Hz, 6H), 1.03 (s, 9H). HRMS (ESI) C 60 H 79 ClN 14 O7PS [M+H] + Calculated value: 1205.5398, measured value: 1205.1640.

[0410] Compound Example 87: Synthesis of 8-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164011)

[0411] SIAIS164011 (yellow solid, 16.6 mg, 47%) was prepared using alectinib analog A and intermediate LM (SIAIS151001) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.09 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.61 (dd, J = 8.1, 1.4 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.36 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.61 (t, J = 5.7 Hz, 1H), 5.04 (dd, J = 12.8, 5.4 Hz, 1H), 3.73 (t, J = 6.5 Hz, 2H), 3.63 (t, J = 5.2 Hz, 6H), 3.48 (dd, J = 10.9, 5.4 Hz, 2H), 2.98 - 2.90 (m, 4H), 2.89-2.81 (m, 1H), 2.73 (q, J = 7.5 Hz, 2H), 2.65 (t, J = 6.6 Hz, 2H), 2.56-2.49 (m, 2H), 2.00-1.97 (m, 1H), 1.73 (s, 6H), 1.27 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 43 H 44 N7O7[M+H] + Calculated value: 770.3297, measured value: 770.2435.

[0412] Compound Example 88: Synthesis of 8-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164012)

[0413] SIAIS164012 (yellow solid, 28 mg, 75%) was prepared using alectinib analog A and intermediate LM (SIAIS151004) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 8.51-8.43 (m, 2H), 8.27 (s, 1H), 7.77 (s, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.46-7.43 (m, 1H), 7.13 (s, 1H), 7.03-7.02 (m, 1H), 6.84 (dd, J = 8.6, 5.0 Hz, 1H), 6.43 (s, 1H), 4.96 (dd, J = 11.8, 5.4 Hz, 1H), 3.88-3.83 (m, 4H), 3.71-3.65 (m, 8H), 3.37 (s, 2H), 3.03 - 2.93 (m, 4H), 2.90-2.88 (m, 1H), 2.77-2.71 (m, 6H), 2.13 (s, 1H), 1.70 (dd, J = 7.3, 2.1 Hz, 6H), 1.34 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 45 H 48 N7O8[M+H] + Calculated value: 814.3559, measured value: 814.2643.

[0414] Compound Example 89: Synthesis of 8-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164013)

[0415] SIAIS164013 (yellow solid, 28.8 mg, 73%) was prepared using alectinib analog A and intermediate LM (SIAIS151005) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.76 (s, 1H), 9.09 (s, 1H), 8.47 (d, J = 8.2 Hz, 1H), 8.27 (s, 1H), 7.75 (s, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.41 (dd, J = 10.1, 5.5 Hz, 1H), 7.13 (s, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 6.42 (s, 1H), 5.03 - 4.87 (m, 1H), 3.83 (t, J = 6.2 Hz, 4H), 3.70 - 3.57 (m, 12H), 3.35 (s, 2H), 3.02 - 2.84 (m, 5H), 2.83 - 2.65 (m, 6H), 2.12 (s, 1H), 1.88-1.65 (m, 6H), 1.37 - 1.26 (m, 3H). HRMS (ESI) C 47 H 52 N7O9[M+H] + Calculated value: 858.3821, measured value: 858.2862.

[0416] Compound Example 90: Synthesis of 8-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164014)

[0417] SIAIS164014 (yellow solid, 16.8 mg, 40%) was prepared using alectinib analog A and intermediate LM (SIAIS151006) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.04 (s, 1H), 8.62 (s, 1H), 8.49 (d, J = 8.2 Hz, 1H), 8.28 (s, 1H), 7.75 (s, 1H), 7.54 (dd, J = 8.2, 1.3 Hz, 1H), 7.48 - 7.41 (m, 1H), 7.14 (s, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H), 6.43 (s, 1 H), 4.94 (dd, J = 12.2, 5.4 Hz, 1H), 3.82 (t, J = 6.3 Hz, 4H), 3.73 - 3.57 (m, 16H), 3.38 (t, J = 5.1 Hz, 2H), 3.02 - 2.94 (m, 4H), 2.91-2.88 (m, 1H), 2.83 - 2.67 (m, 6H), 2.18 - 2.08 (m, 1H), 1.73 (d, J = 5.0 Hz, 6H), 1.33 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 49 H 56 N7O 10 [M+H] + Calculated value: 902.4083, measured value: 902.4401.

[0418] Compound Example 91: Synthesis of 8-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164015)

[0419] SIAIS164015 (yellow solid, 17.8 mg, 41%) was prepared using alectinib analog A and intermediate LM (SIAIS151007) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.12 (s, 1H), 8.64 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H), 8.28 (s, 1H), 7.74 (d, J = 4.2 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.45 (dd, J = 12.4, 5.4 Hz, 1H), 7.17 (s, 1H), 7.09 - 7.02 (m, 1H), 6.84 (d, J = 8.5 Hz, 1H), 6.46 (s, 1H), 4.94 (dd, J = 12.0, 5.6 Hz, 1H), 3.83 (d, J = 3.2 Hz, 4H), 3.74 - 3.60 (m, 20H), 3.41 (d, J = 4.8 Hz, 2H), 2.98 (s, 4H), 2.91-2.88 (m, 1H), 2.81-2.69 (m, 6H), 2.15-2.13 (m, 1H), 1.74 - 1.71 (m, 6H), 1.34 (t, J = 7.4 Hz, 3H). HRMS (ESI) C 51 H 60 N7O 11 [M+H] + Calculated value: 946.4345, measured value: 946.4364.

[0420] Compound example 92:8-(4 -((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) Glycyl Synthesis of )piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164028)

[0421] SIAIS164028 (yellow solid, 17.2 mg, 53%) was prepared using alectinib analog A and intermediate LM (SIAIS151025) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 11.11 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.65-7.60 (m, 2H), 7.42 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.13 (s, 1H), 7.09 (d, J = 7.1 Hz, 1H), 5.08 (dd, J = 12.9, 5.3 Hz, 1H), 4.28 (d, J = 4.4 Hz, 2H), 3.74 (s, 2H), 3.70 (s, 2H), 3.05 (s, 2H), 3.01 (s, 2H), 3.05-2.87 (m, 1H), 2.78 (q, J = 7.5 Hz, 2H), 2.63 (s, 1H), 2.59-2.54 (m, 1H), 2.07-2.04 (m, 1H), 1.75 (s, 6H), 1.30 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 40 H 38 N7O6[M+H] + Calculated value: 712.2878, measured value: 712.2993.

[0422] Compound Example 93: Synthesis of 8-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164029)

[0423] SIAIS164029 (yellow solid, 16.8 mg, 50%) was prepared using alectinib analog A and intermediate LM (SIAIS151026) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.10 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.61 (t, J = 7.5 Hz, 2H), 7.38 (s, 1H), 7.18 (d, J = 8.6 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.82 (t, J = 6.3 Hz, 1H), 5.05 (dd, J = 12.7, 5.4 Hz, 1H), 3.68 (s, 2H), 3.63 (s, 2H), 3.61 - 3.56 (m, 2H), 2.96-2.94 (m, 4H), 2.92 - 2.83 (m, 1H), 2.78 - 2.71 (m, 4H), 2.65 - 2.52 (m, 2H), 2.03-2.01 (m, 1H), 1.74 (s, 6H), 1.28 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 41 H 40 N7O6[M+H] + Calculated value: 726.3035, measured value: 726.3166.

[0424] Compound Example 94: Synthesis of 8-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164024)

[0425] SIAIS164024 (yellow solid, 23.6 mg, 69%) was prepared using alectinib analog A and intermediate LM (SIAIS151019) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 8.53 (d, J = 8.2 Hz, 1H), 8.30 (s, 1H), 8.04 (s, 1H), 7.77 (s, 1H), 7.58 (dd, J = 8.2, 1.3 Hz, 1H), 7.51 (dd, J = 8.5, 7.2 Hz, 1H), 7.14 (s, 1H), 7.10 (d, J = 7.0 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H), 6.34 (s, 1H), 4.93 (dd, J = 12.4, 5.4 Hz, 1H), 3.85 (s, 2H), 3.66 (s, 2H), 3.43 (s, 2H), 2.99 (d, J = 4.5 Hz, 4H), 2.92-2.89 (m, 1H), 2.83 - 2.73 (m, 4H), 2.53 (t, J = 6.9 Hz, 2H), 2.18 - 2.11 (m, 1H), 2.10 - 2.03 (m, 2H), 1.76 (s, 6H), 1.35 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 42 H 42 N7O6[M+H] + Calculated value: 740.3191, measured value: 740.3471.

[0426] Compound Example 95: Synthesis of 8-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164025)

[0427] SIAIS164025 (yellow solid, 21 mg, 61%) was prepared using alectinib analog A and intermediate LM (SIAIS151020) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 9.49 (s, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.30 (s, 1H), 8.09 (s, 1H), 7.77 (d, J = 0.5 Hz, 1H), 7.56 (dd, J = 8.2, 1.3 Hz, 1H), 7.49 (dd, J = 8.5, 7.1 Hz, 1H), 7.16 (s, 1H), 7.09 (d, J = 6.9 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 6.25 (s, 1H), 4.90 (dd, J = 12.4, 5.4 Hz, 1H), 3.86 (s, 2H), 3.69 (s, 2H), 3.32 (t, J = 6.5 Hz, 2H), 3.07 - 2.95 (m, 4H), 2.89 (d, J = 13.2 Hz, 1H), 2.83 - 2.71 (m, 4H), 2.49 (t, J = 7.1 Hz, 2H), 2.16-2.12 (m, 1H), 1.86-1.82 (m, 2H), 1.78-1.75 (m, 8H), 1.35 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 43 H 44 N7O6[M+H] + Calculated value: 754.3348, measured value: 754.3630.

[0428] Compound Example 96: Synthesis of 8-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164026)

[0429] SIAIS164026 (yellow solid, 20.4 mg, 58%) was prepared using alectinib analog A and intermediate LM (SIAIS151027) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.54 (d, J = 8.2 Hz, 1H), 8.31 (s, 1H), 8.05 (s, 1H), 7.77 (s, 1H), 7.58 (dd, J = 8.2, 1.3 Hz, 1H), 7.49 (dd, J = 8.5, 7.1 Hz, 1H), 7.16 (s, 1H), 7.09 (d, J = 6.9 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H), 6.23 (s, 1H), 4.92 (dd, J = 12.3, 5.4 Hz, 1H), 3.85 (s, 2H), 3.69 (s, 2H), 3.29 (t, J = 6.8 Hz, 2H), 3.04 - 2.97 (m, 4H), 2.912-2.89 (m, 1H), 2.82 - 2.73 (m, 4H), 2.45 (t, J = 7.5 Hz, 2H), 2.18 - 2.11 (m, 1H), 1.78 - 1.71 (m, 10H), 1.53-1.52 (m, 2H), 1.36 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 44 H 46 N7O6[M+H] + Calculated value: 768.3504, measured value: 768.3785.

[0430] Compound Example 97: Synthesis of -(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS164030)

[0431] SIAIS164030 (yellow solid, 19.4 mg, 54%) was prepared using alectinib analog A and intermediate LM (SIAIS151086) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.26 (s, 1H), 8.51 (d, J = 8.2 Hz, 1H), 8.30 (s, 2H), 7.76 (d, J = 0.5 Hz, 1H), 7.55 (dd, J = 8.2, 1.3 Hz, 1H), 7.47 (dd, J = 8.5, 7.1 Hz, 1H), 7.16 (s, 1H), 7.06 (t, J = 5.1 Hz, 1H), 6.86 (d, J = 8.5 Hz, 1H), 6.21 (s, 1H), 4.93 (dd, J = 12.2, 5.5 Hz, 1H), 3.88 (s, 2H), 3.72 (s, 2H), 3.25 (t, J = 7.0 Hz, 2H), 3.02 (dd, J = 9.9, 4.8 Hz, 4H), 2.91-2.88 (m, 1H), 2.85 - 2.70 (m, 4H), 2.46 (t, J = 7.5 Hz, 2H), 2.19 - 2.10 (m, 1H), 1.77 - 1.70 (m, 8H), 1.69 - 1.63 (m, 2H), 1.53 - 1.39 (m, 4H), 1.33 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 45 H 48 N7O6[M+H] + Calculated value: 782.3661, measured value: 782.3818.

[0432] Compound Example 98: Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164040)

[0433] SIAIS164040 (white solid, 29.7 mg, 66%) was prepared using alectinib analog A and intermediate LM (SIAIS151010) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.26 (s, 1H), 8.94 (s, 1H), 8.51 (d, J = 8.2 Hz, 1H), 8.29 (s, 1H), 7.78 (s, 1H), 7.56 (dd, J = 8.2, 1.3 Hz, 1H), 7.41 - 7.31 (m, 5H), 7.16 (s, 1H), 4.72 (t, J = 8.1 Hz, 1H), 4.61 - 4.51 (m, 3H), 4.36 (dd, J = 15.2, 5.4 Hz, 1H), 4.28 (s, 2H), 4.14 (d, J = 11.7 Hz, 1H), 4.11-4.00 (m, 2H), 3.85 - 3.58 (m, 9H), 3.46 - 3.39 (m, 2H), 3.00 (s, 4H), 2.88 (s, 3H), 2.76 (q, J = 7.6 Hz, 2H), 2.55 (s, 3H), 2.53-2.49 (m, 1H), 2.45 (t, J = 8.2 Hz, 2H), 2.09 - 2.00 (m, 3H), 1.73 (d, J = 3.4 Hz, 6H), 1.34 (t, J = 7.5 Hz, 3H), 0.97 (s, 9H). HRMS (ESI) C 53 H 63 N8O8S [M+H] + Calculated value: 971.4484, measured value: 971.4483.

[0434] Compound Example 99: Synthesis of (2S,4R)-1-((S)-2-(3-(2-(3-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164036)

[0435] SIAIS164036 (white solid, 16.1 mg, 35%) was prepared using alectinib analog A and intermediate LM (SIAIS151002) in the procedure for preparing compound example 1. 1H NMR (500 MHz, CDCl3) δ 10.34 (s, 1H), 9.08 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H), 8.28 (s, 1H), 7.77 (s, 1H), 7.62 (s, 1H), 7.55 (dd, J = 8.2, 1.3 Hz, 1H), 7.42 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.11 (s, 1H), 4.74 (t, J = 8.2 Hz, 1H), 4.66 (dd, J = 15.5, 6.8 Hz, 1H), 4.58 (s, 1H), 4.54 (d, J = 8.4 Hz, 1H), 4.34 (dd, J = 15.4, 5.2 Hz, 1H), 4.18 (d, J = 11.4 Hz, 1H), 3.85 - 3.72 (m, 5H), 3.71 - 3.58 (m, 8H), 2.96 - 2.95 (m, 4H), 2.77 - 2.72 (m, 2H), 2.70 (t, J = 6.3 Hz, 2H), 2.58 (s, 3H), 2.56 - 2.49 (m, 2H), 2.47 - 2.37 (m, 1H), 2.29 - 2.21 (m, 1H), 1.71 (d, J = 3.1 Hz, 6H), 1.32 (t, J = 7.5 Hz, 3H), 0.97 (s, 9H). HRMS (ESI) C 55 H 67 N8O8S [M+H] + Calculated value: 999.4797, measured value: 999.4847.

[0436] Compound Example 100: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164037)

[0437] Compound Example 1 was prepared using SIAIS 164037 (white solid, 34.6 mg, 72%). 1 H NMR (500 MHz, CDCl3) δ 10.62 (s, 1H), 9.10 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H), 8.28 (s, 1H), 7.78 (s, 1H), 7.54 (dd, J = 8.2, 1.3 Hz, 1H), 7.46 (d, J = 6.2 Hz, 1H), 7.39 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.14 (s, 1H), 4.73 (t, J = 8.3 Hz, 1H), 4.63 (dd, J = 15.3, 6.8 Hz, 1H), 4.57-4.54 (m, 2H), 4.34 (dd, J = 15.3, 5.1 Hz, 1H), 4.17 (d, J = 11.4 Hz, 1H), 3.81-3.75 (m, 5H), 3.72 - 3.59 (m, 12H), 2.99-2.96 (m, 4H), 2.80 - 2.67 (m, 4H), 2.56 (s, 3H), 2.56-2.54 (m, 2H), 2.44 - 2.34 (m, 1H), 2.29-2.24 (m, 1H), 1.72 (d, J = 2.7 Hz, 6H), 1.33 (t, J = 7.5 Hz, 3H), 0.99 (s, 9H). HRMS (ESI) C 57 H 71 N8O9S [M+H] + Calculated value: 1043.5059, measured value: 1043.5097.

[0438] Compound Example 101: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164038)

[0439] SIAIS164038 (white solid, 32.5 mg, 65%) was prepared using alectinib analog A and intermediate LM (SIAIS151008) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, CDCl3) δ 10.78 (s, 1H), 9.08 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H), 8.28 (s, 1H), 7.77 (s, 1H), 7.53 (dd, J = 8.2, 1.3 Hz, 1H), 7.39-7.37 (m, 3H), 7.34 (d, J = 8.2 Hz, 2H), 7.15 (s, 1H), 4.73 (t, J = 8.0 Hz, 1H), 4.65 - 4.56 (m, 2H), 4.54 (d, J = 8.3 Hz, 1H), 4.35 (dd, J = 15.3, 5.2 Hz, 1H), 4.14 (d, J = 11.4 Hz, 1H), 3.82-3.81 (m, 4H), 3.70-3.67 (m, 5H), 3.63-3.61 (m, 12H), 3.00-2.96 (m, 4H), 2.78-2.71 (m, 4H), 2.54 (s, 3H), 2.52 (s, 2H), 2.41-2.39 (m, 1H), 2.28-2.27 (m, 1H), 1.73 (s, 6H), 1.32 (t, J = 7.5 Hz, 3H), 0.98 (s, 9H). HRMS (ESI) C 59 H 75 N8O 10 S [M+H] +Calculated value: 1087.5321, measured value: 1087.5342.

[0440] Compound Example 102: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164039)

[0441] SIAIS164039 (white solid, 40.1 mg, 77%) was prepared using alectinib analog A and intermediate LM (SIAIS151009) in the procedure for preparing compound example 1. 1H NMR (500 MHz, CDCl3) δ 10.84 (s, 1H), 9.03 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H), 8.29 (s, 1H), 7.78 (s, 1H), 7.54 (dd, J = 8.2, 1.3 Hz, 1H), 7.37 (q, J = 8.2 Hz, 5H), 7.22 (d, J = 7.6 Hz, 1H), 7.17 (s, 1H), 4.74 (t, J = 7.8 Hz, 1H), 4.63-4.59 (m, 2H), 4.54 (d, J = 8.4 Hz, 1H), 4.36 (dd, J = 15.2, 5.1 Hz, 1H), 4.14 (d, J = 11.2 Hz, 1H), 3.83 (s, 4H), 3.75 - 3.68 (m, 4H), 3.65-3.61 (m, 16H), 3.01 (s, 2H), 2.97 (s, 2H), 2.79-2.76 (m, 2H), 2.75-2.71 (m, 3H), 2.54 (s, 3H), 2.53-2.52 (m, 2H), 2.44-2.43 (m, 1H), 2.26-2.25 (m, 1H), 1.75 (d, J = 4.9 Hz, 6H), 1.34 (t, J = 7.5 Hz, 3H), 0.98 (s, 9H). HRMS (ESI) C 61 H 79 N8O 11 S [M+H] + Calculated value: 1131.5584, measured value: 1131.5582.

[0442] Compound Example 103: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4-oxobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164093)

[0443] SIAIS164093 (white solid, 21.2 mg, 67%) was prepared using alectinib analog A and intermediate LM (SIAIS074011) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 8.99 (s, 1H), 8.57 (t, J = 6.0 Hz, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.41 (q, J = 8.2 Hz, 5H), 4.55 (d, J = 9.4 Hz, 1H), 4.43 (dd, J = 14.3, 6.9 Hz, 2H), 4.36 (s, 1H), 4.22 (dd, J = 16.0, 5.5 Hz, 1H), 3.64 (s, 7H), 2.99 (s, 2H), 2.93 (s, 2H), 2.76 (q, J = 7.4 Hz, 2H), 2.65 - 2.54 (m, 3H), 2.45-2.42 (m, 4H), 2.09 - 1.99 (m, 1H), 1.96 - 1.86 (m, 1H), 1.74 (s, 6H), 1.29 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H). HRMS (ESI) C 51 H 59 N8O6S [M+H] + Calculated value: 911.4273, measured value: 911.4539.

[0444] Compound Example 104: Synthesis of (2S,4R)-1-((S)-2-(5-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164094)

[0445] SIAIS164094 (white solid, 16.7 mg, 52%) was prepared using alectinib analog A and intermediate LM (SIAIS074012) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 8.97 (s, 1H), 8.56 (t, J = 5.9 Hz, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.92 (d, J = 9.5 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.45 - 7.35 (m, 5H), 4.56 (d, J = 9.3 Hz, 1H), 4.42 (dd, J = 16.5, 8.2 Hz, 2H), 4.35 (s, 1H), 4.21 (dd, J = 15.9, 5.4 Hz, 1H), 3.73 - 3.59 (m, 7H), 2.98 (s, 2H), 2.92 (s, 2H), 2.75 (q, J = 7.4 Hz, 2H), 2.43 (s, 3H), 2.36 (t, J = 7.4 Hz, 2H), 2.33 - 2.19 (m, 2H), 2.06-2.02 (m, 1H), 1.93-1.88 (m, 1H), 1.75-1.72 (m, 8H), 1.28 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H). HRMS (ESI) C 52 H 61 N8O6S [M+H] + Calculated value: 925.4429, measured value: 925.4685.

[0446] Compound Example 105: Synthesis of (2S,4R)-1-((S)-2-(6-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-6-oxohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164095)

[0447] SIAIS164095 (white solid, 19.6 mg, 60%) was prepared using alectinib analog A and intermediate LM (SIAIS074013) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.76 (s, 1H), 8.98 (s, 1H), 8.56 (t, J = 5.8 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.88 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.44 - 7.36 (m, 5H), 4.56 (d, J = 9.5 Hz, 1H), 4.49 - 4.39 (m, 2H), 4.35 (s, 1H), 4.21 (dd, J = 15.8, 5.4 Hz, 1H), 3.68 - 3.64 (m, 8H), 2.98 (s, 2H), 2.92 (s, 2H), 2.75 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 2.37 (s, 2H), 2.34 - 2.28 (m, 1H), 2.20 - 2.12 (m, 1H), 2.07 - 2.00 (m, 1H), 1.94 - 1.87 (m, 1H), 1.75 (s, 6H), 1.53 (d, J = 6.8 Hz, 4H), 1.28 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H). HRMS (ESI) C 53 H 63 N8O6S [M+H] + Calculated value: 939.4586, measured value: 939.4864.

[0448] Compound Example 106: Synthesis of (2S,4R)-1-((S)-2-(7-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164096)

[0449] Compound Example 1 was prepared by using SIAIS 164096 (white solid, 21.6 mg, 66%). 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 8.98 (s, 1H), 8.56 (t, J = 5.9 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.86 (d, J = 9.3 Hz, 1H), 7.61 (dd, J = 8.1, 1.2 Hz, 1H), 7.44 - 7.36 (m, 5H), 4.55 (d, J = 9.4 Hz, 1H), 4.45-4.41 (m, 2H), 4.35 (s, 1H), 4.21 (dd, J = 15.9, 5.5 Hz, 1H), 3.69 - 3.62 (m, 7H), 2.97 (s, 2H), 2.93 (s, 2H), 2.75 (q, J = 7.5 Hz, 2H), 2.44 (s, 3H), 2.37 - 2.32 (m, 2H), 2.31 - 2.24 (m, 1H), 2.18 - 2.11 (m, 1H), 2.06 - 2.00 (m, 1H), 1.94 - 1.87 (m, 1H), 1.75 (s, 6H), 1.55-1.49 (m, 4H), 1.32 - 1.25 (m, 5H), 0.93 (d, J = 11.4 Hz, 9H). HRMS (ESI) C 54 H 65 N8O6S [M+H] + Calculated value: 953.4742, measured value: 953.4991.

[0450] Compound Example 107: Synthesis of (2S,4R)-1-((S)-2-(8-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164097)

[0451] SIAIS164097 (white solid, 22.6 mg, 68%) was prepared using alectinib analog A and intermediate LM (SIAIS074015) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.76 (s, 1H), 8.99 (s, 1H), 8.56 (t, J = 6.0 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.85 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 8.2 Hz, 1H), 7.45 - 7.36 (m, 5H), 4.55 (d, J = 9.4 Hz, 1H), 4.45-4.41 (m, 2H), 4.35 (s, 1H), 4.21 (dd, J = 16.0, 5.3 Hz, 1H), 3.65-3.63 (m, 7H), 2.97 (s, 2H), 2.93 (s, 2H), 2.75 (q, J = 7.5 Hz, 2H), 2.44 (s, 3H), 2.38 - 2.33 (m, 2H), 2.30-2.24 (m, 1H), 2.16-2.10 (m, 1H), 2.06 - 1.99 (m, 1H), 1.94 - 1.86 (m, 1H), 1.75 (s, 6H), 1.52-1.47 (m, 4H), 1.30-1.27 (m, 7H), 0.93 (s, 9H). HRMS (ESI) C 55 H 67 N8O6S [M+H] + Calculated value: 967.4899, measured value: 967.5164.

[0452] Compound Example 108: Synthesis of (2S,4R)-1-((S)-2-(9-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164098)

[0453] SIAIS164098 (white solid, 21.8 mg, 64%) was prepared using alectinib analog A and intermediate LM (SIAIS074016) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 8.99 (s, 1H), 8.55 (t, J = 6.0 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.84 (d, J = 9.3 Hz, 1H), 7.61 (dd, J = 8.1, 1.2 Hz, 1H), 7.44 - 7.36 (m, 5H), 4.55 (d, J = 9.4 Hz, 1H), 4.45-4.41 (m, 2H), 4.35 (s, 1H), 4.21 (dd, J = 16.0, 5.6 Hz, 1H), 3.66-3.63 (m, 7H), 2.97 (s, 2H), 2.92 (s, 2H), 2.75 (q, J = 7.5 Hz, 2H), 2.44 (s, 3H), 2.35 (t, J = 7.5 Hz, 2H), 2.31 - 2.23 (m, 1H), 2.16 - 2.08 (m, 1H), 2.05 - 2.00 (m, 1H), 1.92-1.87 (m, 1H), 1.75 (s, 6H), 1.52-1.46 (m, 4H), 1.30-1.27 (m, 9H), 0.92 (s, 9H). HRMS (ESI) C 56 H 69 N8O6S [M+H] + Calculated value: 981.5055, measured value: 981.5349.

[0454] Compound Example 109: Synthesis of (2S,4R)-1-((S)-2-(10-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164099)

[0455] SIAIS164099 (white solid, 20.1 mg, 59%) was prepared using alectinib analog A and intermediate LM (SIAIS074019) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.77 (s, 1H), 8.99 (s, 1H), 8.56 (t, J = 6.0 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.84 (d, J = 9.4 Hz, 1H), 7.60 (dd, J = 8.1, 1.2 Hz, 1H), 7.42-7.37 (m, 5H), 4.54 (d, J = 9.4 Hz, 1H), 4.45-4.41 (m, 2H), 4.35 (s, 1H), 4.21 (dd, J = 15.9, 5.4 Hz, 1H), 3.69 - 3.63 (m, 7H), 2.97 (s, 2H), 2.92 (s, 2H), 2.75 (q, J = 7.5 Hz, 2H), 2.44 (s, 3H), 2.35 (t, J = 7.4 Hz, 2H), 2.30 - 2.22 (m, 1H), 2.11 (dt, J = 14.4, 6.5 Hz, 1H), 2.06 - 1.99 (m, 1H), 1.93-1.87 (m, 1H), 1.75 (s, 6H), 1.53-1.46 (m, 4H), 1.30-1.27 (m, 11H), 0.92 (s, 9H). HRMS (ESI) C 57 H 71 N8O6S [M+H]+ Calculated value: 995.5212, measured value: 995.5518.

[0456] Compound Example 110: Synthesis of 4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxobutanamide. (SIAIS164154)

[0457] SIAIS164154 (yellow solid, 9 mg, 49%) was prepared using alectinib analog A and intermediate LM (SIAIS164119) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 11.09 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.11 (t, J = 5.3 Hz, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.60 (dd, J = 12.1, 5.6 Hz, 2H), 7.39 (s, 1H), 7.20 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.75 (s, 1H), 5.05 (dd, J = 12.8, 5.4 Hz, 1H), 3.63 (s, 4H), 3.29 - 3.21 (m, 2H), 2.98 (s, 2H), 2.92 (s, 2H), 2.88-2.85 (m, 1H), 2.75 (q, J = 7.4 Hz, 2H), 2.66 - 2.51 (m, 6H), 2.35 (t, J = 7.0 Hz, 2H), 2.05 - 1.98 (m, 1H), 1.75 (s, 6H), 1.29 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 44 H 45 N8O7[M+H] + Calculated value: 797.3406, measured value: 797.1339.

[0458] Compound Example 111: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS164155)

[0459] SIAIS164155 (white solid, 9 mg, 38%) was prepared using alectinib analog A and intermediate LM (SIAIS164128) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.82 (s, 1H), 9.01 (s, 1H), 8.56 (t, J = 6.0 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 7.99 (d, J = 10.0 Hz, 2H), 7.90 (s, 1H), 7.60 (dd, J = 8.1, 1.2 Hz, 1H), 7.46 - 7.34 (m, 6H), 4.53 (d, J = 9.3 Hz, 1H), 4.46 - 4.39 (m, 2H), 4.35 (s, 1H), 4.30 (t, J = 7.1 Hz, 2H), 4.21 (dd, J = 15.8, 5.4 Hz, 1H), 2.97 (s, 2H), 2.93 (s, 2H), 2.75 (q, J = 7.4 Hz, 2H), 2.69-2.64 (m, 3H), 2.49 - 2.34 (m, 7H), 2.29-2.23 (m, 1H), 2.21 - 2.13 (m, 1H), 2.11 - 1.94 (m, 4H), 1.94 - 1.79 (m, 4H), 1.75 (s, 7H), 1.28 (t, J = 7.5 Hz, 3H), 0.93 (s, 9H). HRMS (ESI) C 57 H 68 N 11 O6S [M+H] +Calculated value: 1034.5069, measured value: 1034.2256.

[0460] Compound Example 112: Synthesis of N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propenamide. (SIAIS219023)

[0461] SIAIS219023 (yellow solid, 9.8 mg, 49%) was prepared using alectinib analog B and intermediate LM (SIAIS151004) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 8.41 (d, J = 8.1 Hz, 1H), 8.24 (s, 1H), 7.88 (s, 1H), 7.60 - 7.51 (m, 3H), 7.08 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 5.06 (dd, J = 12.5, 5.5 Hz, 1H), 4.14 (d, J = 17.1 Hz, 1H), 3.96 (t, J = 11.3 Hz, 1H), 3.80-3.73 (m, 2H), 3.69 - 3.61 (m, 6H), 3.50 (t, J = 5.2 Hz, 2H), 3.20 (d, J = 27.6 Hz, 4H), 2.89 - 2.69 (m, 6H), 2.48 (t, J = 6.1 Hz, 2H), 2.10 (d, J = 4.6 Hz, 2H), 1.88 - 1.75 (m, 8H), 1.37-1.29 (m, 2H). HRMS (ESI) C 46 H 50 N7O8[M+H] + Calculated value: 828.3715, measured value: 828.3762.

[0462] Compound Example 113: Synthesis of N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide. (SIAIS219024)

[0463] SIAIS219024 (yellow solid, 11.2 mg, 51%) was prepared using alectinib analog B and intermediate LM (SIAIS151006) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 8.41 (d, J = 8.1 Hz, 1H), 8.33 (s, 1H), 7.88 (s, 2H), 7.58 (dd, J = 8.2, 1.4 Hz, 1H), 7.50 (dd, J = 8.5, 7.1 Hz, 1H), 7.02 (dd, J = 14.9, 7.8 Hz, 2H), 5.06 (dd, J = 12.6, 5.5 Hz, 1H), 4.10 (t, J = 10.9 Hz, 1H), 3.76 (t, J = 6.1 Hz, 2H), 3.69 - 3.54 (m, 14H), 3.47 - 3.41 (m, 2H), 3.17 (s, 4H), 2.94 - 2.83 (m, 3H), 2.77 - 2.67 (m, 2H), 2.49 (t, J = 6.0 Hz, 2H), 2.24 (d, J = 11.8 Hz, 2H), 2.14 - 2.00 (m, 3H), 1.83 (s, 4H), 1.42 (t, J = 7.5 Hz, 3H), 1.35 - 1.24 (m, 2H). HRMS (ESI) C 50 H 58 N7O 10 [M+H] + Calculated value: 916.4240, measured value: 916.4319.

[0464] Compound Example 114: Synthesis of N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide. (SIAIS219001)

[0465] SIAIS219001 (yellow solid, 7.4 mg, 42%) was prepared using alectinib analog B and intermediate LM (SIAIS151025) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 11.11 (s, 1H), 8.31 (d, J = 7.9 Hz, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 7.90 (d, J = 7.7 Hz, 1H), 7.63-7.59 (m, 2H), 7.37 (s, 1H), 7.08 (d, J = 6.7 Hz, 1H), 6.97-6.93 (m, 1H), 6.89 (d, J = 8.7 Hz, 1H), 5.07 (dd, J = 12.8, 5.4 Hz, 1H), 3.97 (s, 4H), 3.82 (s, 2H), 2.86-2.84 (m, 3H), 2.70 (d, J = 7.4 Hz, 4H), 1.90 (s, 2H), 1.75 (s, 6H), 1.66 (s, 2H), 1.27 (t, J = 7.4 Hz, 3H). HRMS (ESI) C 41 H 40 N7O6[M+H] + Calculated value: 726.3035, measured value: 726.3045.

[0466] Compound Example 115: Synthesis of N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanamide. (SIAIS219010)

[0467] SIAIS219010 (yellow solid, 7.2 mg, 40%) was prepared using alectinib analog B and intermediate LM (SIAIS151019) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.10 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.03 (s, 1H), 8.00 (s, 1H), 7.90 (d, J = 7.7 Hz, 1H), 7.63 - 7.58 (m, 2H), 7.36 (s, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.64 (t, J = 6.1 Hz, 1H), 5.06 (dd, J = 12.7, 5.4 Hz, 1H), 3.77 (s, 1H), 3.15 (d, J = 12.3 Hz, 2H), 2.88-2.83 (m, 3H), 2.69 (q, J = 7.4 Hz, 2H), 2.63-2.58 (m, 2H), 2.19 (t, J = 7.2 Hz, 2H), 2.05 - 2.00 (m, 1H), 1.89 (d, J = 10.3 Hz, 2H), 1.85 - 1.79 (m, 2H), 1.75 (s, 6H), 1.62 - 1.53 (m, 2H), 1.28-1.24 (m, 5H). HRMS (ESI) C 43 H 44 N7O6[M+H] + Calculated value: 754.3348, measured value: 754.3170.

[0468] Compound Example 116: Synthesis of N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanamide. (SIAIS219011)

[0469] SIAIS219011 (yellow solid, 8.8 mg, 47%) was prepared using alectinib analog B and intermediate LM (SIAIS151027) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 11.13 (s, 1H), 8.34 (d, J = 8.1 Hz, 1H), 8.04 (s, 1H), 8.02 (s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.65 - 7.59 (m, 2H), 7.37 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 7.0 Hz, 1H), 6.65 (t, J = 6.1 Hz, 1H), 5.08 (dd, J = 12.7, 5.4 Hz, 1H), 3.78 (s, 1H), 3.17 (d, J = 12.3 Hz, 2H), 2.88-2.85 (m, 3H), 2.70 (q, J = 7.4 Hz, 2H), 2.61-2.59 (m, 2H), 2.21 (t, J = 7.2 Hz, 2H), 2.06 - 2.01 (m, 4H), 1.90 (d, J = 10.3 Hz, 2H), 1.86 - 1.79 (m, 2H), 1.77 (s, 6H), 1.62 - 1.54 (m, 2H), 1.29-1.27 (m, 6H). HRMS (ESI) C 45 H 48 N7O6[M+H] + Calculated value: 782.3661, measured value: 782.3465.

[0470] Compound Example 117: Synthesis of N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide. (SIAIS219020)

[0471] SIAIS219020 (white solid, 9.9 mg, 43%) was prepared using alectinib analog B and intermediate LM (SIAIS074013) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 9.81 (s, 1H), 8.43 - 8.39 (m, 1H), 8.32 (s, 1H), 7.89 (s, 1H), 7.88 (s, 1H), 7.58-7.49 (m, 5H), 4.64 (s, 1H), 4.60 - 4.49 (m, 3H), 4.41 (d, J = 15.7 Hz, 1H), 4.08 (s, 1H), 3.92 (d, J = 11.1 Hz, 1H), 3.81 (dd, J = 11.0, 3.9 Hz, 1H), 3.61 (d, J = 9.8 Hz, 2H), 3.54 (s, 2H), 2.94-2.86 (m, 2H), 2.58 (s, 3H), 2.39 - 2.19 (m, 8H), 2.08-2.05 (m, 2H), 1.85 (s, 6H), 1.67-1.66 (m, 4H), 1.41 (t, J = 7.5 Hz, 3H), 1.05 (s, 9H). HRMS (ESI) C 54 H 65 N8O6S [M+H] + Calculated value: 953.4742, measured value: 953.4074.

[0472] Compound Example 118: Synthesis of N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide. (SIAIS219021)

[0473] SIAIS219021 (white solid, 11.2 mg, 46%) was prepared using alectinib analog B and intermediate LM (SIAIS074019) in the procedure for preparing compound example 1.1 H NMR (500 MHz, MeOD) δ 9.60 (s, 1H), 8.41 (d, J = 8.2 Hz, 1H), 8.26 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 7.57 - 7.47 (m, 5H), 4.64 (s, 1H), 4.59 - 4.52 (m, 2H), 4.50 (s, 1H), 4.39 (d, J = 15.7 Hz, 1H), 3.98 (s, 1H), 3.91 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.9 Hz, 1H), 3.45-3.44 (m, 2H), 3.29 - 3.22 (m, 2H), 2.86 (q, J = 7.4 Hz, 2H), 2.55 (d, J = 2.9 Hz, 3H), 2.29-2.21 (m, 5H), 2.14 - 2.06 (m, 3H), 1.89 (d, J = 10.8 Hz, 2H), 1.83 (s, 6H), 1.63 (d, J = 6.4 Hz, 4H), 1.39 - 1.34 (m, 12H), 1.04 (s, 9H). HRMS (ESI) C 58 H 73 N8O6S [M+H] + Calculated value: 1009.5368, measured value: 1009.4649.

[0474] Compound Example 119: Synthesis of 8-(4-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS219018)

[0475] SIAIS219018 (yellow solid, 8.8 mg, 47%) was prepared using alectinib analog C and intermediate LM (SIAIS151004) in the procedure for preparing compound example 1. 1H NMR (500 MHz, DMSO) δ 12.81 (s, 1H), 11.10 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.06 (d, J = 3.0 Hz, 1H), 8.01 (s, 1H), 7.62-7.58 (m, 2H), 7.35 (s, 1H), 7.16 (d, J = 8.5 Hz, 1H), 7.05 (d, J = 6.9 Hz, 1H), 6.61 (s, 1H), 5.06 (dd, J = 12.7, 5.4 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 4.11 (d, J = 15.1 Hz, 1H), 3.67 - 3.46 (m, 14H), 3.33 - 3.24 (m, 6H), 3.12 - 3.05 (m, 1H), 2.92 - 2.78 (m, 3H), 2.73-2.68 (m, 2H), 2.66 - 2.53 (m, 3H), 2.25 - 2.16 (m, 2H), 2.06 - 1.99 (m, 1H), 1.96 - 1.85 (m, 2H), 1.76 (d, J = 2.0 Hz, 6H), 1.30-1.26 (m, 3H). HRMS (ESI) C 50 H 57 N8O8[M+H] + Calculated value: 897.4294, measured value: 897.3670.

[0476] Compound Example 120: Synthesis of 8-(4-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS219019)

[0477] SIAIS219019 (yellow solid, 10.1 mg, 49%) was prepared using alectinib analog C and intermediate LM (SIAIS151006) in the procedure for preparing compound example 1. 1H NMR (500 MHz, DMSO) δ 12.84 (s, 1H), 11.09 (s, 1H), 8.31 (d, J = 8.2 Hz, 1H), 8.06 (d, J = 3.0 Hz, 1H), 8.00 (s, 1H), 7.61 - 7.56 (m, 2H), 7.36 (s, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.60 (s, 1H), 5.05 (dd, J = 12.8, 5.5 Hz, 1H), 4.51 (d, J = 13.5 Hz, 1H), 4.12 (d, J = 13.9 Hz, 1H), 3.66 - 3.60 (m, 4H), 3.60 - 3.46 (m, 20H), 3.30 (s, 4H), 3.12 (t, J = 12.9 Hz, 2H), 2.91 - 2.78 (m, 3H), 2.73-2.68 (m, 3H), 2.26 - 2.19 (m, 2H), 2.3-2.002 (m, 1H), 1.95 - 1.87 (m, 2H), 1.76 (s, 6H), 1.30-1.26 (m, 3H). HRMS (ESI) C 54 H 65 N8O 10 [M+H] + Calculated value: 985.4818, measured value: 985.4897.

[0478] Compound Example 121: Synthesis of 8-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS184194)

[0479] SIAIS184194 (yellow solid, 6.2 mg, 37%) was prepared using alectinib analog C and intermediate LM (SIAIS151025) in the procedure for preparing compound example 1. 1H NMR (500 MHz, DMSO) δ 12.78 (s, 1H), 11.11 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.06 (s, 1H), 8.01 (s, 1H), 7.65 - 7.59 (m, 2H), 7.37 (s, 1H), 7.12 (dd, J = 14.8, 7.8 Hz, 2H), 7.04 (s, 1H), 5.08 (dd, J = 12.5, 5.4 Hz, 1H), 4.58 - 4.52 (m, 1H), 4.28 - 4.21 (m, 1H), 3.61 (s, 2H), 3.48 (d, J = 5.2 Hz, 3H), 3.44 - 3.40 (m, 8H), 2.83 (s, 3H), 2.72 (d, J = 7.5 Hz, 2H), 2.28 - 2.18 (m, 2H), 2.08 - 2.01 (m, 1H), 1.95 - 1.88 (m, 2H), 1.76 (s, 6H), 1.29 (t, J = 7.5 Hz, 3H). HRMS (ESI) C 45 H 47 N8O6[M+H] + Calculated value: 795.3613, measured value: 795.3622.

[0480] Compound Example 122: Synthesis of 8-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS219003)

[0481] Following the procedure for preparing Compound Example 1, SIAIS219003 (yellow solid, 6.6 mg, 38%) was prepared using alectinib analog C and intermediate LM (SIAIS151019). 1H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 11.09 (s, 1H), 8.32 (s, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.33 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.66 (s, 1H), 5.06 (dd, J = 12.8, 5.6 Hz, 1H), 3.26 - 3.18 (m, 6H), 2.78 - 2.68 (m, 10H), 2.40 (s, 4H), 2.07 - 1.99 (m, 2H), 1.89 - 1.78 (m, 6H), 1.75 (s, 6H), 1.61 (t, J = 10.4 Hz, 2H), 1.27 (t, J = 11.8 Hz, 5H). HRMS (ESI) C 47 H 51 N8O6[M+H] + Calculated value: 823.3926, measured value: 823.5145.

[0482] Compound Example 123: Synthesis of 8-(4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. (SIAIS219004)

[0483] SIAIS219004 (yellow solid, 7.1 mg, 40%) was prepared using alectinib analog C and intermediate LM (SIAIS151027) in the procedure for preparing compound example 1. 1H NMR (500 MHz, DMSO) δ 12.67 (s, 1H), 11.08 (s, 1H), 8.30 (s, 1H), 8.00 (s, 1H), 7.95 (s, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.31 (s, 1H), 7.14 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.58 (s, 1H), 5.07 (dd, J = 12.8, 5.6 Hz, 1H), 3.24 - 3.13 (m, 6H), 2.75 - 2.65 (m, 10H), 2.36 (s, 4H), 2.05 - 1.97 (m, 2H), 1.86 - 1.77 (m, 6H), 1.73 (s, 6H), 1.60 (t, J = 10.4 Hz, 2H), 1.25-1.20 (m, 9H). HRMS (ESI) C 49 H 55 N8O6[M+H] + Calculated value: 851.4239, measured value: 851.5517.

[0484] Compound Example 124: Synthesis of (2S,4R)-1-((S)-2-(6-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS219015)

[0485] SIAIS219015 (yellow solid, 10.2 mg, 48%) was prepared using alectinib analog C and intermediate LM (SIAIS074013) in the procedure for preparing compound example 1. 11H NMR (500 MHz, DMSO) δ 12.79 (s, 1H), 10.63 (s, 1H), 8.98 (s, 1H), 8.57 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.06 (s, 1H), 8.01 (s, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.62 - 7.59 (m, 1H), 7.42 (d, J = 8.1 Hz, 2H), 7.40 - 7.34 (m, 3H), 4.57 - 4.50 (m, 2H), 4.47 - 4.40 (m, 2H), 4.35 (s, 1H), 4.22 (d, J = 11.5 Hz, 1H), 4.09 (d, J = 16.2 Hz, 1H), 3.70 - 3.62 (m, 2H), 3.54 (d, J = 16.2 Hz, 3H), 3.14 (d, J = 9.2 Hz, 1H), 3.02 (d, J = 18.4 Hz, 2H), 2.81 (t, J = 10.6 Hz, 2H), 2.74 - 2.68 (m, 2H), 2.44 (s, 3H), 2.40 - 2.35 (m, 2H), 2.32 - 2.25 (m, 1H), 2.19 (t, J = 14.0 Hz, 3H), 2.04 - 1.99 (m, 2H), 1.93 - 1.88 (m, 3H), 1.76 (s, 6H), 1.55 - 1.46 (m, 4H), 1.30 - 1.23 (m, 5H), 0.94 (s, 9H). HRMS (ESI) C 58 H 72 N9O6S [M+H] + Calculated value: 1022.5321, Measured value: 1022.4607.

[0486] Compound Example 125: Synthesis of (2S,4R)-1-((S)-2-(10-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS219016)

[0487] SIAIS219016 (yellow solid, 9.8 mg, 43%) was prepared using alectinib analog C and intermediate LM (SIAIS074019) in the procedure for preparing compound example 1. 1 H NMR (500 MHz, MeOD) δ 9.86 (s, 1H), 8.40 (d, J = 8.1 Hz, 1H), 8.20 (s, 1H), 7.87 (s, 1H), 7.57-7.54 (m, 5H), 7.43 (s, 1H), 4.64 (s, 1H), 4.59-4.53 (m, 3H), 4.41 (d, J = 15.7 Hz, 1H), 4.27 (s, 1H), 3.91 (d, J = 11.1 Hz, 1H), 3.81 (dd, J = 11.0, 3.8 Hz, 1H), 3.72 (s, 2H), 3.43 (d, J = 11.2 Hz, 3H), 3.15 (d, J = 12.9 Hz, 2H), 2.99 (t, J = 11.4 Hz, 2H), 2.81 (q, J = 7.5 Hz, 2H), 2.59 (s, 3H), 2.47 (t, J = 7.4 Hz, 2H), 2.39 - 2.20 (m, 6H), 2.10-2.04 (m, 4H), 1.80 (s, 6H), 1.62 (d, J = 6.2 Hz, 4H), 1.35 (t, J = 7.4 Hz, 12H), 1.04 (s, 9H). HRMS (ESI) C 62 H 80 N9O6S [M+H] + Calculated value: 1078.5947, measured value: 1078.5193.

[0488] Compound Example 126: Synthesis of 4-((2-(3-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151031)

[0489] SIAIS151031 (yellow solid, 20.8 mg, 62%) was prepared using ceritinib and intermediate LM (SIAIS151001) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.45 (d, J = 7.8 Hz, 1H), 8.15 (s, 1H), 7.93 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (s, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.55 - 7.50 (m, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.07 (dd, J = 8.4, 7.0 Hz, 1H), 7.02 (t, J = 7.2 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 5.00 - 4.94 (m, 1H), 4.70 (d, J = 13.0 Hz, 1H), 4.58 (s, 1H), 4.56 - 4.50 (m, 1H), 4.16 (d, J = 13.4 Hz, 1H), 3.90 - 3.77 (m, 2H), 3.73 -3.70 (m, 2H), 3.52 - 3.49 (m, 2H), 3.22 - 3.13 (m, 1H), 3.00 - 2.93 (m, 1H), 2.81 - 2.59 (m, 6H), 2.13 (d, J = 1.0 Hz, 3H), 2.03 - 1.95 (m, 1H), 1.76 (d, J = 13.1 Hz, 2H), 1.67 - 1.54 (m, 2H), 1.28 - 1.25 (m, 12H). HRMS (ESI) C 46 H 54ClN8O9S [M+H] + Calculated value: 929.3418, measured value: 929.2502.

[0490] Compound Example 127: Synthesis of 4-((2-(2-(3-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151023)

[0491] SIAIS151023 (yellow solid, 32.8 mg, 94%) was prepared using ceritinib and intermediate LM (SIAIS151004) following the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.45 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 1.9 Hz, 1H), 7.92 (dd, J = 8.0, 1.5 Hz, 1H), 7.74 (s, 1H), 7.69 - 7.66 (m, 1H), 7.51 - 7.47 (m, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.02 (dd, J = 8.5, 4.0 Hz, 1H), 7.00 (d, J = 7.0 Hz, 2H), 6.79 (s, 1H), 5.01 (dd, J = 12.5, 5.5 Hz, 1H), 4.69 (d, J = 13.1 Hz, 1H), 4.59 - 4.54 (m, 1H), 4.12 (d, J = 13.0 Hz, 1H), 3.81 - 3.74 (m, 2H), 3.71 - 3.60 (m, 6H), 3.45 - 3.41 (m, 2H), 3.36 - 3.32 (m, 1H), 3.21 - 3.13 (m, 1H), 2.99 - 2.93 (m, 1H), 2.84 - 2.64 (m, 5H), 2.63 - 2.55 (m, 1H), 2.13 (s, 3H), 2.07 - 2.03 (m, 1H), 1.79 - 1.71 (m, 2H), 1.67 - 1.52 (m, 2H), 1.31 - 1.28 (m, 6H), 1.26 (d, J = 6.8 Hz, 6H). HRMS (ESI) C 48 H 58 ClNO 10 S [M+H] + Calculated value: 973.3680, measured value: 973.3685.

[0492] Compound Example 128: Synthesis of 4-((2-(2-(2-(3-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151028)

[0493] Compound Example 1 was prepared using SIAIS 151028 (yellow solid, 32.4 mg, 89%) and the intermediate LM (SIAIS 151005). 1 H NMR (500 MHz, MeOD) δ 8.45 (d, J = 8.2 Hz, 1H), 8.15 (s, 1H), 7.92 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (s, 1H), 7.70 - 7.64 (m, 1H), 7.50 (dd, J = 8.4, 7.2 Hz, 1H), 7.37 (t, J = 7.7 Hz, 1H), 7.02 (t, J = 7.2 Hz, 2H), 6.80 (s, 1H), 5.02 (dd, J = 12.5, 5.5 Hz, 1H), 4.70 (d, J = 13.0 Hz, 1H), 4.61 - 4.54 (m, 1H), 4.14 (d, J = 11.9 Hz, 1H), 3.82 - 3.71 (m, 2H), 3.67 - 3.59 (m, 10H), 3.43 (t, J = 5.4 Hz, 2H), 3.35 - 3.31 (m, 1H), 3.22 - 3.16 (m, 1H), 3.01 - 2.95 (m, 1H), 2.83 (s, 1H), 2.81 - 2.67 (m, 4H), 2.63 - 2.56 (m, 1H), 2.15 (s, 3H), 2.10 - 2.04 (m, 1H), 1.80 - 1.75 (m, 2H), 1.70 - 1.52 (m, 2H), 1.29 (t, J = 6.0 Hz, 6H), 1.25 (d, J = 6.8 Hz, 6H). HRMS (ESI) C 50 H 62 ClN8O 11 S [M+H] + Calculated value: 1017.3942, measured value: 1017.3457.

[0494] Compound Example 129: Synthesis of 4-((18-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151029)

[0495] SIAIS151029 (yellow solid, 31.6 mg, 80%) was prepared using ceritinib and intermediate LM (SIAIS151007) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.45 (d, J = 8.3 Hz, 1H), 8.14 (s, 1H), 7.93 - 7.90 (m, 1H), 7.76 (s, 1H), 7.68 - 7.64 (m, 1H), 7.51 (dd, J = 8.5, 7.1 Hz, 1H), 7.38 - 7.34 (m, 1H), 7.03 (dd, J = 12.8, 7.8 Hz, 2H), 6.80 (s, 1H), 5.02 (dd, J = 12.6, 5.5 Hz, 1H), 4.70 (d, J = 13.4 Hz, 1H), 4.61 - 4.55 (m, 2H), 4.15 (d, J = 14.0 Hz, 1H), 3.79 - 3.74 (m, 2H), 3.68 (t, J = 5.3 Hz, 2H), 3.62 - 3.55 (m, 16H), 3.46 - 3.43 (m, 2H), 3.24 - 3.18 (m, 1H), 3.04 - 2.94 (m, 1H), 2.83 - 2.61 (m, 6H), 2.15 (s, 3H), 2.10 - 2.04 (m, 1H), 1.82 - 1.76 (m, 2H), 1.69 - 1.53 (m, 2H), 1.30 (t, J = 6.1 Hz, 6H), 1.26 (s, 3H), 1.24 (s, 3H). HRMS (ESI) C 54 H 70 ClNO 13 S [M+H]+ Calculated value: 1105.4466, measured value: 1105.3969.

[0496] Compound Example 130: Synthesis of 4-((2-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151037)

[0497] SIAIS151037 (yellow solid, 20.1 mg, 64%) was prepared using ceritinib and intermediate LM (SIAIS151025) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, DMSO) δ 11.11 (s, 1H), 9.46 (s, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.25 (s, 1H), 8.06 (s, 1H), 7.84 (dd, J = 8.0, 1.6 Hz, 1H), 7.66 - 7.59 (m, 2H), 7.53 (s, 1H), 7.40 - 7.33 (m, 1H), 7.20 - 7.15 (m, 2H), 7.08 (d, J = 7.0 Hz, 1H), 6.86 (s, 1H), 5.08 (dd, J = 12.9, 5.4 Hz, 1H), 4.60 - 4.54 (m, 2H), 4.35 - 4.13 (m, 2H), 4.05 (d, J = 13.0 Hz, 1H), 3.48 - 3.40 (m, 1H), 3.24 - 3.14 (m, 1H), 3.01 - 2.85 (m, 2H), 2.77 (t, J = 12.1 Hz, 1H), 2.63 - 2.52 (m, 2H), 2.17 (s, 3H), 2.08 - 2.00 (m, 1H), 1.74 - 1.71 (m, 3H), 1.59 - 1.48 (m, 1H), 1.20 - 1.15 (m, 12H). HRMS (ESI) C 43 H 48 ClN8O8S [M+H]+ Calculated value: 871.2999, measured value: 871.0255.

[0498] Compound Example 131: Synthesis of 4-((3-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151034)

[0499] SIAIS151034 (yellow solid, 27.1 mg, 85%) was prepared using ceritinib and intermediate LM (SIAIS151026) in the procedure for preparing Compound Example 1. 1H NMR (500 MHz, DMSO) δ 11.09 (s, 1H), 9.45 (s, 1H), 8.46 (d, J = 8.1 Hz, 1H), 8.25 (s, 1H), 8.04 (s, 1H), 7.83 (dd, J = 8.0, 1.5 Hz, 1H), 7.66 - 7.56 (m, 2H), 7.52 (s, 1H), 7.40 - 7.30 (m, 1H), 7.17 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.87 - 6.77 (m, 2H), 5.04 (dd, J = 12.8, 5.5 Hz, 1H), 4.65 - 4.52 (m, 2H), 3.98 (d, J = 12.6 Hz, 1H), 3.57 (dd, J = 12.4, 6.1 Hz, 2H), 3.46 - 3.41 (m, 1H), 3.11 (t, J = 11.8 Hz, 1H), 2.96 - 2.83 (m, 2H), 2.71 (t, J = 6.3 Hz, 2H), 2.68 - 2.52 (m, 3H), 2.14 (s, 3H), 2.05 - 1.97 (m, 1H), 1.71 - 1.67 (m, 2H), 1.64 - 1.56 (m, 1H), 1.52 - 1.43 (m, 1H), 1.21 - 1.13 (m, 12H). HRMS (ESI) C 44 H 50 ClN8O8S [M+H] + Calculated value: 885.3155, measured value: 885.2667.

[0500] Compound Example 132: Synthesis of 4-((4-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151035)

[0501] SIAIS151035 (yellow solid, 21.5 mg, 67%) was prepared using ceritinib and intermediate LM (SIAIS151019) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.46 (d, J = 8.3 Hz, 1H), 8.15 (s, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 (s, 1H), 7.70 - 7.64 (m, 1H), 7.56 (dd, J = 8.5, 7.1 Hz, 1H), 7.39 - 7.35 (m, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.05 (d, J = 7.1 Hz, 1H), 6.79 (s, 1H), 5.05 - 5.01 (m, 1H), 4.71 (d, J = 11.6 Hz, 1H), 4.59 - 4.52 (m, 1H), 4.09 (d, J = 12.5 Hz, 1H), 3.47 - 3.41 (m, 2H), 3.36 - 3.33 (m, 1H), 3.24 - 3.16 (m, 1H), 3.01 - 2.95 (m, 1H), 2.86 - 2.78 (m, 1H), 2.77 - 2.66 (m, 3H), 2.64 - 2.49 (m, 2H), 2.15 (s, 3H), 2.10 - 1.96 (m, 3H), 1.79 (d, J = 13.1 Hz, 2H), 1.63 - 1.49 (m, 2H), 1.29 (d, J = 6.0 Hz, 6H), 1.26 (d, J = 6.8 Hz, 6H). HRMS (ESI) C 45 H 52 ClN8O8S [M+H] + Calculated value: 899.3312, measured value: 899.0450.

[0502] Compound Example 133: Synthesis of 4-((5-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151036)

[0503] SIAIS151036 (yellow solid, 31.5 mg, 96%) was prepared using ceritinib and intermediate LM (SIAIS151020) according to the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.46 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 7.92 (dd, J = 8.0, 1.5 Hz, 1H), 7.77 (s, 1H), 7.74 - 7.66 (m, 1H), 7.55 (dd, J = 8.5, 7.2 Hz, 1H), 7.39 - 7.35 (m, 1H), 7.08 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 6.79 (s, 1H), 5.03 - 4.95 (m, 1H), 4.69 (d, J = 11.6 Hz, 1H), 4.61 - 4.53 (m, 1H), 4.08 - 4.04 (m, 1H), 3.46 - 3.32 (m, 3H), 3.24 - 3.16 (m, 1H), 3.01 - 2.97 (m, 1H), 2.82 - 2.61 (m, 4H), 2.57 - 2.44 (m, 2H), 2.15 (s, 3H), 2.05 - 1.99 (m, 1H), 1.82 - 1.72 (m, 6H), 1.65 - 1.51 (m, 2H), 1.31 - 1.27 (m, 6H), 1.26 (d, J = 6.8Hz, 6H). HRMS (ESI) C 46 H 54 ClN8O8S [M+H] + Calculated value: 913.3468, measured value: 913.0576.

[0504] Compound Example 134: Synthesis of 4-((6-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151043)

[0505] SIAIS151043 (yellow solid, 26.3 mg, 79%) was prepared using ceritinib and intermediate LM (SIAIS151027) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.26 (d, J = 8.3 Hz, 1H), 8.09 (s, 1H), 7.88 (dd, J = 8.0, 1.4 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.45 (dd, J = 8.5, 7.1 Hz, 1H), 7.40 - 7.36 (m, 2H), 6.95 (dd, J = 13.9, 7.8 Hz, 2H), 6.76 (d, J = 2.2 Hz, 1H), 4.95 - 4.90 (m, 1H), 4.63 - 4.59 (m, 1H), 4.52 - 4.47 (m, 1H), 4.00 (d, J = 13.1 Hz, 1H), 3.27 (t, J = 6.9 Hz, 3H), 3.14 - 3.08 (m, 1H), 2.95 - 2.89 (m, 1H), 2.75 - 2.54 (m, 4H), 2.38 (t, J = 7.4 Hz, 2H), 2.09 (s, 3H), 2.01 - 1.93 (m, 1H), 1.74 - 1.66 (m, 2H), 1.66 - 1.58 (m, 4H), 1.55 - 1.38 (m, 4H), 1.17 - 1.15 (m, 12H). HRMS (ESI) C 47 H 56 ClN8O8S [M+H] + Calculated value: 927.3625, measured value: 927.0642.

[0506] Compound Example 135: Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151042)

[0507] SIAIS151042 (white solid, 36.8 mg, 91%) was prepared using ceritinib and intermediate LM (SIAIS151010) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.91 (d, J = 1.6 Hz, 1H), 8.28 (s, 1H), 8.19 (s, 1H), 7.99 (dd, J = 8.0, 1.4 Hz, 1H), 7.75 - 7.69 (m, 1H), 7.53 - 7.49 (m, 1H), 7.47 - 7.34 (m, 5H), 6.86 (d, J = 6.2 Hz, 1H), 4.72 - 4.53 (m, 4H), 4.51 - 4.31 (m, 5H), 4.13 - 4.01 (m, 3H), 3.88 - 3.86 (m, 1H), 3.83 - 3.69 (m, 5H), 3.39 - 3.34 (m, 1H), 3.24 - 3.16 (m, 1H), 3.07 - 2.97 (m, 1H), 2.79 - 2.71 (m, 1H), 2.47 - 2.45 (m, 3H), 2.26 - 2.14 (m, 1H), 2.18 (s, 3H), 2.12 - 2.04 (m, 1H), 1.82 - 1.77 (m, 2H), 1.73 - 1.53 (m, 2H), 1.27 - 1.24 (m, 12H), 1.05 (d, J = 4.5 Hz, 9H). HRMS (ESI) C 56 H 73 ClNO 10 S2 [M+H] +Calculated value: 1130.4605, measured value: 1130.0737.

[0508] Compound Example 136: Synthesis of (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151038)

[0509] SIAIS151038 (white solid, 39.4 mg, 95%) was prepared using ceritinib and intermediate LM (SIAIS151002) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, MeOD) δ 8.92 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 7.2 Hz, 1H), 8.19 (s, 1H), 7.99 (dd, J = 8.0, 1.5 Hz, 1H), 7.71 (t, J = 7.8 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.48 - 7.35 (m, 5H), 6.87 (s, 1H), 4.72 - 4.69 (m, 1H), 4.67 - 4.64 (m, 1H), 4.64 - 4.47 (m, 4H), 4.35 (d, J = 15.3 Hz, 1H), 4.16 (d, J = 12.2 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.82 - 3.67 (m, 5H), 3.66 - 3.60 (m, 4H), 3.40 - 3.35 (m, 1H), 3.25 - 3.19 (m, 1H), 3.03 (t, J = 10.9 Hz, 1H), 2.77 - 2.65 (m, 3H), 2.58 - 2.52 (m, 1H), 2.50 - 2.43 (m, 4H), 2.24 - 2.18 (m, 1H), 2.20 (s, 3H), 2.11 - 2.05 (m, 1H), 1.86 - 1.75 (m, 2H), 1.71 - 1.52 (m, 2H), 1.28 - 1.24 (m, 12H), 1.03 (s, 9H). HRMS (ESI) C 58 H 77 ClN9O 10 S2[M+H] + Calculated value: 1158.4918, Measured value: 1158.4604.

[0510] Compound Example 137: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151039)

[0511] SIAIS151039 (white solid, 40.2 mg, 93%) was prepared using ceritinib and intermediate LM (SIAIS151003) according to the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 8.20 (s, 1H), 7.99 (dd, J = 8.0, 1.5 Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.48 - 7.36 (m, 5H), 6.88 (s, 1H), 4.74 - 3.70 (m, 1H), 4.66 - 4.47 (m, 5H), 4.35 (d, J = 15.5 Hz, 1H), 4.16 (d, J = 12.6 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.81 - 3.76 (m, 3H), 3.74 - 3.67 (m, 2H), 3.63 - 3.58 (m, 8H), 3.40 - 3.35 (m, 1H), 3.23 (t, J = 12.9 Hz, 1H), 3.06 - 3.00 (m, 1H), 2.78 - 2.64 (m, 3H), 2.59 - 2.53 (m, 1H), 2.50 - 2.42 (m, 4H), 2.25 - 2.17 (m, 1H), 2.20 (s, 3H), 2.11 - 2.05 (m, 1H), 1.80 (t, J = 15.3 Hz, 2H), 1.73 - 1.53 (m, 2H), 1.28 - 1.24 (m, 12H), 1.03 (s, 9H). HRMS (ESI) C 60 H 81 ClN9O 11 S2[M+H] + Calculated value: 1202.5180, measured value: 1203.4829.

[0512] Compound Example 138: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151040)

[0513] SIAIS151040 (white solid, 34.3 mg, 77%) was prepared using ceritinib and intermediate LM (SIAIS151008) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, MeOD) δ 8.94 (s, 1H), 8.32 (d, J = 7.8 Hz, 1H), 8.20 (s, 1H), 7.99 (dd, J = 8.0, 1.5 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.48 - 7.41 (m, 4H), 7.36 (s, 1H), 6.89 (s, 1H), 4.72 (d, J = 13.5 Hz, 1H), 4.65 - 4.47 (m, 5H), 4.35 (d, J = 15.5 Hz, 1H), 4.17 (d, J = 13.7 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.81 - 3.76 (m,3H), 3.74 - 3.67 (m, 2H), 3.63 - 3.56 (m, 14H), 3.41 - 3.35 (m, 1H), 3.23 (t, J = 12.3 Hz, 1H), 3.07 - 3.01 (m, 1H), 2.80 - 2.64 (m, 3H), 2.59 - 2.53 (m, 1H), 2.49 - 2.45 (m, 4H), 2.25 - 2.18 (m, 1H), 2.20 (s, 3H), 2.11 - 2.05 (m, 1H), 1.80 (t, J = 15.2 Hz, 2H), 1.74 - 1.55 (m, 2H), 1.28 - 1.24 (m, 12H), 1.03 (s, 9H). HRMS (ESI) C 62 H 85 ClN9O 12 S2[M+H] + Calculated value: 1246.5442, measured value: 1246.5029.

[0514] Compound Example 139: Synthesis of (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS151041)

[0515] SIAIS151041 (white solid, 40 mg, 86%) was prepared using ceritinib and intermediate LM (SIAIS151009) following the procedure for preparing Compound Example 1. 1H NMR (500 MHz, MeOD) δ 8.93 (s, 1H), 8.32 (d, J = 7.5 Hz, 1H), 8.19 (s, 1H), 7.99 (dd, J = 8.0, 1.5 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.53 - 7.49 (m, 1H), 7.43 (ddd, J = 19.0, 15.8, 9.5 Hz, 5H), 6.89 (s, 1H), 4.72 (d, J = 13.5 Hz, 1H), 4.66 - 4.48 (m, 5H), 4.37 - 4.33 (m, 1H), 4.17 (d, J = 13.5 Hz, 1H), 3.88 (d, J = 11.1 Hz, 1H), 3.84 - 3.76 (m, 3H), 3.75 - 3.67 (m, 2H), 3.63 - 3.58 (m, 16H), 3.40 - 3.35 (m, 1H), 3.23 (t, J = 12.0 Hz, 1H), 3.07 - 3.01 (m, 1H), 2.78 - 2.65 (m, 3H), 2.61 - 2.52 (m, 1H), 2.50 - 2.42 (m, 1H), 2.47 (s, 3H), 2.24 - 2.18 (m, 4H), 2.10 - 2.05 (m, 1H), 1.81 (t, J = 15.2 Hz, 2H), 1.74 - 1.52 (m, 2H), 1.28 - 1.24 (m, 12H), 1.03 (s, 9H). HRMS (ESI) C 64 H 89 ClN9O 13 S2[M+H] + Calculated value: 1290.5704, measured value: 1290.5117.

[0516] Compound Example 140: Synthesis of (2S,4R)-1-((S)-2-(4-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-4-oxobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074017)

[0517] SIAIS074017 (white solid, 72 mg, 75%) was prepared using ceritinib and intermediate LM (SIAIS074011) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, MeOD) δ 8.86 (d, J = 1.7 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 (s, 1H), 7.69 - 7.64 (m, 1H), 7.48 - 7.44 (m, 2H), 7.42 - 7.40 (m, 2H), 7.38 - 7.35 (m, 1H), 6.80 (d, J = 7.1 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 4.63 (d, J = 7.4 Hz, 1H), 4.61 - 4.53 (m, 3H), 4.53 - 4.44 (m, 2H), 4.36 (dd, J = 15.4, 4.3 Hz, 1H), 4.12 (d, J = 13.5 Hz, 1H), 3.90 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 11.0, 3.8 Hz, 1H), 3.24 - 3.19 (m, 1H), 3.03 - 2.97 (m, 1H), 2.80 - 2.68(m, 3H), 2.67 - 2.53 (m, 2H), 2.47 (d, J = 3.0 Hz, 3H), 2.25 - 2.18 (m, 1H), 2.16 (s, 3H), 2.11 - 2.05 (m, 1H), 1.83 - 1.76 (m, 2H), 1.71 - 1.63 (m, 1H), 1.59 - 1.51 (m, 1H), 1.32 - 1.29 (m, 6H), 1.25 (d, J = 6.8 Hz, 6H), 1.05 (s, 9H). HRMS (ESI) C 54 H[[ID=③]]<0001の177> ClN9O8S2 + [M+H] + Calculated value: 1070.4394, measured value: 1070.4352.

[0518] It should be noted that there seems to be an incorrect tag format in " 69 " which is translated as "[[ID=③]]<0001の177> " here. It might need to be corrected according to the correct original content for a more accurate translation.Compound Example 141: Synthesis of (2S,4R)-1-((S)-2-(5-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074018)

[0519] SIAIS074018 (white solid, 25.2 mg, 65%) was prepared using ceritinib and intermediate LM (SIAIS074012) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, CDCl3) δ 10.63 - 10.18 (m, 1H), 9.28 - 8.52 (m, 3H), 8.42 (d, J = 7.9 Hz, 1H), 8.09 - 7.86 (m, 1H), 7.59 - 7.43 (m, 1H), 7.35 (t, J = 15.5 Hz, 6H), 7.13 (s, 1H), 6.73 (d, J = 14.8 Hz, 1H), 6.27 (s, 1H), 4.76 (s, 1H), 4.52 (d, J = 24.2 Hz, 3H), 4.34 (d, J = 13.3 Hz, 1H), 4.06 (d, J = 72.7 Hz, 2H), 3.75 - 3.45 (m, 1H), 3.28 - 3.08 (m, 2H), 2.88 (d, J = 43.8 Hz, 2H), 2.67 (s, 3H), 2.60 - 2.25 (m, 7H), 2.19 (s, 4H), 2.10 - 1.72 (m, 4H), 1.57 (s, 2H), 1.32 (dd, J = 42.6, 36.2 Hz, 13H), 1.11 - 0.82 (m, 9H). HRMS (ESI) C 55 H 71 ClN9O8S2 + [M+H] + Calculated value: 1084.4550, measured value: 1084.4549.

[0520] Compound Example 142: Synthesis of (2S,4R)-1-((S)-2-(6-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-6-oxohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074021)

[0521] SIAIS074021 (white solid, 27.3 mg, 69%) was prepared using ceritinib and intermediate LM (SIAIS074013) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, CDCl3) δ 10.27 (s, 1H), 10.23 - 10.07 (m, 1H), 8.83 (s, 1H), 8.45 (d, J = 8.3 Hz, 1H), 7.99 (s, 1H), 7.91 (dd, J = 7.9, 1.4 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.40 (dd, J = 15.4, 6.9 Hz, 1H), 7.38 - 7.28 (m, 4H), 6.73 (d, J = 3.8 Hz, 1H), 6.42 (dd, J = 25.8, 8.5 Hz, 1H), 5.35 (t, J = 4.8 Hz, 1H), 4.88 - 4.70 (m, 2H), 4.59 (dd, J = 15.0, 6.7 Hz, 1H), 4.51 (dd, J = 11.9, 5.4 Hz, 2H), 4.34 (dd, J = 14.9, 5.1 Hz, 1H), 4.13 (d, J = 11.8 Hz, 1H), 4.00 (d, J = 12.3 Hz, 1H), 3.80 - 3.42 (m, 6H), 3.26 - 3.09 (m, 2H), 2.92 (t, J = 12.0 Hz, 1H), 2.65 (s, 1H), 2.57 (ddd, J = 16.5, 8.1, 4.0 Hz, 1H), 2.53 (s, 2H), 2.39 (s, 1H), 2.34 - 2.21 (m, 2H), 2.21 - 2.12 (m, 3H), 2.04 - 1.97 (m, 1H), 1.88 - 1.77 (m, 2H), 1.75 - 1.47 (m, 5H), 1.34 - 1.23 (m, 12H), 1.01 - 0.75 (m, 7H). HRMS (ESI) C 56 H 73 ClN9O8S2 + [M+H] + Calculated value: 1098.4707, Measured value: 1098.6188.

[0522] Compound Example 143: Synthesis of (2S,4R)-1-((S)-2-(7-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074022)

[0523] SIAIS074022 (white solid, 29.5 mg, 74%) was prepared using ceritinib and intermediate LM (SIAIS074014) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, CDCl3) δ 10.11 (s, 1H), 9.63 (s, 1H), 8.76 (s, 1H), 8.48 (d, J = 8.3 Hz, 1H), 8.02 (s, 1H), 7.92 (dd, J = 7.9, 1.5 Hz, 1H), 7.58 (s, 1H), 7.45 (t, J = 7.3 Hz, 1H), 7.40 - 7.32 (m, 4H), 7.29 (t, J = 7.7 Hz, 1H), 6.72 (d, J = 9.6 Hz, 1H), 6.19 (d, J = 6.8 Hz, 1H), 4.77 (dd, J = 19.4, 11.3 Hz, 2H), 4.64 - 4.46 (m, 4H), 4.34 (dd, J = 15.0, 5.1 Hz, 2H), 4.05 (dd, J = 56.9, 11.8 Hz, 3H), 3.60 (dd, J = 11.3, 3.2 Hz, 1H), 3.27 - 3.18 (m, 1H), 3.14 (dd, J = 19.6, 13.0 Hz, 1H), 2.91 (t, J = 10.7 Hz, 1H), 2.69 - 2.58 (m, 1H), 2.57 - 2.49 (m, 3H), 2.45 - 2.31 (m, 2H), 2.31 - 2.11 (m, 6H), 1.80 (dd, J = 33.7, 17.8 Hz, 2H), 1.74 - 1.48 (m, 6H), 1.43 - 1.23 (m, 15H), 1.01 - 0.82 (m, 9H). HRMS (ESI) C 57 H 75 ClN9O8S2 + [M+H] + Calculated value: 1112.4863, Measured value: 1112.6343.

[0524] Compound Example 144: Synthesis of (2S,4R)-1-((S)-2-(8-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074008)

[0525] SIAIS074008 (white solid, 30.1 mg, 75%) was prepared using ceritinib and intermediate LM (SIAIS074015) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, CDCl3) δ 9.89 (s, 1H), 8.92 (s, 1H), 8.71 (s, 1H), 8.51 (d, J = 8.4 Hz, 1H), 8.08 (d, J = 17.2 Hz, 1H), 7.92 (dd, J = 8.0, 1.5 Hz, 1H), 7.74 (s, 1H), 7.51 (t, J = 7.3 Hz, 1H), 7.37 (p, J = 8.3 Hz, 3H), 7.29 (dd, J = 11.4, 4.4 Hz, 1H), 6.70 (d, J = 4.5 Hz, 1H), 6.18 - 6.05 (m, 1H), 5.35 (dd, J = 12.6, 7.8 Hz, 1H), 4.77 (dd, J = 20.6, 12.4 Hz, 2H), 4.62 - 4.48 (m, 3H), 4.35 (dt, J = 14.9, 5.3 Hz, 1H), 4.13 (d, J = 11.3 Hz, 1H), 3.98 (d, J = 12.5 Hz, 1H), 3.59 (dd, J = 11.3, 3.3 Hz, 1H), 3.23 (dt, J = 13.7, 6.9 Hz, 1H), 3.14 (dd, J = 19.2, 12.6 Hz, 1H), 3.07 - 2.67 (m, 5H), 2.67 - 2.59 (m, 1H), 2.59 - 2.48 (m, 3H), 2.41 - 2.30 (m, 2H), 2.28 - 2.09 (m, 5H), 2.04 - 1.97 (m, 1H), 1.87 - 1.75 (m, 2H), 1.70 - 1.46 (m, 5H), 1.39 - 1.22 (m, 14H), 0.96 - 0.84 (m, 6H). HRMS (ESI) C 58 H 77 ClN9O8S2 + [M+H] + Calculated value: 1126.5020, Measured value: 1126.6505.

[0526] Compound Example 145: Synthesis of (2S,4R)-1-((S)-2-(9-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074024)

[0527] SIAIS074024 (white solid, 31.2 mg, 76%) was prepared using ceritinib and intermediate LM (SIAIS074016) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 8.90 (t, J = 2.2 Hz, 1H), 8.35 (d, J = 7.5 Hz, 1H), 8.19 (s, 1H), 7.98 (dd, J = 8.0, 1.4 Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.53 - 7.38 (m, 6H), 6.86 (d, J = 1.7 Hz, 1H), 4.70 (d, J = 12.8 Hz, 1H), 4.66 - 4.47 (m, 5H), 4.36 (d, J = 15.5 Hz, 1H), 4.11 (d, J = 13.5 Hz, 1H), 3.91 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 10.9, 3.8 Hz, 1H), 3.36 (td, J = 13.3, 6.4 Hz, 2H), 3.23 (t, J = 13.1 Hz, 1H), 3.03 (t, J = 11.9 Hz, 1H), 2.72 (t, J = 13.2 Hz, 1H), 2.51 - 2.39 (m, 5H), 2.35 - 2.16 (m, 7H), 2.12 - 1.99 (m, 2H), 1.84 (d, J = 12.9 Hz, 1H), 1.78 (d, J = 12.8Hz, 1H), 1.69 - 1.49 (m, 7H), 1.32 - 1.21 (m, 14H), 1.02 (s, 9H). HRMS (ESI) C59 H 79 ClN9O8S2 + [M+H] + Calculated value: 1140.5176, measured value: 1140.5167.

[0528] Compound Example 146: Synthesis of (2S,4R)-1-((S)-2-(10-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074025)

[0529] SIAIS074025 (white solid, 31.5 mg, 76%) was prepared using ceritinib and intermediate LM (SIAIS074019) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, MeOD) δ 8.90 (s, 1H), 8.37 (d, J = 8.0 Hz, 1H), 8.18 (s, 1H), 7.97 (dd, J = 8.0, 1.4 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.50 - 7.40 (m, 6H), 6.85 (s, 1H), 4.70 (d, J = 13.1 Hz, 1H), 4.66 - 4.44 (m, 6H), 4.38 - 4.33 (m, 1H), 4.11 (d, J = 13.6 Hz, 1H), 3.90 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 10.9, 3.8 Hz, 1H), 3.39 - 3.32 (m, 2H), 3.23 (t, J = 12.3 Hz, 1H), 3.03 (t, J = 11.9 Hz, 1H), 2.72 (t, J = 12.3 Hz, 1H), 2.50 - 2.41 (m, 5H), 2.34 - 2.20 (m, 4H), 2.19 (s, 3H), 2.14 - 1.97 (m, 2H), 1.81 (dd, J = 28.9, 13.0 Hz, 3H), 1.67 - 1.50 (m, 7H), 1.28 (dd, J = 6.0, 2.0 Hz, 8H), 1.25 (d, J = 6.8 Hz, 6H), 1.02 (d, J = 13.8 Hz, 9H). HRMS (ESI) C 60 H 61 ClN9O8S2 + [M+H] + Calculated value: 1154.5333, measured value: 1154.2914.

[0530] Compound Example 147: Synthesis of (2S,4R)-1-((S)-2-(11-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-11-oxoundecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. (SIAIS074026)

[0531] SIAIS074026 (white solid, 32.0 mg, 76%) was prepared using ceritinib and intermediate LM (SIAIS074020) following the procedure for preparing Compound Example 1. 11H NMR (500 MHz, MeOD) δ 8.89 (s, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.17 (s, 1H), 7.96 (dd, J = 8.0, 1.5 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.51 - 7.37 (m, 5H), 6.84 (s, 1H), 4.71 (d, J = 13.0 Hz, 1H), 4.67 - 4.46 (m, 5H), 4.35 (dd, J = 15.3, 7.4 Hz, 1H), 4.11 (d, J = 13.3 Hz, 1H), 3.90 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 10.9, 3.9 Hz, 1H), 3.39 - 3.32 (m, 2H), 3.23 (t, J = 12.2 Hz, 1H), 3.02 (t, J = 12.0 Hz, 1H), 2.72 (t, J = 12.2 Hz, 1H), 2.50 - 2.40 (m, 5H), 2.34 - 2.15 (m, 6H), 2.12 - 2.00 (m, 2H), 1.83 (t, J = 11.2 Hz, 1H), 1.78 (d, J = 13.2 Hz, 1H), 1.67 - 1.51 (m, 6H), 1.36 (s, 3H), 1.29 (dd, J = 6.0、 2.0 Hz, 8H), 1.25 (d, J = 6.8 Hz, 6H), 1.02 (d, J = 13.3 Hz, 9H). HRMS (ESI) C 61 H 63 ClN9O8S2 + [M+H] + Calculated value: 1168.5489, measured value: 1168.3009.

[0532] Compound Example 148: Synthesis of 4-((2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151049)

[0533] SIAIS151049 (yellow solid, 21.4 mg, 59%) was prepared using crizotinib and intermediate LM (SIAIS151001) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.84 (dd, J = 10.1, 6.3 Hz, 1H), 7.55 - 7.49 (m, 3H), 7.48 - 7.43 (m, 1H), 7.35 - 7.26 (m, 1H), 7.12 - 7.05 (m, 1H), 7.05 - 6.99 (m, 1H), 6.90 (dd, J = 12.7, 6.8 Hz, 1H), 6.36 - 6.28 (m, 1H), 5.02 - 4.97 (m, 1H), 4.65 (d, J = 13.5 Hz, 1H), 4.44 - 4.38 (m, 1H), 4.20 (d, J = 13.3 Hz, 1H), 3.91 - 3.77 (m, 2H), 3.75 - 3.68 (m, 2H), 3.51 - 3.45 (m, 2H), 3.29 - 3.21 (m, 1H), 2.86 - 2.77 (m, 3H), 2.74 - 2.60 (m, 3H), 2.12 (d, J = 11.7 Hz, 2H), 2.08 - 2.01 (m, 1H), 1.99 - 1.84 (m, 5H). HRMS (ESI) C 39 H 40 Cl2FN8O7 + [M+H] + Calculated value: 821.2376, measured value: 821.2334.

[0534] Compound Example 149: Synthesis of 4-((2-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151050)

[0535] SIAIS151050 (yellow solid, 31.8 mg, 83%) was prepared using crizotinib and intermediate LM (SIAIS151004) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.88 (d, J = 5.5 Hz, 1H), 7.61 - 7.56 (m, 1H), 7.55 - 7.49 (m, 2H), 7.48 - 7.41 (m, 1H), 7.31 - 7.27 (m, 1H), 7.08 (d, J = 1.7 Hz, 1H), 6.98 - 6.90 (m, 2H), 6.32 - 6.27 (m, 1H), 5.06 - 4.99 (m, 1H), 4.64 (d, J = 13.2 Hz, 1H), 4.44 - 4.36 (m, 1H), 4.15 (d, J = 13.7 Hz, 1H), 3.85 - 3.71 (m, 2H), 3.70 - 3.61 (m, 6H), 3.40 - 3.34 (m, 2H), 3.25 (t, J = 13.0 Hz, 1H), 2.90 - 2.66 (m, 5H), 2.60 - 2.52 (m, 1H), 2.14 - 2.05 (m, 3H), 2.01 - 1.83 (m, 5H). HRMS (ESI) C 41 H 44 Cl2FN8O8 + [M+H] + Calculated value: 865.2638, measured value: 865.2602.

[0536] Compound Example 150: Synthesis of 4-((2-(2-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151051)

[0537] SIAIS151051 (yellow solid, 36.7 mg, 91%) was prepared using crizotinib and intermediate LM (SIAIS151005) according to the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.91 (d, J = 1.6 Hz, 1H), 7.60 (s, 1H), 7.56 - 7.54 (m, 1H), 7.52 - 7.46 (m, 2H), 7.31 - 7.27 (t, J = 8.6 Hz, 1H), 7.12 - 7.08 (m, 1H), 7.01 - 6.92 (m, 2H), 6.33 - 6.27 (m, 1H), 5.07 - 5.01 (m, 1H), 4.63 (d, J = 11.1 Hz, 1H), 4.45 - 4.39 (m, 1H), 4.16 (d, J = 13.5 Hz, 1H), 3.80 - 3.70 (m, 2H), 3.66 - 3.59 (m, 10H), 3.45 - 3.34 (m, 2H), 3.29 - 3.24 (m, 1H), 2.87 - 2.64 (m, 5H), 2.61 - 2.52 (m, 1H), 2.19 - 2.06 (m, 3H), 2.03 - 1.83 (m, 5H). HRMS (ESI) C 43 H 48 Cl2FN8O9 + [M+H] + Calculated value: 909.2900, measured value: 909.3068.

[0538] Compound Example 151: Synthesis of 4-((15-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151060)

[0539] SIAIS151060 (yellow solid, 27.7 mg, 65%) was prepared using crizotinib and intermediate LM (SIAIS151006) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.92 (s, 1H), 7.59 (d, J = 17.3 Hz, 2H), 7.52 - 7.42 (m, 2H), 7.29 (td, J = 8.7, 1.8 Hz, 1H), 7.11 (d, J = 1.6 Hz, 1H), 7.02 - 6.98 (m, 2H), 6.33 - 6.29 (m, 1H), 5.03 (dd, J = 12.8, 5.5 Hz, 1H), 4.62 (d, J = 13.2 Hz, 1H), 4.48 - 4.38 (m, 1H), 4.16 (d, J = 13.4 Hz, 1H), 3.77 - 3.73 (m, 2H), 3.69 - 3.66 (m, 2H), 3.63 - 3.59 (m, 12H), 3.45 - 3.38 (m, 2H), 3.29 - 3.25 (m, 1H), 2.89 - 2.80 (m, 2H), 2.78 - 2.68 (m, 3H), 2.64 - 2.59 (m, 1H), 2.17 - 2.07 (m, 3H), 2.03 - 1.86 (m, 5H). HRMS (ESI) C 45 H 52 Cl2FN8O 10 + [M+H] + Calculated value: 953.3162, measured value: 953.4072.

[0540] Compound Example 152: Synthesis of 4-((18-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151061)

[0541] SIAIS151061 (yellow solid, 27.0 mg, 61%) was prepared using crizotinib and intermediate LM (SIAIS151007) according to the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.93 (s, 1H), 7.60 (d, J = 14.4 Hz, 2H), 7.53 - 7.47 (m, 2H), 7.29 (t, J = 8.6 Hz, 1H), 7.11 (s, 1H), 7.02 - 6.99 (m, 2H), 6.34 - 6.28 (m, 1H), 5.03 (dd, J = 12.8, 5.5 Hz, 1H), 4.63 (d, J = 12.9 Hz, 1H), 4.48 - 4.38 (m, 1H), 4.15 (d, J = 13.9 Hz, 1H), 3.77 - 3.73 (m, 2H), 3.72 - 3.66 (m, 2H), 3.63 (s, 3H), 3.62 - 3.55 (m, 13H), 3.44 - 3.41 (m, 2H), 3.29 - 3.25 (m, 1H), 2.87 - 2.59 (m, 6H), 2.20 - 2.06 (m, 3H), 2.01 - 1.84 (m, 5H). HRMS (ESI) C 47 H 56 Cl2FN8O 11 + [M+H] + Calculated value: 997.3424, measured value: 997.4381.

[0542] Compound Example 153: Synthesis of 4-((2-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151083)

[0543] SIAIS151083 (yellow solid, 18.4 mg, 54%) was prepared using crizotinib and intermediate LM (SIAIS151025) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.95 (s, 1H), 7.64 (s, 1H), 7.59 (d, J = 1.4 Hz, 1H), 7.56 - 7.45 (m, 2H), 7.28 (t, J = 8.5 Hz, 1H), 7.15 (s, 1H), 7.05 (d, J = 7.1 Hz, 1H), 6.98 (dd, J = 8.5, 2.5 Hz, 1H), 6.34 (q, J = 6.6 Hz, 1H), 5.06 (dd, J = 12.5, 5.4 Hz, 1H), 4.64 (d, J = 13.5 Hz, 1H), 4.55 - 4.46 (m, 1H), 4.29 - 4.16 (m, 2H), 4.08 (d, J = 13.3 Hz, 1H), 3.35 - 3.31 (m, 1H), 2.95 (t, J = 12.6 Hz, 1H), 2.88 - 2.80 (m, 1H), 2.78 - 2.64 (m, 2H), 2.24 - 2.04 (m, 4H), 1.94 (d, J = 6.6 Hz, 4H). HRMS (ESI) C 36 H 34 Cl2FN8O6[M+ H] + Calculated value: 763.1957, measured value: 763.1696.

[0544] Compound Example 154: Synthesis of 4-((3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151084)

[0545] SIAIS151084 (yellow solid, 22 mg, 64%) was prepared using crizotinib and intermediate LM (SIAIS151026) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.85 (s, 1H), 7.65 - 7.54 (m, 3H), 7.51 (dd, J = 8.9, 4.7 Hz, 1H), 7.29 (t, J = 8.6 Hz, 1H), 7.16 - 7.11 (m, 2H), 7.05 - 7.01 (m, 1H), 6.35 (q, J = 6.0 Hz, 1H), 5.06 - 4.97 (m, 1H), 4.65 (d, J = 11.5 Hz, 1H), 4.45 - 4.39 (m, 1H), 4.12 - 4.06 (m, 1H), 3.75 - 3.63 (m, 2H), 3.26 - 3.22 (m, 1H), 2.89 - 2.78 (m, 3H), 2.74 - 2.61 (m, 3H), 2.10 - 2.00 (m, 3H), 1.95 (d, J = 6.6 Hz, 3H), 1.82 - 1.70 (m, 2H). HRMS (ESI) C 37 H 36 Cl2FN8O6[M+ H] + Calculated value: 777.2113, measured value: 777.1842.

[0546] Compound Example 155: Synthesis of 4-((4-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151081)

[0547] SIAIS151081 (yellow solid, 26.3 mg, 75%) was prepared using crizotinib and intermediate LM (SIAIS151019) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.88 (d, J = 2.8 Hz, 1H), 7.62 (s, 1H), 7.57 (d, J = 1.4 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.31 - 7.25 (m, 1H), 7.14 (d, J = 1.3 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 7.02 - 6.94 (m, 1H), 6.34 (q, J = 6.6 Hz, 1H), 5.07 - 4.99 (m, 1H), 4.64 (d, J = 13.5 Hz, 1H), 4.48 - 4.38 (m, 1H), 4.08 (d, J = 13.5 Hz, 1H), 3.42 (t, J = 6.7 Hz, 2H), 3.25 (t, J = 13.0 Hz, 1H), 2.87 - 2.80 (m, 2H), 2.75 - 2.65 (m, 2H), 2.62 - 2.57 (d, J = 7.1 Hz, 1H), 2.56 - 2.50 (m, 1H), 2.16 - 2.04 (m, 3H), 2.03 - 1.96 (m, 2H), 1.95 (d, J = 6.6 Hz, 3H), 1.87 - 1.77 (m, 2H). HRMS (ESI) C 38 H 38 Cl2FN8O6[M+ H] + Calculated value: 791.2270, measured value: 791.1991.

[0548] Compound Example 156: Synthesis of 4-((5-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151082)

[0549] SIAIS151082 (yellow solid, 25.0 mg, 70%) was prepared using crizotinib and intermediate LM (SIAIS151020) in the same manner as in preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.91 (s, 1H), 7.64 - 7.62 (m, 2H), 7.59 (m, 1H), 7.55 - 7.49 (m, 2H), 7.28 (t, J = 8.6 Hz, 1H), 7.15 (s, 1H), 7.06 (d, J = 8.6 Hz, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.37 - 6.32 (m, 1H), 5.06 - 4.95 (m, 1H), 4.63 (d, J = 14.0 Hz, 1H), 4.48 - 4.42 (m, 1H), 4.08 (d, J = 13.3 Hz, 1H), 3.41 - 3.35 (m, 2H), 3.30 - 3.24 (m, 1H), 2.88 - 2.76 (m, 2H), 2.75 - 2.62 (m, 2H), 2.55 - 2.48 (m, 2H), 2.17 - 2.03 (m, 3H), 1.95 (d, J = 6.6 Hz, 3H), 1.91 - 1.78 (m, 2H), 1.77 - 1.68 (m, 4H). HRMS (ESI) C 39 H 40 Cl2FN8O6[M+ H] + Calculated value: 805.2426, measured value 805.2123.

[0550] Compound Example 157: Synthesis of 4-((6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. (SIAIS151085)

[0551] SIAIS151085 (yellow solid, 19.5 mg, 54%) was prepared using crizotinib and intermediate LM (SIAIS151027) following the procedure for preparing Compound Example 1. 1 H NMR (500 MHz, MeOD) δ 7.91 (s, 1H), 7.63 (s, 1H), 7.58 (d, J = 1.5 Hz, 1H), 7.53 - 7.49 (m, 2H), 7.28 (t, J = 8.6 Hz, 1H), 7.16 - 7.11 (m, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.99 (dd, J = 7.1, 1.8 Hz, 1H), 6.36 - 6.31 (m, 1H), 5.04 - 5.00 (m, 1H), 4.64 (d, J = 13.5 Hz, 1H), 4.48 - 4.42 (m, 1H), 4.10 (d, J = 13.7 Hz, 1H), 3.35 (t, J = 6.8 Hz, 2H), 3.30 - 3.23 (m, 1H), 2.87 - 2.78 (m, 2H), 2.75 - 2.65 (m, 2H), 2.53 - 2.43 (m, 2H), 2.21 - 2.05 (m, 3H), 1.95 (d, J = 6.7 Hz, 3H), 1.93 - 1.79 (m, 2H), 1....

Claims

1. <1> 4-((2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <2> 4-((2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <3> 4-((2-(2-(2-(3-(4-(4-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <4> 4-((15-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <5> 4-((18-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <6> 3-(4-((2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <7> 3-(4-((2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <8> 3-(4-((2-(2-(2-(3-(4-(4-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <9> 3-(4-((15-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <10> 3-(4-((18-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <11> 4-((2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)propoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <12> 4-(2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <13> 3-(4-(2-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <14> 3-(4-(19-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,7,10,13,16-pentaoxanonadecyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <15> 4-((2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <16> 4-((3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <17> 4-((4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <18> 4-((5-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <19> 4-((6-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <20> 4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <21> 3-(4-((2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <22> 3-(4-((3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <23> 3-(4-((4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <24> 3-(4-((5-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <25> 3-(4-((6-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-6-oxohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <26> 3-(4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <27> 7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-7-oxoheptanamide <28> 7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-7-oxoheptanamide <29> 4-((2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <30> 3-(4-((2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <31> 4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)heptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <32> 3-(4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)heptyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <33> 7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)heptanamide <34> 4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <35> 3-(4-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <36> 4-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <37> 3-(4-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <38> 4-((5-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)sulfinyl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <39> 4-((5-((7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)sulfonyl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <40> 4-((12-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-12-oxododec-5-en-1-yl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <41> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <42> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <43> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)propoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <44> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <45> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <46> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <47> (2S,4R)-1-((S)-2-(4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <48> (2S,4R)-1-((S)-2-(5-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <49> (2S,4R)-1-((S)-2-(6-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <50> (2S,4R)-1-((S)-2-(7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <51> (2S,4R)-1-((S)-2-(7-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)heptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <52> (2S,4R)-1-((S)-2-(8-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-8-oxooctanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <53> (2S,4R)-1-((S)-2-(9-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <54> (2S,4R)-1-((S)-2-(10-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <55> N1-(4-(4-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-4-oxobutyl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide <56> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanamide <57> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanamide <58> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanamide <59> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide <60> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-amide <61> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)propanamide <62> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanamide <63> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanamide <64> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide <65> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-amide <66> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)propanamide <67> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)propanamide <68> 4-((2-(2-(2-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)propoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <69> 3-(4-((2-(2-(2-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)propoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <70> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propoxy)ethoxy)ethoxy)propanamide <71> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide <72> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanamide <73> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanamide <74> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanamide <75> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanamide <76> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanamide <77> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)acetamide <78> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)propanamide <79> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butanamide <80> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentanamide <81> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanamide <82> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)heptanamide <83> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptanamide <84> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)heptanamide <85> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylbutanamide <86> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-N-methylbutanamide <87> 4-((4-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <88> 3-(4-((4-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <89> 4-((4-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)(methyl)amino)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <90> 4-((7-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)heptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <91> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propanamide <92> N-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide <93> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)heptanediamide <94> (2S,4R)-1-((S)-2-(2-(2-(2-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <95> (2S,4R)-1-((S)-2-(3-(2-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <96> (2S,4R)-1-((S)-2-(tert-butyl)-16-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <97> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N16-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13-tetraoxahexadecanediamide <98> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13,16-pentaoxanonadecanediamide <99> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide <100> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide <101> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide <102> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N7-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)heptanediamide <103> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)octanediamide <104> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide <105> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide <106> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N11-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)undecanediamide <107> (2S,4R)-1-((S)-2-(8-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)octanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <108> (2S,4R)-1-((S)-2-((8-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)octyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <109> (2S,4R)-1-((S)-2-(11-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <110> (2S,4R)-1-((S)-2-((11-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-11-oxoundecyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <111> (2S,4R)-1-((S)-2-((11-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)undecyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <112> (2S,4R)-1-((S)-2-(3-(4-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-3-oxopropyl)piperazin-1-yl)propanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <113> (2S,4R)-1-((S)-2-(3-(4-(3-((1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)amino)-3-oxopropyl)phenyl)propanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <114> N1-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)succinamide <115> 4-((2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <116> 4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <117> 4-((2-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <118> 4-((15-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <119> 4-((18-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <120> 3-(4-((2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <121> 3-(4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <122> 3-(4-((2-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <123> 3-(4-((15-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <124> 3-(4-((18-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <125> 4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <126> 3-(4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <127> 4-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <128> 3-(4-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)ethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <129> 4-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <130> 3-(4-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <131> 4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <132> 4-((3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <133> 4-((4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <134> 4-((5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <135> 4-((6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <136> 4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <137> 3-(4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <138> 3-(4-((3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <139> 3-(4-((4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <140> 3-(4-((5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <141> 3-(4-((6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <142> 3-(4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <143> 4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <144> 3-(4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <145> 4-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <146> 3-(4-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <147> 4-(5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <148> 4-((4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <149> 4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <150> 3-(4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <151> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <152> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <153> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <154> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <155> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <156> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <157> (2S,4R)-1-((S)-2-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <158> (2S,4R)-1-((S)-2-(5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <159> (2S,4R)-1-((S)-2-(6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <160> (2S,4R)-1-((S)-2-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <161> (2S,4R)-1-((S)-2-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <162> (2S,4R)-1-((S)-2-(8-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <163> (2S,4R)-1-((S)-2-(9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-9-oxononamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <164> (2S,4R)-1-((S)-2-(10-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <165> 4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxobutanamide <166> (2S,4R)-1-((S)-2-(4-(4-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <167> (2S,4R)-1-((S)-2-(3-(4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)piperazin-1-yl)propanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <168> (2S,4R)-1-((S)-2-(3-(4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)phenyl)propanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <169> 3-(4-((2-(4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)piperazin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <170> 3-(4-((4-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)phenethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <171> 8-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <172> 8-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <173> 8-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <174> 8-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <175> 8-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <176> 8-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <177> 8-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <178> 8-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <179> 8-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <180> 8-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <181> 8-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <182> 8-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <183> 8-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <184> 8-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)glycyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <185> 8-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <186> 8-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <187> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <188> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <189> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <190> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <191> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <192> (2S,4R)-1-((S)-2-(4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <193> (2S,4R)-1-((S)-2-(5-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-5-oxopentanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <194> (2S,4R)-1-((S)-2-(6-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <195> (2S,4R)-1-((S)-2-(7-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-7-oxoheptanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <196> (2S,4R)-1-((S)-2-(8-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-8-oxooctanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <197> (2S,4R)-1-((S)-2-(9-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-9-oxononamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <198> (2S,4R)-1-((S)-2-(10-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <199> 4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxobutanamide <200> (2S,4R)-1-((S)-2-(4-(4-(4-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <201> (2S,4R)-1-((S)-2-(8-(4-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperazin-1-yl)octanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <202> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanamide <203> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanamide <204> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanamide <205> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide <206> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-amide <207> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide <208> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanamide <209> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanamide <210> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanamide <211> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanamide <212> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)acetamide <213> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butanamide <214> N-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanamide <215> (2S,4R)-1-((S)-2-(2-(2-(2-((1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)amino)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <216> (2S,4R)-1-((S)-2-(3-(2-(3-((1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)amino)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <217> (2S,4R)-1-((S)-2-(tert-butyl)-16-((1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)amino)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <218> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N16-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13-tetraoxahexadecanediamide <219> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4,7,10,13,16-pentaoxanonadecanediamide <220> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide <221> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide <222> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide <223> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N7-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)heptanediamide <224> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)octanediamide <225> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide <226> N1-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide <227> (2S,4R)-1-((S)-2-(4-(4-(4-((1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)amino)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <228> 8-(4-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <229> 8-(4-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <230> 8-(4-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <231> 8-(4-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <232> 8-(4-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <233> 8-(4-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <234> 8-(4-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <235> 8-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <236> 8-(4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <237> 8-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <238> 8-(4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <239> 8-(4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <240> 8-(4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <241> 8-(4-(4-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)heptanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <242> 8-(4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <243> 8-(4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <244> 8-(4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <245> 8-(4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile <246> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <247> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <248> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <249> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <250> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <251> (2S,4R)-1-((S)-2-(4-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <252> (2S,4R)-1-((S)-2-(5-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-5-oxopentanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <253> (2S,4R)-1-((S)-2-(6-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <254> (2S,4R)-1-((S)-2-(7-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <255> (2S,4R)-1-((S)-2-(8-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-8-oxooctanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <256> (2S,4R)-1-((S)-2-(9-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-9-oxononamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <257> (2S,4R)-1-((S)-2-(10-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <258> (2S,4R)-1-((S)-2-(4-(4-(4-(4-(1-(3-cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)butanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <295> 4-((2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <296> 4-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <297> 4-((2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)propoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <298> 3-(4-((2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)propoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <299> 3-(4-(3-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)propoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <300> 4-((2-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <301> 4-((2-(2-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <302> 4-((15-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <303> 4-((18-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <304> 4-((2-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <305> 4-((3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <306> 4-((4-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <307> 4-((5-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <308> 4-((6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <309> 4-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-8-oxooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <310> 3-(4-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-8-oxooctyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <311> 3-(4-(9-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-9-oxononyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <312> 4-(9-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-9-oxononyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <313> 4-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-8-oxooctyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <314> 8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-8-oxooctaneamide <315> 4-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)octyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <316> 3-(4-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)octyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <317> 4-((12-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-12-oxododecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <318> 4-((16-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-16-oxohexadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <319> 8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-N-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)-8-oxooctaneamide <320> 4-((5-(4-(6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)-1H-1,2,3-triazol-1-yl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <321> 4-((5-((6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)thio)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <322> 4-((5-((6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)sulfinyl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <323> 4-((5-((6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexyl)sulfonyl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <324> 1-(5-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-5-oxopentyl)-3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)urea <325> 4-(((E)-10-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-10-oxodec-4-en-1-yl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <326> 4-((10-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-5,6-dihydroxy-10-oxodecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <327> 4-((7-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-7-oxohept-3-en-1-yl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <328> (2S,4R)-1-((S)-2-(4-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <329> (2S,4R)-1-((S)-2-(6-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <330> (2S,4R)-1-((S)-2-(8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-8-oxooctanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <331> (2S,4R)-1-((S)-2-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-8-oxooctyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <332> (2S,4R)-1-((S)-2-(8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)octanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <333> (2S,4R)-1-((S)-2-((8-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)octyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <334> (2S,4R)-1-((S)-2-(10-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <335> (2S,4R)-1-((S)-2-(4-(5-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-5-oxopentanamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <336> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <337> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)propoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <338> (2S,4R)-1-((S)-16-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-(tert-butyl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <339> (2S,4R)-1-((S)-19-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-(tert-butyl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <340> (2S,4R)-1-((S)-22-(4-(4-(6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-(tert-butyl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <341> 4-((2-(3-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <342> 4-((2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <343> 4-((2-(2-(2-(3-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <344> 4-((18-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <345> 4-((2-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <346> 4-((3-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <347> 4-((4-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <348> 4-((5-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <349> 4-((6-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <350> 4-((7-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <351> 4-((8-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione <352> 3-(4-((2-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <353> 3-(4-((8-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <354> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <355> (2S,4R)-1-((S)-2-(3-(2-(3-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <356> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <357> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <358> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <359> (2S,4R)-1-((S)-2-(4-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <360> (2S,4R)-1-((S)-2-(5-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <361> (2S,4R)-1-((S)-2-(6-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <362> (2S,4R)-1-((S)-2-(6-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <363> (2S,4R)-1-((S)-2-(7-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <364> (2S,4R)-1-((S)-2-(8-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <365> (2S,4R)-1-((S)-2-(9-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-9-oxononamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <366> (2S,4R)-1-((S)-2-(10-(4-(1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <367> 2-(2,6-dioxopiperidin-3-yl)-4-((2-(3-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)isoindoline-1,3-dione <368> 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(3-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione <369> 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(3-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione <370> 2-(2,6-dioxopiperidin-3-yl)-4-((15-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)isoindoline-1,3-dione <371> 2-(2,6-dioxopiperidin-3-yl)-4-((18-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)isoindoline-1,3-dione <372> 2-(2,6-dioxopiperidin-3-yl)-4-((2-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)isoindoline-1,3-dione <373> 2-(2,6-dioxopiperidin-3-yl)-4-((3-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)isoindoline-1,3-dione <374> 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)isoindoline-1,3-dione <375> 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)isoindoline-1,3-dione <376> 2-(2,6-dioxopiperidin-3-yl)-4-((6-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)isoindoline-1,3-dione <377> 2-(2,6-dioxopiperidin-3-yl)-4-((7-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)isoindoline-1,3-dione <378> 2-(2,6-dioxopiperidin-3-yl)-4-((12-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-12-oxododecyl)amino)isoindoline-1,3-dione <379> 3-(4-((12-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-12-oxododecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <380> N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-12-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-12-oxododecanamide <381> 3-(4-((2-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione <382> (2S,4R)-4-hydroxy-1-((S)-2-(2-(2-(2-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <383> (2S,4R)-4-hydroxy-1-((S)-2-(3-(2-(3-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <384> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <385> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <386> (2S,4R)-1-((S)-2-(tert-butyl)-19-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4,19-dioxo-7,10,13,16-tetraoxa-3-azanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <387> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <388> (2S,4R)-4-hydroxy-1-((S)-2-(4-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <389> (2S,4R)-4-hydroxy-1-((S)-2-(5-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <390> (2S,4R)-4-hydroxy-1-((S)-2-(6-(4-(1-(5-isopropoxy-4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <391> (2S,4R)-4-hydroxy-1-((S)-2-(7-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <392> (2S,4R)-4-hydroxy-1-((S)-2-(8-(4-(1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <393> (2S,4R)-4-hydroxy-1-((S)-2-(9-(4-(1-(5-isopropoxy-4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-9-oxononamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <394> (2S,4R)-4-hydroxy-1-((S)-2-(10-(4-(1-(5-isopropoxy-4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <395> (2S,4R)-4-hydroxy-1-((S)-2-(13-(4-(1-(5-isopropoxy-4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)-13-oxotridecanamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <396> 2-((2-((1-(N-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <397> 2-((2-((1-(N-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <398> 2-((2-((1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-13-methyl-12-oxo-3,6,9-trioxa-13-azapentadecan-15-oyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <399> 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N-methyl-3,6,9,12-tetraoxapentadecan-15-amide <400> 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N-methyl-3,6,9,12,15-pentaoxaoctadecane-18-amide <401> 2-((2-((1-(N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <402> 2-((2-((1-(N-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <403> 2-((2-((1-(N-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <404> 2-((2-((1-(N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <405> 2-((2-((1-(N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <406> 2-((2-((1-(N-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <407> 2-((2-((1-(N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <408> 2-((2-((1-(N-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)octanoyl)-N-methylglycyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide <409> N1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N8-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N8-methyloctanediamide <410> (2S,4R)-1-((S)-2-(tert-butyl)-14-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-12-methyl-4,11,14-trioxo-6,9-dioxa-3,12-diazatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <411> (2S,4R)-1-((S)-2-(tert-butyl)-16-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-14-methyl-4,13,16-trioxo-7,10-dioxa-3,14-diazahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <412> (2S,4R)-1-((S)-2-(tert-butyl)-19-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-17-methyl-4,16,19-trioxo-7,10,13-trioxa-3,17-diazanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <413> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N16-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyl-4,7,10,13-tetraoxahexadecanediamide <414> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyl-4,7,10,13,16-pentaoxanonadecanediamide <415> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide <416> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylglutaramide <417> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyladipamide <418> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N7-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylheptanediamide <419> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyloctanediamide <420> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylnonanediamide <421> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyldecanediamide <422> N1-(2-(6-((4-((3-fluoro-2-(methylcarbamoyl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-methoxyindolin-1-yl)-2-oxoethyl)-N13-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyltridecanediamide <423> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)-N-methylpropanamide <424> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)-N-methylpropanamide <425> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)-N-methylpropanamide <426> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methyl-3,6,9,12-tetraoxapentadecan-15-amide <427> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methyl-3,6,9,12,15-pentaoxaoctadecane-18-amide <428> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylacetamide <429> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylpropanamide <430> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylbutanamide <431> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylpentanamide <432> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylhexanamide <433> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methylheptanamide <434> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-methyldodecanamide <435> N-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-12-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-N-methyldodecanamide <436> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N12-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N1-methyldodecanediamide <437> (2S,4R)-1-((S)-12-(tert-butyl)-2-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3,10-dioxo-5,8-dioxa-2,11-diazatridecane-13-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <438> (2S,4R)-1-((S)-17-(tert-butyl)-2-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-3,15-dioxo-6,9,12-trioxa-2,16-diazaoctadecane-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <439> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyl-4,7,10,13,16-pentaoxanonadecanediamide <440> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide <441> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyladipamide <442> (2S,4R)-1-((S)-2-(6-((1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)(methyl)amino)hexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <443> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyloctanediamide <444> N1-(1-(4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyldecanediamide <445> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <446> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <447> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <448> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <449> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-(2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <450> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <451> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <452> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <453> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <454> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <455> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <456> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <457> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <458> N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)dodecanoyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide <459> (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <460> (2S,4R)-1-((S)-2-(tert-butyl)-16-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-4,16-dioxo-7,10,13-trioxa-3-azahexadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <461> (2S,4R)-1-((S)-2-(tert-butyl)-22-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-4,22-dioxo-7,10,13,16,19-pentaoxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <462> (2S,4R)-1-((S)-2-(4-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-4-oxobutanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <463> (2S,4R)-1-((S)-2-(6-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-6-oxohexanamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <464> (2S,4R)-1-((S)-2-(8-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <465> (2S,4R)-1-((S)-2-(10-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-10-oxodecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <466> (2S,4R)-1-((S)-2-(13-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)-13-oxotridecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <467> (2S,4R)-1-((S)-2-(13-(4-(4-((5-(3,5-difluorobenzyl)-1H-indazol-3-yl)carbamoyl)-3-((tetrahydro-2H-pyran-4-yl)amino)phenyl)piperazin-1-yl)tridecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide <468> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <469> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <470> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <471> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <472> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecane-18-oyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <473> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <474> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <475> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <476> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <477> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <478> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <479> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <480> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(10-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)decanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <481> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(10-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)decyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <482> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)acetyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <483> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-((S)-15-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-16,16-dimethyl-13-oxo-4,7,10-trioxa-14-azaheptadecanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <484> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-((S)-21-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-22,22-dimethyl-19-oxo-4,7,10,13,16-pentaoxa-20-azatricosanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <485> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <486> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(6-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <487> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide <488> 6-amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3S,5R)-4-(10-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecanoyl)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide or a salt, enantiomer, stereoisomer, or solvate thereof, selected from the group consisting of:

2. A pharmaceutical composition for preventing and / or treating cancer, comprising: A compound according to claim 1 or a salt, enantiomer, stereoisomer or solvate thereof; A pharmaceutical composition comprising:

3. The pharmaceutical composition according to claim 2, further comprising at least one additive for treating and / or preventing cancer.

4. 3. The pharmaceutical composition of claim 2, wherein the cancer is selected from the group consisting of lung cancer, lymphoma, diffuse large B-cell lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor (IMT), colorectal cancer, glioma, glioblastoma, acute myeloid leukemia and ovarian cancer.

5. The pharmaceutical composition according to claim 4, characterized in that the lung cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC), ROS1-positive non-small cell lung cancer, MET mutant or amplified lung cancer, and EGFR mutant non-small cell lung cancer.

6. The pharmaceutical composition according to claim 4, wherein the lung cancer is lung adenocarcinoma.

7. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is administered to a subject in at least one administration form selected from the group consisting of nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration, and intravenous administration.

8. 13. Use of the compound according to claim 1 or a salt, enantiomer, stereoisomer or solvate thereof in the manufacture of a medicament for preventing and / or treating cancer.

9. 9. The use according to claim 8, wherein the cancer is selected from the group consisting of lung cancer, lymphoma, diffuse large B-cell lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, colorectal cancer, glioma, glioblastoma, acute myeloid leukemia and ovarian cancer.

10. 10. The use of claim 9, wherein the lung cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC), ROS1 positive non-small cell lung cancer, MET mutant or amplified lung cancer, and EGFR mutant non-small cell lung cancer.

11. The use according to claim 9, wherein the lung cancer is lung adenocarcinoma.

Citation Information

Patent Citations

  • Phosphorus derivatives as kinase inhibitors

    JP2011523646A

  • Imido-based proteolytic modulators and related methods of use

    JP2017513862A

  • ALK PROTEIN DEGRADERS AND THEIR USE IN CANCER THERAPY

    JP2021506820A

  • Tetracyclic compound

    WO2010143664A1

  • Proteolysis targeting chimera compounds and methods of preparing and using same

    WO2017079267A1